MSH|^~\&|CoPathPlus|X|caBIG||20060210135109||ORU^R01|1000000004499|P|2.3
PID|1||100003654^^^RG|tpmc9388394|TESTRED^ANITA^M||19540314|F||MWB|1234 BACK STREET^^PITTSBURGH^PA^99999^United States||(412)555-1212|||||||||||||||||N
PV1|1||MWSURG^3610||||MW091900^KRUPSKI^CAROL||||||||||pmc12162^KRUPSKI^CAROL|MWM|71398465|MWR||||||||||||||||||||||||200511150740
ORC|RE|00001|MWS05-100^CoPathPlus||CM||||200511161405|z41^LOSOS^FRANK||505074^PLANET^MARS
OBR|1|00001|MWS05-100^CoPathPlus^tpmc0157183|MWSP^MW Pathology|||200511161404|||||||200511161404||505074||||^51^Y|-1|200511161503||SP|F|||||||987654^PATHOID^DOCTOR|987654^PATHOID^DOCTOR
OBX|1|CE|ANT|tpmc0157183.1|^Colon - Neoplastic^L||||||F||1^1
OBX|2|ST|BLOCK|tpmc0157183.1.1|A||||||||1^A|200512121425
OBX|3|ST|BLOCK|tpmc0157183.1.2|B||||||||2^B|200512121425
OBX|4|ST|BLOCK|tpmc0157183.1.3|C||||||||3^C|200512121425
OBX|5|ST|BLOCK|tpmc0157183.1.4|D||||||||4^D|200512121425
OBX|6|ST|BLOCK|tpmc0157183.1.5|E||||||||5^E|200512121425
OBX|7|ST|BLOCK|tpmc0157183.1.6|F||||||||6^F|200512121425
OBX|8|ST|BLOCK|tpmc0157183.1.7|G||||||||7^G|200512121425
OBX|9|ST|BLOCK|tpmc0157183.1.8|H||||||||8^H|200512121425
OBX|10|ST|BLOCK|tpmc0157183.1.9|I||||||||9^I|200512121425
OBX|11|ST|BLOCK|tpmc0157183.1.10|J||||||||10^J|200512121425
OBX|12|CE|PROCESS|tpmc0157183.1.1.1|$hinit^Initial H&E^L||||||||1^H&E|200512121431
OBX|13|CE|PROCESS|tpmc0157183.1.2.2|$hinit^Initial H&E^L||||||||1^H&E|200512121431
OBX|14|CE|PROCESS|tpmc0157183.1.3.3|$hinit^Initial H&E^L||||||||1^H&E|200512121431
OBX|15|CE|PROCESS|tpmc0157183.1.4.4|$hinit^Initial H&E^L||||||||1^H&E|200512121431
OBX|16|CE|PROCESS|tpmc0157183.1.5.5|$hinit^Initial H&E^L||||||||1^H&E|200512121431
OBX|17|CE|PROCESS|tpmc0157183.1.6.6|$hinit^Initial H&E^L||||||||1^H&E|200512121431
OBX|18|CE|PROCESS|tpmc0157183.1.7.7|$hinit^Initial H&E^L||||||||1^H&E|200512121431
OBX|19|CE|PROCESS|tpmc0157183.1.8.8|$hinit^Initial H&E^L||||||||1^H&E|200512121431
OBX|20|CE|PROCESS|tpmc0157183.1.9.9|$hinit^Initial H&E^L||||||||1^H&E|200512121431
OBX|21|CE|PROCESS|tpmc0157183.1.10.10|$hinit^Initial H&E^L||||||||1^H&E|200512121431
OBX|22|TX|GDT|tpmc0157183|\.br\This is the Gross Description\.br\||||||F
OBX|23|TX|MDT|tpmc0157183|This is the Microscopic Description     \.br\||||||F
OBX|24|TX|FIN|tpmc0157183|THIS IS THE FINAL DIAGNOSIS\.br\||||||F
OBR|2|00001|tpmc0157183^CoPathPlus^tpmc0157183.A1|ADD^Addendum||||||||||200511161503|||||||1|200511161503||SP|F|||||||987654^PATHOID^DOCTOR|987654^PATHOID^DOCTOR
OBX|1|TX|ADX|tpmc0157183|Radioactive Serum Asphalt Test123.4 millibars\.br\||||||F

MSH|^~\&|CoPathPlus|X|caBIG||20060210135109||ORU^R01|1000000004502|P|2.3
PID|1||112233445^^^RS|tpmc6198394|TESTVTWOFIVE^PATRICIA||19650502|F||||||||||||||||||||||N
PV1|1||SUR||||987654^PATHOID^DOCTOR||||||||||pmc3304^PATHOID^DOCTOR|I|1800555121202|||||||||||||||||||||||||200511160629
ORC|RE||MWS05-101^CoPathPlus||CM||||200511161636|^LASSIGE^KAREN||987654^PATHOID^DOCTOR
OBR|1||MWS05-101^CoPathPlus^tpmc2357183|MWSP^MW Pathology|||200511161621|||||||200511161621|BCW|987654||||^40^Y|-1|200511180730||SP|F|||||||987654^PATHOID^DOCTOR|987654^PATHOID^DOCTOR
OBX|1|CE|ANT|tpmc2357183.1|BCW^3:00 LB Core Bx w/Calcification^L||||||F||1^1
OBX|2|CE|ANT|tpmc2357183.2|BCWO^3:00 LB Core Bx w/o Calcification^L||||||F||2^2
OBX|3|ST|BLOCK|tpmc2357183.1.1|A||||||||1^A|200512121425
OBX|4|ST|BLOCK|tpmc2357183.2.2|A||||||||1^A|200512121425
OBX|5|ST|BLOCK|tpmc2357183.2.3|B||||||||2^B|200512121425
OBX|6|ST|BLOCK|tpmc2357183.2.4|C||||||||3^C|200512121425
OBX|7|CE|PROCESS|tpmc2357183.1.1.1|pmc4115^Blank Slide (MW)^L||||||||4^BLANK|200512121428
OBX|8|CE|PROCESS|tpmc2357183.1.1.2|$hinit^Initial H&E^L||||||||5^H&E Lv1|200512121431
OBX|9|CE|PROCESS|tpmc2357183.1.1.3|pmc4115^Blank Slide (MW)^L||||||||6^BLANK|200512121428
OBX|10|CE|PROCESS|tpmc2357183.1.1.4|pmc5553^HH&E (HISTO)^L||||||||7^H&E Lv2|200512121431
OBX|11|CE|PROCESS|tpmc2357183.1.1.5|pmc4115^Blank Slide (MW)^L||||||||8^BLANK|200512121428
OBX|12|CE|PROCESS|tpmc2357183.1.1.6|pmc5553^HH&E (HISTO)^L||||||||9^H&E Lv3|200512121431
OBX|13|CE|PROCESS|tpmc2357183.1.1.7|pmc4115^Blank Slide (MW)^L||||||||10^BLANK|200512121428
OBX|14|CE|PROCESS|tpmc2357183.1.1.8|pmc5553^HH&E (HISTO)^L||||||||11^H&E Lv4|200512121431
OBX|15|CE|PROCESS|tpmc2357183.2.2.9|pmc4115^Blank Slide (MW)^L||||||||1^BLANK|200512121428
OBX|16|CE|PROCESS|tpmc2357183.2.2.10|$hinit^Initial H&E^L||||||||2^H&E Lv1|200512121431
OBX|17|CE|PROCESS|tpmc2357183.2.2.11|pmc4115^Blank Slide (MW)^L||||||||3^BLANK|200512121428
OBX|18|CE|PROCESS|tpmc2357183.2.2.12|pmc5553^HH&E (HISTO)^L||||||||4^H&E Lv2|200512121431
OBX|19|CE|PROCESS|tpmc2357183.2.2.13|pmc4115^Blank Slide (MW)^L||||||||5^BLANK|200512121428
OBX|20|CE|PROCESS|tpmc2357183.2.2.14|pmc5553^HH&E (HISTO)^L||||||||6^H&E Lv3|200512121431
OBX|21|CE|PROCESS|tpmc2357183.2.2.15|pmc4115^Blank Slide (MW)^L||||||||7^BLANK|200512121428
OBX|22|CE|PROCESS|tpmc2357183.2.2.16|pmc5553^HH&E (HISTO)^L||||||||8^H&E Lv4|200512121431
OBX|23|CE|PROCESS|tpmc2357183.2.3.17|pmc4115^Blank Slide (MW)^L||||||||16^BLANK|200512121428
OBX|24|CE|PROCESS|tpmc2357183.2.3.18|$hinit^Initial H&E^L||||||||17^H&E Lv1|200512121431
OBX|25|CE|PROCESS|tpmc2357183.2.3.19|pmc4115^Blank Slide (MW)^L||||||||18^BLANK|200512121428
OBX|26|CE|PROCESS|tpmc2357183.2.3.20|pmc5553^HH&E (HISTO)^L||||||||19^H&E Lv2|200512121431
OBX|27|CE|PROCESS|tpmc2357183.2.3.21|pmc4115^Blank Slide (MW)^L||||||||20^BLANK|200512121428
OBX|28|CE|PROCESS|tpmc2357183.2.3.22|pmc5553^HH&E (HISTO)^L||||||||21^H&E Lv3|200512121431
OBX|29|CE|PROCESS|tpmc2357183.2.3.23|pmc4115^Blank Slide (MW)^L||||||||22^BLANK|200512121428
OBX|30|CE|PROCESS|tpmc2357183.2.3.24|pmc5553^HH&E (HISTO)^L||||||||23^H&E Lv4|200512121431
OBX|31|CE|PROCESS|tpmc2357183.2.4.25|pmc4115^Blank Slide (MW)^L||||||||31^BLANK|200512121428
OBX|32|CE|PROCESS|tpmc2357183.2.4.26|$hinit^Initial H&E^L||||||||32^H&E Lv1|200512121431
OBX|33|CE|PROCESS|tpmc2357183.2.4.27|pmc4115^Blank Slide (MW)^L||||||||33^BLANK|200512121428
OBX|34|CE|PROCESS|tpmc2357183.2.4.28|pmc5553^HH&E (HISTO)^L||||||||34^H&E Lv2|200512121431
OBX|35|CE|PROCESS|tpmc2357183.2.4.29|pmc4115^Blank Slide (MW)^L||||||||35^BLANK|200512121428
OBX|36|CE|PROCESS|tpmc2357183.2.4.30|pmc5553^HH&E (HISTO)^L||||||||36^H&E Lv3|200512121431
OBX|37|CE|PROCESS|tpmc2357183.2.4.31|pmc4115^Blank Slide (MW)^L||||||||37^BLANK|200512121428
OBX|38|CE|PROCESS|tpmc2357183.2.4.32|pmc5553^HH&E (HISTO)^L||||||||38^H&E Lv4|200512121431
OBX|39|CE|PROCESS|tpmc2357183.1.1.33|pmc4115^Blank Slide (MW)^L||||||||12^BLANK|200512121428
OBX|40|CE|PROCESS|tpmc2357183.1.1.34|$hinit^Initial H&E^L||||||||13^H&E Lv1|200512121431
OBX|41|CE|PROCESS|tpmc2357183.1.1.35|pmc4115^Blank Slide (MW)^L||||||||14^BLANK|200512121428
OBX|42|CE|PROCESS|tpmc2357183.1.1.36|pmc5553^HH&E (HISTO)^L||||||||15^H&E Lv2|200512121431
OBX|43|CE|PROCESS|tpmc2357183.1.1.37|pmc4115^Blank Slide (MW)^L||||||||16^BLANK|200512121428
OBX|44|CE|PROCESS|tpmc2357183.1.1.38|pmc5553^HH&E (HISTO)^L||||||||17^H&E Lv3|200512121431
OBX|45|CE|PROCESS|tpmc2357183.1.1.39|pmc4115^Blank Slide (MW)^L||||||||18^BLANK|200512121428
OBX|46|CE|PROCESS|tpmc2357183.1.1.40|pmc5553^HH&E (HISTO)^L||||||||19^H&E Lv4|200512121431
OBX|47|CE|PROCESS|tpmc2357183.2.2.41|pmc4115^Blank Slide (MW)^L||||||||9^BLANK|200512121428
OBX|48|CE|PROCESS|tpmc2357183.2.2.42|$hinit^Initial H&E^L||||||||10^H&E Lv1|200512121431
OBX|49|CE|PROCESS|tpmc2357183.2.2.43|pmc4115^Blank Slide (MW)^L||||||||11^BLANK|200512121428
OBX|50|CE|PROCESS|tpmc2357183.2.2.44|pmc5553^HH&E (HISTO)^L||||||||12^H&E Lv2|200512121431
OBX|51|CE|PROCESS|tpmc2357183.2.2.45|pmc4115^Blank Slide (MW)^L||||||||13^BLANK|200512121428
OBX|52|CE|PROCESS|tpmc2357183.2.2.46|pmc5553^HH&E (HISTO)^L||||||||14^H&E Lv3|200512121431
OBX|53|CE|PROCESS|tpmc2357183.2.2.47|pmc4115^Blank Slide (MW)^L||||||||15^BLANK|200512121428
OBX|54|CE|PROCESS|tpmc2357183.2.2.48|pmc5553^HH&E (HISTO)^L||||||||16^H&E Lv4|200512121431
OBX|55|CE|PROCESS|tpmc2357183.2.3.49|pmc4115^Blank Slide (MW)^L||||||||24^BLANK|200512121428
OBX|56|CE|PROCESS|tpmc2357183.2.3.50|$hinit^Initial H&E^L||||||||25^H&E Lv1|200512121431
OBX|57|CE|PROCESS|tpmc2357183.2.3.51|pmc4115^Blank Slide (MW)^L||||||||26^BLANK|200512121428
OBX|58|CE|PROCESS|tpmc2357183.2.3.52|pmc5553^HH&E (HISTO)^L||||||||27^H&E Lv2|200512121431
OBX|59|CE|PROCESS|tpmc2357183.2.3.53|pmc4115^Blank Slide (MW)^L||||||||28^BLANK|200512121428
OBX|60|CE|PROCESS|tpmc2357183.2.3.54|pmc5553^HH&E (HISTO)^L||||||||29^H&E Lv3|200512121431
OBX|61|CE|PROCESS|tpmc2357183.2.3.55|pmc4115^Blank Slide (MW)^L||||||||30^BLANK|200512121428
OBX|62|CE|PROCESS|tpmc2357183.2.3.56|pmc5553^HH&E (HISTO)^L||||||||31^H&E Lv4|200512121431
OBX|63|CE|PROCESS|tpmc2357183.2.4.57|pmc4115^Blank Slide (MW)^L||||||||39^BLANK|200512121428
OBX|64|CE|PROCESS|tpmc2357183.2.4.58|$hinit^Initial H&E^L||||||||40^H&E Lv1|200512121431
OBX|65|CE|PROCESS|tpmc2357183.2.4.59|pmc4115^Blank Slide (MW)^L||||||||41^BLANK|200512121428
OBX|66|CE|PROCESS|tpmc2357183.2.4.60|pmc5553^HH&E (HISTO)^L||||||||42^H&E Lv2|200512121431
OBX|67|CE|PROCESS|tpmc2357183.2.4.61|pmc4115^Blank Slide (MW)^L||||||||43^BLANK|200512121428
OBX|68|CE|PROCESS|tpmc2357183.2.4.62|pmc5553^HH&E (HISTO)^L||||||||44^H&E Lv3|200512121431
OBX|69|CE|PROCESS|tpmc2357183.2.4.63|pmc4115^Blank Slide (MW)^L||||||||45^BLANK|200512121428
OBX|70|CE|PROCESS|tpmc2357183.2.4.64|pmc5553^HH&E (HISTO)^L||||||||46^H&E Lv4|200512121431
OBX|71|CE|PROCESS|tpmc2357183.1.9.65|$hinit^Initial H&E^L||||||||21^H&E|200512121431
OBX|72|CE|PROCESS|tpmc2357183.1.9.66|pmc0653^Hematoxylin & Eosin Recut (Histo)^L||||||||22^H&E Recut|200512121428
OBX|73|CE|PROCESS|tpmc2357183.1.10.67|$hinit^Initial H&E^L||||||||21^H&E|200512121431
OBX|74|CE|PROCESS|tpmc2357183.1.1.68|pmc1884^Her-2/neu (IPEX)^L||||||||20^Her- 2/neu|200512121428
OBX|75|CE|PROCESS|tpmc2357183.1.1.69|pmc0884^Her-2/neu (WLO) (IPEX)^L||||||||21^Her-2/neu|200512121428
OBX|76|CE|PROCESS|tpmc2357183.1.0.70|pmc2043^Estrogen Receptor (IPEX)^L||||||||1^AER|200512121428
OBX|77|CE|PROCESS|tpmc2357183.1.0.71|pmc8784^Estrogen Receptor (WLO) (IPEX)^L||||||||2^ER|200512121428
OBX|78|TX|GDT|tpmc2357183|The specimen is received in formalin in two parts.\.br\\.br\Part 1 is labeled with the patient's name with initials JW and "Left Breast 3 o'clock, calcifications".  It consists of multiple cylindrical, tan-yellow breast core biopsy fragments ranging from 0.3 cm in length x less than 0.1 cm in diameter up to 0.8 cm in length x 0.4 cm in diameter.  The specimen is totally submitted in a cassettes labeled 1A and 1B.\.br\\.br\Part 2 is labeled with the patient's name, initials, JW and "Left Breast 3 o'clock, without calcification".  It consists of multiple cylindrical, tan-yellow breast core biopsy fragments ranging from 0.3 cm in length x 0.2 cm in diameter up to 3.0 cm in length x 0.3 cm in diameter.  The specimen is totally submitted in cassettes labeled 2A ,2B and 2C.\.br\||||||F
OBX|79|TX|MDT|tpmc2357183|Microscopic examination substantiates the above diagnosis.\.br\||||||F
OBX|80|TX|FIN|tpmc2357183|PART 1:  BREAST, LEFT, 3 O' CLOCK, WITH CALCIFICATIONS, STEREOTACTIC CORE BIOPSY\.br\A.           ATYPICAL DUCT EPITHELIAL HYPERPLASIA WITH MICROCALCIFICATIONS.\.br\B.     SCLEROSING ADENOSIS.\.br\C.     COLUMNAR CELL HYPERPLASIA.\.br\\.br\\.br\PART 2:  BREAST, LEFT, 3 O' CLOCK, WITHOUT CALCIFICATIONS, STEREOTACTIC CORE BIOPSY\.br\A.          ATYPICAL DUCT EPITHELIAL HYPERPLASIA.\.br\B.     COLUMNAR CELL CHANGE WITH MICROCALCIFICATIONS.\.br\C.     DUCT EPITHELIAL HYPERPLASIA.\.br\||||||F
OBX|81|CE|IMP|tpmc2357183|M55400^^SNO||||||||1||A
OBX|82|CE|IMP|tpmc2357183|M72000^^SNO||||||||1||A
OBX|83|CE|IMP|tpmc2357183|M72175^^SNO||||||||1||A
OBX|84|CE|IMP|tpmc2357183|M74220^^SNO||||||||1||A
OBX|85|CE|IMP|tpmc2357183|P1140^^SNO||||||||1||A
OBX|86|CE|IMP|tpmc2357183|T04030^^SNO||||||||1||A
OBX|87|CE|IMP|tpmc2357183|M55400^^SNO||||||||1||A
OBX|88|CE|IMP|tpmc2357183|M72175^^SNO||||||||1||A
OBX|89|CE|IMP|tpmc2357183|P1140^^SNO||||||||1||A
OBX|90|CE|IMP|tpmc2357183|T04030^^SNO||||||||1||A
OBX|91|CE|IMP|tpmc2357183|V72.84^^ICD||||||||1
OBR|2||tpmc2357183^CoPathPlus^tpmc2357183.A1|ADD^Addendum||||||||||200511180842|||||||1|200511180842||SP|F||||||||987654^PATHOID^DOCTOR
OBX|1|TX|ADX|tpmc2357183|ESTROGEN / PROGESTERONE AND HER-2/NEU REPORT\.br\\.br\Using appropriate positive and negative controls, the test for the presence of these hormone receptor proteins is performed by the immunoperoxidase method, and reported according to the NIH consensus statement on adjuvant therapy for breast cancer, of November 3, 2000.  A positive ER or PR tumor shows any nuclear immunostaining, and is semiquantitated as indicated below.\.br\\.br\ResultSemiquantitative Statement\.br\\.br\ER POSITIVEPercent cells staining as: (0  0%; 1+  0%, 2+  10%, 3+  90%)\.br\\.br\PR NEGATIVEPercent cells staining as: (0  100%, 1+  0%, 2+  0%, 3+  0%)\.br\\.br\Estrogen receptor antibody 6F11, an IVD, is performed using the IVIEW detection on the Benchmark XT (Ventana, Tucson, AZ).\.br\Progesterone receptor antibody 1A6 , an IVD, is performed using the IVEW detection on the Benchmark XT, (Ventana, Tucson, AZ).\.br\\.br\HER-2/NEU TEST:  A FAINT/BARELY PERCEPTIBLE MEMBRANE STAINING IS DETECTED IN MORE THAN 10% OF THE TUMOR CELLS.  THE CELLS ARE ONLY STAINED IN PART OF THEIR MEMBRANE.  HER-2/NEU IS INTERPRETED AS NEGATIVE (SCORE 1+).\.br\\.br\Interpretation of Her2/neu immunostaining: Using clone CB11 as an ASR validated against the Herceptest with Basic DAB detection on the Benchmark XT (Ventana, Tucson, AZ).\.br\||||||F

MSH|^~\&|CoPathPlus|X|caBIG||20060210135109||ORU^R01|1000000004503|P|2.3
PID|1||185185185^^^RA|tst8415394|TEST^BATGIRL||19500731|F||W|100 MAIN STREET^^PITTSBURGH^PA^15216^United States||(412)555-8888|(412)555-2222|||||185-18-5185|||||||||||N
PV1|1||A3B^363||||080750^WERNER^KATHLEEN||||||||||pmc68581^WERNER^KATHLEEN|I|0056718335109|P||||||||||||||||||||||||200504191052
ORC|RE||PHS05-103^CoPathPlus||CM||||200506071354|UXD^Cerner^User||080750^WERNER^KATHLEEN
OBR|1||PHS05-103^CoPathPlus^tst3507183|PHSP^PH Surgical Pathology|||200506071350|||||||200506071350|APP|080750||||^54^Y|-1|200506071415||SP|F|||||||000906^BAKER^EVAN|UXD^Cerner^User
OBX|1|CE|ANT|tst3507183.1|APP^Appendix^L||||||F||1^1
OBX|2|ST|BLOCK|tst3507183.1.1|A||||||||1^A|200507221753
OBX|3|CE|PROCESS|tst3507183.1.1.1|$hinit^Initial H&E^L||||||||1^H&E|200508180859
OBX|4|TX|FIN|tst3507183|\.br\46,X#,t(11;19)(q23;p13)[#]\.br\\.br\The 11;19 translocation has been reported in therapy-related AML and in childhood ALL [Behm EG et al. (1996) Blood 87:1134-1139; Rowley JD (1998) Annu Rev Genet 32:495-519].  The breakpoint at band 11q23 splits the MLL gene that might be responsible for the development of leukemia that is frequently characterized by mixed markers and a poor prognosis [Bernard OA, Berger R (1995) Genes Chromosomes Cancer 13:75-85; Ziemin-van der Poel S et al. (1991) Proc Ntl Acad Sci USA 88:10735-10739].\.br\||||||F
OBX|5|CE|IMP|tst3507183|M98003^^SNO||||||||1||A
OBX|6|CE|IMP|tst3507183|M98613^^SNO||||||||1||A
OBX|7|CE|IMP|tst3507183|T0X000^^SNO||||||||1||A
OBX|8|CE|IMP|tst3507183|000^^ICD||||||||1
OBR|2||tst3507183^CoPathPlus^tst3507183.A1|ADD^Addendum||||||||||200506071356|||||||1|200506071356||SP|F|||||||000906^BAKER^EVAN|UXD^Cerner^User
OBX|1|TX|ADX|tst3507183|\.br\\.br\COLONIC MUCOSA.\.br\NEGATIVE FOR LYMPHOCYTIC/COLLAGENOUS COLITIS. \.br\||||||F
OBR|3||tst3507183^CoPathPlus^tst3507183.P2|ADVPCR^Adenovirus||||||||||200506071358|||||||2|200506071358||SP|F|||||||000906^BAKER^EVAN|UXD^Cerner^User
OBX|1|TX|PIN|tst3507183|\.br\\.br\Negative for high/intermediate HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and/or 68\.br\\.br\The sample, a crude cell lysate, was tested for the presence of Human Papillomavirus  (HPV) using the Hybrid Capture 2 (HC2) High Risk HPV DNA test from Digene.  The technology utilizes a specific HPV RNA probe cocktail to detect types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68 in cervical specimens.  The target DNA hybridizes with a specific RNA probe that is captured by antibodies specific for RNA:DNA hybrids.  Hybrid detection occurs via chemiluminescent substrate and subsequent light emission.\.br\\.br\The Digene HC2 assay is an FDA-cleared, qualitative, in vitro diagnostic test for the detection  of HPV from cervical specimens.  \.br\Negative for high/intermediate HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and/or 68\.br\\.br\The sample, a crude cell lysate, was tested for the presence of Human Papillomavirus  (HPV) using the Hybrid Capture 2 (HC2) High Risk HPV DNA test from Digene.  The technology utilizes a specific HPV RNA probe cocktail to detect types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68 in cervical specimens.  The target DNA hybridizes with a specific RNA probe that is captured by antibodies specific for RNA:DNA hybrids.  Hybrid detection occurs via chemiluminescent substrate and subsequent light emission.\.br\\.br\The Digene HC2 assay is an FDA-cleared, qualitative, in vitro diagnostic test for the detection  of HPV from cervical specimens.  \.br\||||||F
OBR|4||tst3507183^CoPathPlus^tst3507183.P3|CANA^Canavan||||||||||200506071400|||||||3|200506071400||SP|F|||||||000906^BAKER^EVAN|UXD^Cerner^User
OBX|1|TX|PIN|tst3507183|Negative for high/intermediate HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and/or 68\.br\\.br\The sample, a crude cell lysate, was tested for the presence of Human Papillomavirus  (HPV) using the Hybrid Capture 2 (HC2) High Risk HPV DNA test from Digene.  The technology utilizes a specific HPV RNA probe cocktail to detect types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68 in cervical specimens.  The target DNA hybridizes with a specific RNA probe that is captured by antibodies specific for RNA:DNA hybrids.  Hybrid detection occurs via chemiluminescent substrate and subsequent light emission.\.br\\.br\The Digene HC2 assay is an FDA-cleared, qualitative, in vitro diagnostic test for the detection  of HPV from cervical specimens.  \.br\\.br\\.br\Negative for high/intermediate HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and/or 68\.br\\.br\The sample, a crude cell lysate, was tested for the presence of Human Papillomavirus  (HPV) using the Hybrid Capture 2 (HC2) High Risk HPV DNA test from Digene.  The technology utilizes a specific HPV RNA probe cocktail to detect types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68 in cervical specimens.  The target DNA hybridizes with a specific RNA probe that is captured by antibodies specific for RNA:DNA hybrids.  Hybrid detection occurs via chemiluminescent substrate and subsequent light emission.\.br\\.br\The Digene HC2 assay is an FDA-cleared, qualitative, in vitro diagnostic test for the detection  of HPV from cervical specimens.  \.br\||||||F

MSH|^~\&|CoPathPlus|X|caBIG||20060210135109||ORU^R01|1000000004504|P|2.3
PID|1||N0000085^^^RV|tpmc3531494|TESTVTWOFIVE^PASSAVANT^PAUL||19300520|M||PVW|888 STREET^^PITTSBURGH^PA^15237^United States||412-367-6100|724-625-3184|||||888-55-2223|||||||||||N
PV1|1||PVLAB||||ABU.KA^ABU-HAMAD^GHASSAN|||||||||||PVSDC|N00000001370|PVBC||||||||||||||||||||||||200511210857
ORC|RE||MWS05-103^CoPathPlus||CM||||200511301755|z41^LOSOS^FRANK
OBR|1||MWS05-103^CoPathPlus^tpmc2067183|MWSP^MW Pathology|||200511301755|||||||200511301755||||||^75^Y|-1|200511301758||SP|C|||||||987654^PATHOID^DOCTOR|z41^LOSOS^FRANK
OBX|1|CE|ANT|tpmc2067183.1|^Colon - Neoplastic^L||||||C||1^1
OBX|2|ST|BLOCK|tpmc2067183.1.1|A||||||||1^A|200512121425
OBX|3|ST|BLOCK|tpmc2067183.1.2|B||||||||2^B|200512121425
OBX|4|ST|BLOCK|tpmc2067183.1.3|C||||||||3^C|200512121425
OBX|5|ST|BLOCK|tpmc2067183.1.4|D||||||||4^D|200512121425
OBX|6|ST|BLOCK|tpmc2067183.1.5|E||||||||5^E|200512121425
OBX|7|ST|BLOCK|tpmc2067183.1.6|F||||||||6^F|200512121425
OBX|8|ST|BLOCK|tpmc2067183.1.7|G||||||||7^G|200512121425
OBX|9|ST|BLOCK|tpmc2067183.1.8|H||||||||8^H|200512121425
OBX|10|ST|BLOCK|tpmc2067183.1.9|I||||||||9^I|200512121425
OBX|11|ST|BLOCK|tpmc2067183.1.10|J||||||||10^J|200512121425
OBX|12|CE|PROCESS|tpmc2067183.1.1.1|$hinit^Initial H&E^L||||||||1^H&E|200512121431
OBX|13|CE|PROCESS|tpmc2067183.1.2.2|$hinit^Initial H&E^L||||||||1^H&E|200512121431
OBX|14|CE|PROCESS|tpmc2067183.1.3.3|$hinit^Initial H&E^L||||||||1^H&E|200512121431
OBX|15|CE|PROCESS|tpmc2067183.1.4.4|$hinit^Initial H&E^L||||||||1^H&E|200512121431
OBX|16|CE|PROCESS|tpmc2067183.1.5.5|$hinit^Initial H&E^L||||||||1^H&E|200512121431
OBX|17|CE|PROCESS|tpmc2067183.1.6.6|$hinit^Initial H&E^L||||||||1^H&E|200512121431
OBX|18|CE|PROCESS|tpmc2067183.1.7.7|$hinit^Initial H&E^L||||||||1^H&E|200512121431
OBX|19|CE|PROCESS|tpmc2067183.1.8.8|$hinit^Initial H&E^L||||||||1^H&E|200512121431
OBX|20|CE|PROCESS|tpmc2067183.1.9.9|$hinit^Initial H&E^L||||||||1^H&E|200512121431
OBX|21|CE|PROCESS|tpmc2067183.1.10.10|$hinit^Initial H&E^L||||||||1^H&E|200512121431
OBX|22|TX|GDT|tpmc2067183|THIS IS THE GROSS DESCRIPTION\.br\||||||C
OBX|23|TX|MDT|tpmc2067183|Microscopic Descrtiption entered here     \.br\||||||C
OBX|24|TX|FIN|tpmc2067183|THIS IS THE FINAL DIAGNOSIS\.br\||||||C

MSH|^~\&|CoPathPlus|X|caBIG||20060210135109||ORU^R01|1000000004505|P|2.3
PID|1||112233445^^^RR|tpmc6198394|TESTVTWOFIVE^PATRICIA||19650502|F||||||||||||||||||||||N
PV1|1||10N^N1073||||505071^PLANET^MERCURY||||||||||pmc58361^PLANET^NIBIRU|I|0277645553017|||||||||||||||||||||||||200512011455
ORC|RE||MWS05-104^CoPathPlus||CM||||200512020734|^LASSIGE^KAREN||505071^PLANET^MERCURY
OBR|1||MWS05-104^CoPathPlus^tpmc2267183|MWSP^MW Pathology|||200512020732|||||||200512020732||505071||||^40^Y|-1|200512020815||SP|F|||||||987654^PATHOID^DOCTOR|987654^PATHOID^DOCTOR
OBX|1|CE|ANT|tpmc2267183.1|^1paraffin block and 2 slides, left breast^L||||||F||1^1
OBX|2|TX|MDT|tpmc2267183|Microscopic examination substantiates the above diagnosis.\.br\||||||F
OBX|3|TX|FIN|tpmc2267183|BREAST, LEFT, MASS, CORE BIOPSY (OSS R05-8141, 11/23/05, THE WESTERN PENNSYLVANIA HOSPITAL  FORBES REGIONAL CAMPUS) \.br\INFILTRATING DUCTAL CARCINOMA, NUCLEAR GRADE 3 (see comment).\.br\||||||F
OBX|4|CE|IMP|tpmc2267183|710.0^^ICD||||||||1
OBR|2||tpmc2267183^CoPathPlus^tpmc2267183.A2|ADD^Addendum||||||||||200512061505|||||||2|200512061505||SP|F||||||||^LASSIGE^KAREN
OBX|1|TX|ADX|tpmc2267183|ESTROGEN/PROGESTERONE AND HER-2/NEU REPORT\.br\\.br\Using appropriate positive and negative controls, the test for the presence of these hormone receptor proteins is performed by the immunoperoxidase method, and reported according to the NIH consensus statement on adjuvant therapy for breast cancer, of November 3, 2000.  A positive ER or PR tumor shows any nuclear immunostaining, and is semiquantitated as indicated below.\.br\\.br\Result          Semiquantitative Statement\.br\\.br\ER Positive     Percent cells staining as: (0  0%; 1+  0%, 2+  10%, 3+  90%)\.br\\.br\PR Negative     Percent cells staining as: (0  0%, 1+  0%, 2+  0%, 3+  0%)\.br\\.br\||||||F

MSH|^~\&|CoPathPlus|X|caBIG||20060210135109||ORU^R01|1000000004506|P|2.3
PID|1||112233456^^^SY|tpmc8198394|TESTVTWOFIVE^MAURICE||19660912|M|||||||||||112-23-3456|||||||||||N
PV1|1||I7P||||987654^PATHOID^DOCTOR||||||||||pmc3304^PATHOID^DOCTOR|SYA|1800555121204|||||||||||||||||||||||||200511160636
ORC|RE||MWS05-105^CoPathPlus||CM||||200512021139|^LASSIGE^KAREN||505074^PLANET^MARS
OBR|1||MWS05-105^CoPathPlus^tpmc4267183|MWSP^MW Pathology|||200512020000|||||||200512021417|BNBXMW|505074||||^39^Y|-1|200512051017||SP|C|||||||987654^PATHOID^DOCTOR|987654^PATHOID^DOCTOR
OBX|1|CE|ANT|tpmc4267183.2|BNBXMW^Breast Core Biopsy^L||||||C||1^1
OBX|2|TX|GDT|tpmc4267183|The specimen is received in formalin in one part labeled with the patient's name, initials WJ, and "Left breast at 12 o'clock".  It consists of three cylindrical cores of white-tan tissue ranging from 1.1 to 1.4 cm in length and up to 0.2 cm in diameter.  The entire specimen is submitted in cassette A.\.br\||||||C
OBX|3|TX|MDT|tpmc4267183|Microscopic examination substantiates the diagnosis indicated above.\.br\||||||C
OBX|4|TX|FIN|tpmc4267183|BREAST, LEFT, 12 O' CLOCK, CORE BIOPSY \.br\GYNECOMASTIA WITH DUCTAL EPITHELIAL HYPERPLASIA.\.br\||||||C
OBX|5|CE|IMP|tpmc4267183|M71000^^SNO||||||||1||A
OBX|6|CE|IMP|tpmc4267183|M72170^^SNO||||||||1||A
OBX|7|CE|IMP|tpmc4267183|P1140^^SNO||||||||1||A
OBX|8|CE|IMP|tpmc4267183|T04060^^SNO||||||||1||A
OBX|9|CE|IMP|tpmc4267183|V72.6^^ICD||||||||1

MSH|^~\&|CoPathPlus|X|caBIG||20060210135109||ORU^R01|1000000004507|P|2.3
PID|1||123456790^^^RR|tpmc5198394|TESTVTWOFIVE^BARBARA||19501215|F||||||||||||||||||||||N
PV1|1||PPAT||||^PLANET^VENUS||||||||||pmc28361^PLANET^NEPTUNE|OSD|0244276653054|||||||||||||||||||||||||200512011506
ORC|RE||MWS05-106^CoPathPlus||CM||||200512051621|^LASSIGE^KAREN||^PLANET^VENUS
OBR|1||MWS05-106^CoPathPlus^tpmc5367183|MWSP^MW Pathology|||200512051000|||||||200512051611||||||^55^Y|-1|200512061209||SP|C|||||||987654^PATHOID^DOCTOR|987654^PATHOID^DOCTOR
OBX|1|CE|ANT|tpmc5367183.1|^1Consult block and 4 slides^L||||||C||1^1
OBX|2|CE|PROCESS|tpmc5367183.1.0.1|pmc7533^Reticulin Stain (Histo)^L||||||||1^Retic|200512061137
OBX|3|CE|PROCESS|tpmc5367183.1.0.2|pmc4115^Blank Slide (MW)^L||||||||2^BLANK|200512061137
OBX|4|TX|MDT|tpmc5367183|Microscopic examination substantiates the above diagnosis.\.br\||||||C
OBX|5|TX|FIN|tpmc5367183|BREAST, RIGHT, LUMPECTOMY (OSS S-05-6154, 11/10/05, JAMESON HOSPITAL) \.br\A.DUCTAL CARCINOMA IN SITU, SOLID AND CRIBRIFORM TYPES WITH COMEDO NECROSIS AND CANCERIZATION OF LOBULES.\.br\B.NEOPLASM EXTENDS TO THE POSTERIOR MARGIN.\.br\C.      ALL OTHER SURGICAL MARGINS OF RESECTION ARE NEGATIVE (SEE COMMENT).\.br\D.ONE (1) BENIGN LYMPH NODE NEGATIVE FOR TUMOR (0/1).\.br\E.FIBROCYSTIC CHANGES.\.br\||||||C
OBX|6|CE|IMP|tpmc5367183|280.9^^ICD||||||||1
OBR|2||tpmc5367183^CoPathPlus^tpmc5367183.P1|FISH^FISH (PCL)||||||||||200512061142|||||||1|200512061142||SP|F||||||||987654^PATHOID^DOCTOR
OBX|1|TX|PIN|tpmc5367183|No amplification of the HER-2/NEU gene was seen by interphase FISH analysis.\.br\\.br\RESULTS:\.br\\.br\Fluorescence in situ hybridization (FISH) analysis was performed on MWH Surgical  MWS05-106  ,(Breast Cancer) using the DNA probe for the HER-2/NEU gene (Vysis, Inc., lot 12345).  The ratio of HER-2/NEU signals to chromosome 17 centromere signals was determined to be 1.35.  A ratio of 2.2 or greater is considered to be amplified; therefore, this specimen is not amplified.\.br\\.br\||||||C

MSH|^~\&|CoPathPlus|X|caBIG||20060210135109||ORU^R01|1000000004508|P|2.3
PID|1||111111-00^^^RG|tpmc3670494|TESTVTWOFIVE^MW ONE||19430112|F||W|||||||||123-23-2323|||||||||||N
PV1|1||MWBRI||||505079^PLANET^PLUTO||||||||||pmc48361^PLANET^PLUTO|MWO|32323232|||||||||||||||||||||||||200511210734
ORC|RE||MWS05-107^CoPathPlus||CM||||200512081443|^BROMBERG^DEBORAH||505079^PLANET^PLUTO
OBR|1||MWS05-107^CoPathPlus^tpmc0667183|MWSP^MW Pathology|||200512070000|||||||200512081441||505079||||^62^Y|-1|200601041124||SP|F|||||||^PARWANI^ANIL|^PARWANI^ANIL
OBX|1|CE|ANT|tpmc0667183.1|^10:00 Cervix Biopsy^L||||||F||1^1
OBX|2|CE|ANT|tpmc0667183.2|^ECC^L||||||F||2^2
OBX|3|CE|ANT|tpmc0667183.3|UTBAN^Neoplastic Uterus with Bilateral Adnexa^L||||||F||3^3
OBX|4|CE|ANT|tpmc0667183.4|^Omentum^L||||||F||4^4
OBX|5|CE|ANT|tpmc0667183.5|YPLN^Right Pelvic Lymph Nodes^L||||||F||5^5
OBX|6|CE|ANT|tpmc0667183.6|APP^Appendix^L||||||F||6^6
OBX|7|ST|BLOCK|tpmc0667183.1.1|A||||||||1^A|200512121425
OBX|8|ST|BLOCK|tpmc0667183.2.2|A||||||||1^A|200512121425
OBX|9|ST|BLOCK|tpmc0667183.3.3|A||||||||1^A|200512121425
OBX|10|ST|BLOCK|tpmc0667183.3.4|B||||||||2^B|200512121425
OBX|11|ST|BLOCK|tpmc0667183.3.5|C||||||||3^C|200512121425
OBX|12|ST|BLOCK|tpmc0667183.3.6|D||||||||4^D|200512121425
OBX|13|ST|BLOCK|tpmc0667183.3.7|E||||||||5^E|200512121425
OBX|14|ST|BLOCK|tpmc0667183.3.8|F||||||||6^F|200512121425
OBX|15|ST|BLOCK|tpmc0667183.3.9|G||||||||7^G|200512121425
OBX|16|ST|BLOCK|tpmc0667183.3.10|H||||||||8^H|200512121425
OBX|17|ST|BLOCK|tpmc0667183.3.11|I||||||||9^I|200512121425
OBX|18|ST|BLOCK|tpmc0667183.3.12|J||||||||10^J|200512121425
OBX|19|ST|BLOCK|tpmc0667183.3.13|K||||||||11^K|200512121425
OBX|20|ST|BLOCK|tpmc0667183.3.14|L||||||||12^L|200512121425
OBX|21|ST|BLOCK|tpmc0667183.4.15|A||||||||1^A|200512121425
OBX|22|ST|BLOCK|tpmc0667183.4.16|B||||||||2^B|200512121425
OBX|23|ST|BLOCK|tpmc0667183.4.17|C||||||||3^C|200512121425
OBX|24|ST|BLOCK|tpmc0667183.5.18|A||||||||1^A|200512121425
OBX|25|ST|BLOCK|tpmc0667183.5.19|B||||||||2^B|200512121425
OBX|26|ST|BLOCK|tpmc0667183.6.20|A||||||||1^A|200512121425
OBX|27|ST|BLOCK|tpmc0667183.1.21|B||||||||2^B|200512161225
OBX|28|CE|PROCESS|tpmc0667183.1.1.1|$hinit^Initial H&E^L||||||||1^H&E Lvs|200512121431
OBX|29|CE|PROCESS|tpmc0667183.2.2.2|$hinit^Initial H&E^L||||||||1^H&E Lvs|200512121431
OBX|30|CE|PROCESS|tpmc0667183.3.3.3|$hinit^Initial H&E^L||||||||1^H&E|200512121431
OBX|31|CE|PROCESS|tpmc0667183.3.4.4|$hinit^Initial H&E^L||||||||1^H&E|200512121431
OBX|32|CE|PROCESS|tpmc0667183.3.5.5|$hinit^Initial H&E^L||||||||1^H&E|200512121431
OBX|33|CE|PROCESS|tpmc0667183.3.6.6|$hinit^Initial H&E^L||||||||1^H&E|200512121431
OBX|34|CE|PROCESS|tpmc0667183.3.7.7|$hinit^Initial H&E^L||||||||1^H&E|200512121431
OBX|35|CE|PROCESS|tpmc0667183.3.8.8|$hinit^Initial H&E^L||||||||1^H&E|200512121431
OBX|36|CE|PROCESS|tpmc0667183.3.9.9|$hinit^Initial H&E^L||||||||1^H&E|200512121431
OBX|37|CE|PROCESS|tpmc0667183.3.10.10|$hinit^Initial H&E^L||||||||1^H&E|200512121431
OBX|38|CE|PROCESS|tpmc0667183.3.11.11|$hinit^Initial H&E^L||||||||1^H&E|200512121431
OBX|39|CE|PROCESS|tpmc0667183.3.12.12|$hinit^Initial H&E^L||||||||1^H&E|200512121431
OBX|40|CE|PROCESS|tpmc0667183.3.13.13|$hinit^Initial H&E^L||||||||1^H&E|200512121431
OBX|41|CE|PROCESS|tpmc0667183.3.14.14|$hinit^Initial H&E^L||||||||1^H&E|200512121431
OBX|42|CE|PROCESS|tpmc0667183.4.15.15|$hinit^Initial H&E^L||||||||1^H&E|200512121431
OBX|43|CE|PROCESS|tpmc0667183.4.16.16|$hinit^Initial H&E^L||||||||1^H&E|200512121431
OBX|44|CE|PROCESS|tpmc0667183.4.17.17|$hinit^Initial H&E^L||||||||1^H&E|200512121431
OBX|45|CE|PROCESS|tpmc0667183.5.18.18|$hinit^Initial H&E^L||||||||1^H&E|200512121431
OBX|46|CE|PROCESS|tpmc0667183.5.19.19|$hinit^Initial H&E^L||||||||1^H&E|200512121431
OBX|47|CE|PROCESS|tpmc0667183.6.20.20|$hinit^Initial H&E^L||||||||1^H&E|200512121431
OBX|48|CE|PROCESS|tpmc0667183.1.1.21|pmc4115^Blank Slide (MW)^L||||||||2^BLANK|200601031433
OBX|49|CE|PROCESS|tpmc0667183.1.1.22|pmc5553^HH&E (HISTO)^L||||||||3^H/E Lv1|200601031433
OBX|50|CE|PROCESS|tpmc0667183.1.1.23|pmc4115^Blank Slide (MW)^L||||||||4^BLANK|200601031433
OBX|51|CE|PROCESS|tpmc0667183.1.1.24|pmc5553^HH&E (HISTO)^L||||||||5^H/E Lv2|200601031433
OBX|52|CE|PROCESS|tpmc0667183.1.1.25|pmc4115^Blank Slide (MW)^L||||||||6^BLANK|200601031433
OBX|53|CE|PROCESS|tpmc0667183.1.1.26|pmc5553^HH&E (HISTO)^L||||||||7^H/E Lv3|200601031433
OBX|54|CE|PROCESS|tpmc0667183.1.1.27|pmc4115^Blank Slide (MW)^L||||||||8^BLANK|200601031433
OBX|55|CE|PROCESS|tpmc0667183.1.1.28|pmc5553^HH&E (HISTO)^L||||||||9^H/E Lv4|200601031433
OBX|56|TX|GDT|tpmc0667183|The specimen is received in 3 parts each labeled with the patient's name.\.br\\.br\It consists of lots and lots of tissue.  It took more than 20 minutes to gross.\.br\||||||F
OBX|57|TX|MDT|tpmc0667183|     SYNOPTIC - PRIMARY UTERINE CERVIX TUMORS: HYSTERECTOMY AND CONIZATION\.br\TUMOR TYPE:      Squamous cell carcinoma\.br\     Squamous intraepithelial lesion (SIL)\.br\HISTOLOGIC GRADE:      Well differentiated\.br\     Low grade squamous intraepithelial lesion (LSIL)\.br\TUMOR SIZE:      Maximum dimension:  8 cm\.br\TUMOR LOCATION:      Ectocervix\.br\DEPTH OF INVASION:      1/3 of cervical thickness\.br\TUMOR THICKNESS:      Tumor thickness:  20 mm\.br\HORIZONTAL SPREAD:      Horizontal Spread:  8 cm.\.br\EXTENSION OF TUMOR  (invasive neoplasias only):      Extension of Tumor:  fd\.br\STRUCTURES INVOLVED:      Parametrium, Upper 2/3 of vagina\.br\KOILOCYTES:      Present\.br\INTRAGLANDULAR INVOLVEMENT BY SIL:      Present\.br\NON-NEOPLASTIC UTERUS:      Endometriosis\.br\MARGINS OF RESECTION:      Vaginal margin is negative for tumor\.br\MITOTIC RATE:      Mitotic rate: 5 / 10 HPF\.br\ANGIOLYMPHATIC INVASION:      No angiolymphatic invasion\.br\LYMPH NODES POSITIVE:      Number of lymph nodes positive: 0\.br\LYMPH NODES EXAMINED:      Total number of lymph nodes examined: 10\.br\LYMPH NODE GROUPS INVOLVED:      Paracervical lymph nodes, Right, Paracervical lymph nodes, Left, Obturator lymph nodes, Right, Obturator lymph nodes, Left, Internal iliac lymph nodes, Right, Internal iliac lymph nodes, Left\.br\EXTRANODAL EXTENSION:      No\.br\T STAGE, PATHOLOGIC:      pT1a2\.br\N STAGE, PATHOLOGIC:      pN0\.br\M STAGE, PATHOLOGIC:      pM0\.br\FIGO STAGE:      III\.br\RESIDUAL TUMOR:      R0\.br\--------------------------------------------------------\.br\Looked at the slides     \.br\||||||F
OBX|58|TX|FIN|tpmc0667183|She has cancer.\.br\||||||F
OBX|59|CE|IMP|tpmc0667183|M80003^^SNO||||||||1||A
OBX|60|CE|IMP|tpmc0667183|V10.43^^ICD||||||||1

MSH|^~\&|CoPathPlus|X|caBIG||20060210135109||ORU^R01|1000000004509|P|2.3
PID|1||222222-00^^^RG|tpmc4670494|TESTVTWOFIVE^MW TWO||19671118|F||W|||||||||145-45-4545|||||||||||N
PV1|1||MWCYT||||505079^PLANET^PLUTO||||||||||pmc48361^PLANET^PLUTO|MWO|45454545|||||||||||||||||||||||||200511210740
ORC|RE||MWS05-108^CoPathPlus||CM||||200512081448|^BROMBERG^DEBORAH||505079^PLANET^PLUTO
OBR|1||MWS05-108^CoPathPlus^tpmc1667183|MWSP^MW Pathology|||200512050000|||||||200512081447|BCW|505079||||^38^Y|-1|200601041125||SP|F|||||||^PARWANI^ANIL|^PARWANI^ANIL
OBX|1|CE|ANT|tpmc1667183.1|BCW^5:00 LB Core Bx w/Calcification^L||||||F||1^1
OBX|2|CE|ANT|tpmc1667183.2|BCWO^5:00 LB Core Bx w/o Calcification^L||||||F||2^2
OBX|3|CE|ANT|tpmc1667183.3|BRNL^Left Breast Tissue, Needle Localization Biopsy^L||||||F||3^3
OBX|4|CE|ANT|tpmc1667183.4|^Left #1 Sentinel Lymph Node^L||||||F||4^4
OBX|5|CE|ANT|tpmc1667183.5|^Left #2 Sentinel Lymph Node^L||||||F||5^5
OBX|6|ST|BLOCK|tpmc1667183.1.1|A||||||||1^A|200512121425
OBX|7|ST|BLOCK|tpmc1667183.2.2|A||||||||1^A|200512121425
OBX|8|ST|BLOCK|tpmc1667183.2.3|B||||||||2^B|200512121425
OBX|9|ST|BLOCK|tpmc1667183.2.4|C||||||||3^C|200512121425
OBX|10|ST|BLOCK|tpmc1667183.3.5|A||||||||1^A|200512121425
OBX|11|ST|BLOCK|tpmc1667183.3.6|B||||||||2^B|200512121425
OBX|12|ST|BLOCK|tpmc1667183.3.7|C||||||||3^C|200512121425
OBX|13|ST|BLOCK|tpmc1667183.3.8|D||||||||4^D|200512121425
OBX|14|ST|BLOCK|tpmc1667183.3.9|E||||||||5^E|200512121425
OBX|15|ST|BLOCK|tpmc1667183.3.10|F||||||||6^F|200512121425
OBX|16|ST|BLOCK|tpmc1667183.3.11|G||||||||7^G|200512121425
OBX|17|ST|BLOCK|tpmc1667183.3.12|H||||||||8^H|200512121425
OBX|18|ST|BLOCK|tpmc1667183.3.13|I||||||||9^I|200512121425
OBX|19|ST|BLOCK|tpmc1667183.3.14|J||||||||10^J|200512121425
OBX|20|ST|BLOCK|tpmc1667183.3.15|K||||||||11^K|200512121425
OBX|21|ST|BLOCK|tpmc1667183.3.16|L||||||||12^L|200512121425
OBX|22|ST|BLOCK|tpmc1667183.3.17|M||||||||13^M|200512121425
OBX|23|ST|BLOCK|tpmc1667183.3.18|N||||||||14^N|200512121425
OBX|24|ST|BLOCK|tpmc1667183.3.19|O||||||||15^O|200512121425
OBX|25|ST|BLOCK|tpmc1667183.4.20|A||||||||1^A|200512121425
OBX|26|ST|BLOCK|tpmc1667183.5.21|A||||||||1^A|200512121425
OBX|27|ST|BLOCK|tpmc1667183.3.22|P||||||||16^P|200512141132
OBX|28|ST|BLOCK|tpmc1667183.3.23|Q||||||||17^Q|200512141132
OBX|29|ST|BLOCK|tpmc1667183.3.24|R||||||||18^R|200512141132
OBX|30|ST|BLOCK|tpmc1667183.3.25|S||||||||19^S|200512141132
OBX|31|ST|BLOCK|tpmc1667183.3.26|T||||||||20^T|200512141132
OBX|32|ST|BLOCK|tpmc1667183.5.27|B||||||||2^B|200512161233
OBX|33|ST|BLOCK|tpmc1667183.5.28|C||||||||3^C|200512161233
OBX|34|CE|PROCESS|tpmc1667183.1.1.1|pmc4115^Blank Slide (MW)^L||||||||1^BLANK|200512121428
OBX|35|CE|PROCESS|tpmc1667183.1.1.2|$hinit^Initial H&E^L||||||||2^H&E Lv1|200512121431
OBX|36|CE|PROCESS|tpmc1667183.1.1.3|pmc4115^Blank Slide (MW)^L||||||||3^BLANK|200512121428
OBX|37|CE|PROCESS|tpmc1667183.1.1.4|pmc5553^HH&E (HISTO)^L||||||||4^H&E Lv2|200512121431
OBX|38|CE|PROCESS|tpmc1667183.1.1.5|pmc4115^Blank Slide (MW)^L||||||||5^BLANK|200512121428
OBX|39|CE|PROCESS|tpmc1667183.1.1.6|pmc5553^HH&E (HISTO)^L||||||||6^H&E Lv3|200512121431
OBX|40|CE|PROCESS|tpmc1667183.1.1.7|pmc4115^Blank Slide (MW)^L||||||||7^BLANK|200512121428
OBX|41|CE|PROCESS|tpmc1667183.1.1.8|pmc5553^HH&E (HISTO)^L||||||||8^H&E Lv4|200512121431
OBX|42|CE|PROCESS|tpmc1667183.2.2.9|pmc4115^Blank Slide (MW)^L||||||||1^BLANK|200512121428
OBX|43|CE|PROCESS|tpmc1667183.2.2.10|$hinit^Initial H&E^L||||||||2^H&E Lv1|200512121431
OBX|44|CE|PROCESS|tpmc1667183.2.2.11|pmc4115^Blank Slide (MW)^L||||||||3^BLANK|200512121428
OBX|45|CE|PROCESS|tpmc1667183.2.2.12|pmc5553^HH&E (HISTO)^L||||||||4^H&E Lv2|200512121431
OBX|46|CE|PROCESS|tpmc1667183.2.2.13|pmc4115^Blank Slide (MW)^L||||||||5^BLANK|200512121428
OBX|47|CE|PROCESS|tpmc1667183.2.2.14|pmc5553^HH&E (HISTO)^L||||||||6^H&E Lv3|200512121431
OBX|48|CE|PROCESS|tpmc1667183.2.2.15|pmc4115^Blank Slide (MW)^L||||||||7^BLANK|200512121428
OBX|49|CE|PROCESS|tpmc1667183.2.2.16|pmc5553^HH&E (HISTO)^L||||||||8^H&E Lv4|200512121431
OBX|50|CE|PROCESS|tpmc1667183.2.3.17|pmc4115^Blank Slide (MW)^L||||||||9^BLANK|200512121428
OBX|51|CE|PROCESS|tpmc1667183.2.3.18|$hinit^Initial H&E^L||||||||10^H&E Lv1|200512121431
OBX|52|CE|PROCESS|tpmc1667183.2.3.19|pmc4115^Blank Slide (MW)^L||||||||11^BLANK|200512121428
OBX|53|CE|PROCESS|tpmc1667183.2.3.20|pmc5553^HH&E (HISTO)^L||||||||12^H&E Lv2|200512121431
OBX|54|CE|PROCESS|tpmc1667183.2.3.21|pmc4115^Blank Slide (MW)^L||||||||13^BLANK|200512121428
OBX|55|CE|PROCESS|tpmc1667183.2.3.22|pmc5553^HH&E (HISTO)^L||||||||14^H&E Lv3|200512121431
OBX|56|CE|PROCESS|tpmc1667183.2.3.23|pmc4115^Blank Slide (MW)^L||||||||15^BLANK|200512121428
OBX|57|CE|PROCESS|tpmc1667183.2.3.24|pmc5553^HH&E (HISTO)^L||||||||16^H&E Lv4|200512121431
OBX|58|CE|PROCESS|tpmc1667183.2.4.25|pmc4115^Blank Slide (MW)^L||||||||17^BLANK|200512121428
OBX|59|CE|PROCESS|tpmc1667183.2.4.26|$hinit^Initial H&E^L||||||||18^H&E Lv1|200512121431
OBX|60|CE|PROCESS|tpmc1667183.2.4.27|pmc4115^Blank Slide (MW)^L||||||||19^BLANK|200512121428
OBX|61|CE|PROCESS|tpmc1667183.2.4.28|pmc5553^HH&E (HISTO)^L||||||||20^H&E Lv2|200512121431
OBX|62|CE|PROCESS|tpmc1667183.2.4.29|pmc4115^Blank Slide (MW)^L||||||||21^BLANK|200512121428
OBX|63|CE|PROCESS|tpmc1667183.2.4.30|pmc5553^HH&E (HISTO)^L||||||||22^H&E Lv3|200512121431
OBX|64|CE|PROCESS|tpmc1667183.2.4.31|pmc4115^Blank Slide (MW)^L||||||||23^BLANK|200512121428
OBX|65|CE|PROCESS|tpmc1667183.2.4.32|pmc5553^HH&E (HISTO)^L||||||||24^H&E Lv4|200512121431
OBX|66|CE|PROCESS|tpmc1667183.3.5.33|$hinit^Initial H&E^L||||||||16^H&E|200512121431
OBX|67|CE|PROCESS|tpmc1667183.3.6.34|$hinit^Initial H&E^L||||||||17^H&E|200512121431
OBX|68|CE|PROCESS|tpmc1667183.3.7.35|$hinit^Initial H&E^L||||||||18^H&E|200512121431
OBX|69|CE|PROCESS|tpmc1667183.3.8.36|$hinit^Initial H&E^L||||||||19^H&E|200512121431
OBX|70|CE|PROCESS|tpmc1667183.3.9.37|$hinit^Initial H&E^L||||||||20^H&E|200512121431
OBX|71|CE|PROCESS|tpmc1667183.3.10.38|$hinit^Initial H&E^L||||||||1^H&E|200512121431
OBX|72|CE|PROCESS|tpmc1667183.3.11.39|$hinit^Initial H&E^L||||||||2^H&E|200512121431
OBX|73|CE|PROCESS|tpmc1667183.3.12.40|$hinit^Initial H&E^L||||||||3^H&E|200512121431
OBX|74|CE|PROCESS|tpmc1667183.3.13.41|$hinit^Initial H&E^L||||||||4^H&E|200512121431
OBX|75|CE|PROCESS|tpmc1667183.3.14.42|$hinit^Initial H&E^L||||||||5^H&E|200512121431
OBX|76|CE|PROCESS|tpmc1667183.3.15.43|$hinit^Initial H&E^L||||||||6^H&E|200512121431
OBX|77|CE|PROCESS|tpmc1667183.3.16.44|$hinit^Initial H&E^L||||||||7^H&E|200512121431
OBX|78|CE|PROCESS|tpmc1667183.3.17.45|$hinit^Initial H&E^L||||||||8^H&E|200512121431
OBX|79|CE|PROCESS|tpmc1667183.3.18.46|$hinit^Initial H&E^L||||||||9^H&E|200512121431
OBX|80|CE|PROCESS|tpmc1667183.3.19.47|$hinit^Initial H&E^L||||||||10^H&E|200512121431
OBX|81|CE|PROCESS|tpmc1667183.4.20.48|$hinit^Initial H&E^L||||||||1^H&E|200512121431
OBX|82|CE|PROCESS|tpmc1667183.5.21.49|$hinit^Initial H&E^L||||||||1^H&E|200512121431
OBX|83|CE|PROCESS|tpmc1667183.3.22.50|$hinit^Initial H&E^L||||||||11^H&E|200601031433
OBX|84|CE|PROCESS|tpmc1667183.3.23.51|$hinit^Initial H&E^L||||||||12^H&E|200601031433
OBX|85|CE|PROCESS|tpmc1667183.3.24.52|$hinit^Initial H&E^L||||||||13^H&E|200601031433
OBX|86|CE|PROCESS|tpmc1667183.3.25.53|$hinit^Initial H&E^L||||||||14^H&E|200601031433
OBX|87|CE|PROCESS|tpmc1667183.3.26.54|$hinit^Initial H&E^L||||||||15^H&E|200601031433
OBX|88|CE|PROCESS|tpmc1667183.1.1.55|pmc0653^Hematoxylin & Eosin Recut (Histo)^L||||||||9^H&E Recut|200512161237
OBX|89|CE|PROCESS|tpmc1667183.5.27.56|$hinit^Initial H&E^L||||||||2^H&E|200601031433
OBX|90|CE|PROCESS|tpmc1667183.5.28.57|$hinit^Initial H&E^L||||||||3^H&E|200601031433
OBX|91|CE|PROCESS|tpmc1667183.1.1.58|pmc0653^Hematoxylin & Eosin Recut (Histo)^L||||||||10^H&E Recut|200512161237
OBX|92|CE|PROCESS|tpmc1667183.2.2.59|pmc0653^Hematoxylin & Eosin Recut (Histo)^L||||||||9^H&E Recut|200512161237
OBX|93|CE|PROCESS|tpmc1667183.2.3.60|pmc0653^Hematoxylin & Eosin Recut (Histo)^L||||||||17^H&E Recut|200512161237
OBX|94|CE|PROCESS|tpmc1667183.2.4.61|pmc0653^Hematoxylin & Eosin Recut (Histo)^L||||||||25^H&E Recut|200512161237
OBX|95|CE|PROCESS|tpmc1667183.3.5.62|pmc0653^Hematoxylin & Eosin Recut (Histo)^L||||||||17^H&E Recut|200512161237
OBX|96|CE|PROCESS|tpmc1667183.3.6.63|pmc0653^Hematoxylin & Eosin Recut (Histo)^L||||||||18^H&E Recut|200512161237
OBX|97|CE|PROCESS|tpmc1667183.3.7.64|pmc0653^Hematoxylin & Eosin Recut (Histo)^L||||||||19^H&E Recut|200512161237
OBX|98|CE|PROCESS|tpmc1667183.3.8.65|pmc0653^Hematoxylin & Eosin Recut (Histo)^L||||||||20^H&E Recut|200512161237
OBX|99|CE|PROCESS|tpmc1667183.3.9.66|pmc0653^Hematoxylin & Eosin Recut (Histo)^L||||||||21^H&E Recut|200512161237
OBX|100|CE|PROCESS|tpmc1667183.3.10.67|pmc0653^Hematoxylin & Eosin Recut (Histo)^L||||||||2^H&E Recut|200512161237
OBX|101|CE|PROCESS|tpmc1667183.3.11.68|pmc0653^Hematoxylin & Eosin Recut (Histo)^L||||||||3^H&E Recut|200512161237
OBX|102|CE|PROCESS|tpmc1667183.3.12.69|pmc0653^Hematoxylin & Eosin Recut (Histo)^L||||||||4^H&E Recut|200512161237
OBX|103|CE|PROCESS|tpmc1667183.3.13.70|pmc0653^Hematoxylin & Eosin Recut (Histo)^L||||||||5^H&E Recut|200512161237
OBX|104|CE|PROCESS|tpmc1667183.3.14.71|pmc0653^Hematoxylin & Eosin Recut (Histo)^L||||||||6^H&E Recut|200512161237
OBX|105|CE|PROCESS|tpmc1667183.3.15.72|pmc0653^Hematoxylin & Eosin Recut (Histo)^L||||||||7^H&E Recut|200512161237
OBX|106|CE|PROCESS|tpmc1667183.3.16.73|pmc0653^Hematoxylin & Eosin Recut (Histo)^L||||||||8^H&E Recut|200512161237
OBX|107|CE|PROCESS|tpmc1667183.3.17.74|pmc0653^Hematoxylin & Eosin Recut (Histo)^L||||||||9^H&E Recut|200512161237
OBX|108|CE|PROCESS|tpmc1667183.3.18.75|pmc0653^Hematoxylin & Eosin Recut (Histo)^L||||||||10^H&E Recut|200512161237
OBX|109|CE|PROCESS|tpmc1667183.3.19.76|pmc0653^Hematoxylin & Eosin Recut (Histo)^L||||||||11^H&E Recut|200512161237
OBX|110|CE|PROCESS|tpmc1667183.3.22.77|pmc0653^Hematoxylin & Eosin Recut (Histo)^L||||||||12^H&E Recut|200512161237
OBX|111|CE|PROCESS|tpmc1667183.3.23.78|pmc0653^Hematoxylin & Eosin Recut (Histo)^L||||||||13^H&E Recut|200512161237
OBX|112|CE|PROCESS|tpmc1667183.3.24.79|pmc0653^Hematoxylin & Eosin Recut (Histo)^L||||||||14^H&E Recut|200512161237
OBX|113|CE|PROCESS|tpmc1667183.3.25.80|pmc0653^Hematoxylin & Eosin Recut (Histo)^L||||||||15^H&E Recut|200512161237
OBX|114|CE|PROCESS|tpmc1667183.3.26.81|pmc0653^Hematoxylin & Eosin Recut (Histo)^L||||||||16^H&E Recut|200512161237
OBX|115|CE|PROCESS|tpmc1667183.4.20.82|pmc0653^Hematoxylin & Eosin Recut (Histo)^L||||||||2^H&E Recut|200512161237
OBX|116|CE|PROCESS|tpmc1667183.5.21.83|pmc0653^Hematoxylin & Eosin Recut (Histo)^L||||||||2^H&E Recut|200512161237
OBX|117|CE|PROCESS|tpmc1667183.5.27.84|pmc0653^Hematoxylin & Eosin Recut (Histo)^L||||||||3^H&E Recut|200512161237
OBX|118|CE|PROCESS|tpmc1667183.5.28.85|pmc0653^Hematoxylin & Eosin Recut (Histo)^L||||||||4^H&E Recut|200512161237
OBX|119|TX|GDT|tpmc1667183|The specimen is received in numerous parts all appropriately labeled.       \.br\||||||F
OBX|120|TX|MDT|tpmc1667183|Slides reviewed.\.br\||||||F
OBX|121|TX|FIN|tpmc1667183|ATYPICAL DUCTAL HYPERPLASIA\.br\\.br\Immunostains for the Her2/Neu oncoprotein, Estrogen receptor, and Progesterone receptor have been ordered.  Results will be reported in an addendum. \.br\||||||F
OBX|122|CE|IMP|tpmc1667183|M72000^^SNO||||||||1||A
OBX|123|CE|IMP|tpmc1667183|E8550^^SNO||||||||1||A

MSH|^~\&|CoPathPlus|X|caBIG||20060210135109||ORU^R01|1000000004510|P|2.3
PID|1||333333333^^^RR|tst1704394|RUBBLE^BARNEY^R||19560304|M|||||||||||333-33-3333|||||||||||N
PV1|1||C1017RR^10C 8-1||||505075^PLANET^JUPITER||||||||||pmc08361^PLANET^JUPITER|I|1234333333333|||||||||||||||||||||||||200503151514
ORC|RE||PHS05-109^CoPathPlus||CM||||200506291429|z196^DEVINE^LISA||505075^PLANET^JUPITER
OBR|1||PHS05-109^CoPathPlus^tst8807183|PHSP^PH Surgical Pathology|||200506291427|||||||200506291427|VALV|505075||||^49^Y|-1|200507051756||SP|F|||||||987654^PATHOID^DOCTOR|z196^DEVINE^LISA
OBX|1|CE|ANT|tst8807183.1|VALV^Aortic valve^L||||||F||1^1
OBX|2|CE|ANT|tst8807183.2|AAA^Ascending aortic aneurysm^L||||||F||2^2
OBX|3|ST|BLOCK|tst8807183.1.1|A||||||||1^A|200507221753
OBX|4|ST|BLOCK|tst8807183.2.2|A||||||||1^A|200507221753
OBX|5|ST|BLOCK|tst8807183.1.3|B||||||||2^B|200507221753
OBX|6|CE|PROCESS|tst8807183.1.1.1|$hinit^Initial H&E^L||||||||2^H&E|200508180859
OBX|7|CE|PROCESS|tst8807183.2.2.2|$hinit^Initial H&E^L||||||||1^H&E|200508180859
OBX|8|CE|PROCESS|tst8807183.1.1.3|pmc2233^Acid Fast Stain (Histo)^L||||||||3^AcidFast|200512191038
OBX|9|CE|PROCESS|tst8807183.1.3.4|$hinit^Initial H&E^L||||||||4^H&E|200508180859
OBX|10|CE|PROCESS|tst8807183.1.3.5|pmc2233^Acid Fast Stain (Histo)^L||||||||5^AcidFast|200512191038
OBX|11|CE|PROCESS|tst8807183.1.1.6|pmc2233^Acid Fast Stain (Histo)^L||||||||4^AcidFast|200512191038
OBX|12|CE|PROCESS|tst8807183.1.3.7|pmc9333^Giemsa Stain (Histo)^L||||||||6^Giemsa|200512191038
OBX|13|CE|PROCESS|tst8807183.1.3.8|pmc0653^Hematoxylin & Eosin Recut (Histo)^L||||||||7^H&E Recut|200601132341
OBX|14|CE|PROCESS|tst8807183.1.0.9|pmc3904^Eber Probe for EBV mRNA (PHIS)^L||||||||1^EBER Probe|200506291603
OBX|15|CE|PROCESS|tst8807183.1.0.10|pmc7873^In situ Blank Slide (IPEX) (WLO)^L||||||||2^IBNKNC|200601132341
OBX|16|TX|GDT|tst8807183|specimen is mid-unfixed in two parts.\.br\\.br\Part 1 is identified as "aortic valve" and is labeled with the patient's name and initials JLM. Received are two, opaque,calcific, yellow, semi-lunar, cardiac valve cusps 3.6 x 1.6 x 0.5 cm and 3.0 x 1.5 x 0.2 cm.  A representative cross-section of each cusp is submitted after decalcification labeled 1A.\.br\\.br\Part 2 is identified as "ascending aortic aneurysm" and is labeled with the patient's name and initials JLM.  Received are three, unoriented excisions of rubbery, arterial vascular tissue 10.0 x 2.6 x 0.3 cm in aggregate.  The intimal surfaces are smooth and uniformly yellow.  The adventitial surfaces are grossly hemorrhagic.  Representative tissue is submitted in one cassette labeled 2A.\.br\HAS  \.br\||||||F
OBX|17|TX|MDT|tst8807183|\.br\||||||F
OBX|18|TX|FIN|tst8807183|CARDIOMYOPATHY\.br\\.br\||||||F
OBX|19|CE|IMP|tst8807183|D7100^^SNO||||||||1||A
OBX|20|CE|IMP|tst8807183|380.12^^ICD||||||||1

MSH|^~\&|CoPathPlus|X|caBIG||20060210135109||ORU^R01|1000000004511|P|2.3
PID|1||123456790^^^RR|tpmc5198394|TESTVTWOFIVE^BARBARA||19501215|F||||||||||||||||||||||N
PV1|1||PPAT||||^PLANET^VENUS||||||||||pmc28361^PLANET^NEPTUNE|OSD|0244276653054|||||||||||||||||||||||||200512011506
ORC|RE||MWS05-109^CoPathPlus||CM||||200512091316|^LASSIGE^KAREN||^PLANET^VENUS
OBR|1||MWS05-109^CoPathPlus^tpmc0767183|MWSP^MW Pathology|||200512091349|||||||200512091349|BRSEGMW|||||^55^Y|-1|200512091444||SP|F|||||||987654^PATHOID^DOCTOR|987654^PATHOID^DOCTOR
OBX|1|CE|ANT|tpmc0767183.2|BRSEGMW^Breast, Segmental Biopsy^L||||||F||1^1
OBX|2|TX|GDT|tpmc0767183|The specimen is received unfixed labeled with the patient's name, initials RC and "right segmental mastectomy tissue-new posteriorl margin".  It consists of a 6.0 x 5.5 x 1.4 cm oriented portion of pink-yellow fibrofatty tissue.  The medial aspect is dense and indurated, grossly consistent with a previous excision site.  Margins are inked and the specimen is serially sectioned from superior to inferior.  Cut surfaces show predominantly yellow lobular adipose and scant pink-white fibrous tissue.  No lesions or nodules are seen grossly.  The specimen is submitted entirely from superior to inferior in sequential cut sections as follows:\.br\A- two slices\.br\B- one slice\.br\C- one slice\.br\D- one slice\.br\E- one slice\.br\F-G- one slice\.br\H-I- one slice\.br\J-K- one slice\.br\L-N- one slice\.br\O-P- one slice\.br\Q- one slice. \.br\Inking Key:  red-superior, orange-anterior, yellow-lateral, green-inferior, blue-medial, black-posterior.\.br\||||||F
OBX|3|TX|MDT|tpmc0767183|     SYNOPTIC - PRIMARY INVASIVE CARCINOMA OF BREAST\.br\LATERALITY:      Right\.br\PROCEDURE:      Segmental\.br\LOCATION:      Not specified\.br\SIZE OF TUMOR:      Maximum dimension invasive component:  0 cm\.br\MULTICENTRICITY/MULTIFOCALITY OF INVASIVE FOCI: \.br\     No\.br\TUMOR TYPE (invasive component): \.br\     Ductal adenocarcinoma, NOS\.br\ANGIOLYMPHATIC INVASION:      No\.br\DERMAL LYMPHATIC INVASION:      Not applicable\.br\CALCIFICATION:      No\.br\TUMOR TYPE, IN SITU:      Papillary\.br\     Ductal carcinoma in situ, multifocal\.br\SURGICAL MARGINS INVOLVED BY INVASIVE COMPONENT: \.br\     No\.br\SURG MARGINS INVOLVED BY IN SITU COMPONENT: \.br\     No\.br\PAGET'S DISEASE OF NIPPLE:      No\.br\LYMPH NODES EXAMINED:      0\.br\METHOD(S) OF LYMPH NODE EXAMINATION: \.br\     Other: none\.br\SENTINEL NODE METASTASIS:      No\.br\ONLY KERATIN POSITIVE CELLS ARE PRESENT: \.br\     No\.br\T STAGE, PATHOLOGIC:      pT0\.br\N STAGE, PATHOLOGIC:      pN0(i-)\.br\M STAGE, PATHOLOGIC:      pM0\.br\ESTROGEN RECEPTORS:      unknown\.br\PROGESTERONE RECEPTORS:      unknown\.br\HER2/NEU:      zero or 1+\.br\--------------------------------------------------------\.br\Microscopic examination substantiates the above diagnosis.\.br\||||||F
OBX|4|CE|IMP|tpmc0767183|280.9^^ICD||||||||1

MSH|^~\&|CoPathPlus|X|caBIG||20060210135109||ORU^R01|1000000004512|P|2.3
PID|1||110000000^^^SYSPATH|tst2187394|Patient^110||19450526|F||W||||||||||||||||||||N
PV1|1||ILAB||||^JUKIC^DRAZEN||||||||||pmc72782^JUKIC^DRAZEN|SY2|1100000000000|||||||||||||||||||||||||200506291139
ORC|RE||PVS05-110^CoPathPlus||CM||||200506291249|z40^KOKAL^ELLEN||^JUKIC^DRAZEN
OBR|1||PVS05-110^CoPathPlus^tst6807183|PVAP^PV Pathology|||200506291248|||||||200506291248|BLADBIO|||||^60^Y|-1|200601041120||SP|C|||||||^PARWANI^ANIL|^PARWANI^ANIL
OBX|1|CE|ANT|tst6807183.1|BLADBIO^Bladder Tumor^L||||||C||1^1
OBX|2|ST|BLOCK|tst6807183.1.1|A||||||||1^A|200510251135
OBX|3|CE|PROCESS|tst6807183.1.1.1|$hinit^Initial H&E^L||||||||1^H&E L1|200512191445
OBX|4|CE|PROCESS|tst6807183.1.1.2|pmc5553^HH&E (HISTO)^L||||||||2^H&E L2|200512191445
OBX|5|TX|GDT|tst6807183|The specimen is received appropriately identified with the patient' s name and medical record number.  It is received in formalin and is labeled "bladder tumor".  It consists of two irregular fragments of pale brown soft tissue, the larger measuring 0.8 x 0.5 x 0.2 cm and the smaller measuring 0.3 x 0.3 x 0.2 cm.  The entire specimen is submitted in cassette labeled A.\.br\||||||C
OBX|6|TX|FIN|tst6807183|PART 1: URINARY BLADDER, "TUMOR", TURBT-\.br\A.          HIGH GRADE PAPILLARY UROTHELIAL CARICOMA WITH FOCAL AREA SUSPICIOUS FOR INVASION INTO LAMINA PROPRIA (See Comment).\.br\B.     DETRUSOR MUSCLE IS NOT PRESENT FOR EVALUATION.\.br\\.br\COMMENT:\.br\There is a suspicious area where individual tumor cells are present in the lamina propria.  This is suspicious but not definite for invasion into lamina propria and may be due to tangential sectioning and processing artifacts.\.br\||||||C

MSH|^~\&|CoPathPlus|X|caBIG||20060210135109||ORU^R01|1000000004513|P|2.3
PID|1||357159258^^^UPCMWH|tpmc6250305|SMITH^DANA^A||19660529|F|||||||||||357-15-9258|||||||||||N
PV1|1||PATHOS||||505074^PLANET^MARS||||||||||pmc97361^PLANET^MARS|OSD|0002357159258|||||||||||||||||||||||||200512211523
ORC|RE||MWS05-112^CoPathPlus||CM||||200512211630|^FRANCIS^DANA||505074^PLANET^MARS
OBR|1||MWS05-112^CoPathPlus^tpmc2477183|MWSP^MW Pathology|||200512211603|||||||200512211603|BRE|505074||||^39^Y|-1|200512221112||SP|F|||||||987654^PATHOID^DOCTOR|987654^PATHOID^DOCTOR
OBX|1|CE|ANT|tpmc2477183.1|BRE^RT 3:00 Breast, Excisional Biopsy^L||||||F||1^1
OBX|2|ST|BLOCK|tpmc2477183.1.1|A||||||||1^A|200512211610
OBX|3|ST|BLOCK|tpmc2477183.1.2|B||||||||2^B|200512211613
OBX|4|ST|BLOCK|tpmc2477183.1.3|C||||||||3^C|200512211613
OBX|5|CE|PROCESS|tpmc2477183.1.1.1|$hinit^Initial H&E^L||||||||1^H&E|200601031433
OBX|6|CE|PROCESS|tpmc2477183.1.2.2|$hinit^Initial H&E^L||||||||1^H&E|200601031433
OBX|7|CE|PROCESS|tpmc2477183.1.3.3|$hinit^Initial H&E^L||||||||1^H&E|200601031433
OBX|8|CE|PROCESS|tpmc2477183.1.0.4|pmc7764^Frozen Sect Single Block (Surg)^L||||||||1^FRZ Single|200601031433
OBX|9|TX|GDT|tpmc2477183|The specimen is received in formalin labeled with the patient's name, initials AD and "right breast at 3 o'clock".  It consists of a 3.0 x 2.8 x 0.6 cm aggregate of minimally hemorrhagic tan-yellow irregular soft tissue fragments. The specimen is submitted entirely in cassettes A and B.\.br\||||||F
OBX|10|TX|MDT|tpmc2477183|Microscopic examination substantiates the above diagnosis.\.br\||||||F
OBX|11|TX|FIN|tpmc2477183|BREAST, RIGHT 3 O'CLOCK, MRI GUIDED CORE BIOPSY \.br\A.MIXED NFILTRATING CARCINOMA, WITH DUCTAL(NUCLEAR GRADE 3) AND PLEOMORPHIC LOBULAR CARCINOMA TYPES ( SEE COMMENT)\.br\B.DUCTAL CARCINOMA IN-SITU, CRIBRIFORM TYPE WITH ASSOCIATED WITH COMEDONECROSIS, NUCLEAR GRADE 3 (See comment).\.br\C.LOBULAR CARCINOMA-IN-SITU\.br\D.MICROCALCIFICATIONS ASSOCIATED WITH IN-SITU AS WELL AS INVASIVE COMPONENTS.\.br\||||||F
OBX|12|CE|IMP|tpmc2477183|M80102^^SNO||||||||1||A
OBX|13|CE|IMP|tpmc2477183|M82013^^SNO||||||||1||A
OBX|14|CE|IMP|tpmc2477183|M85003^^SNO||||||||1||A
OBX|15|CE|IMP|tpmc2477183|M85202^^SNO||||||||1||A
OBX|16|CE|IMP|tpmc2477183|P1140^^SNO||||||||1||A
OBX|17|CE|IMP|tpmc2477183|T04020^^SNO||||||||1||A
OBX|18|CE|IMP|tpmc2477183|M55400^^SNO||||||||1||A
OBX|19|CE|IMP|tpmc2477183|V65.9^^ICD||||||||1
OBR|2||tpmc2477183^CoPathPlus^tpmc2477183.P1|FISH^FISH (PCL)||||||||||200512221110|||||||1|200512221110||SP|F|||||||^LASSIGE^KAREN|^LASSIGE^KAREN
OBX|1|TX|PIN|tpmc2477183|No amplification of the HER-2/NEU gene was seen by interphase FISH analysis.\.br\\.br\RESULTS:\.br\\.br\Fluorescence in situ hybridization (FISH) analysis was performed on MWH Surgical  MWS05-112  , Block A (Breast Cancer) using the DNA probe for the HER-2/NEU gene (Vysis, Inc., lot 1234321).  The ratio of HER-2/NEU signals to chromosome 17 centromere signals was determined to be 1.3.  A ratio of 2.2 or greater is considered to be amplified; therefore, this specimen is not amplified.\.br\\.br\||||||F

MSH|^~\&|CoPathPlus|X|caBIG||20060210135109||ORU^R01|1000000004514|P|2.3
PID|1||333333333^^^RR|tst1704394|RUBBLE^BARNEY^R||19560304|M|||||||||||333-33-3333|||||||||||N
PV1|1||C1017RR^10C 8-1||||505075^PLANET^JUPITER||||||||||pmc08361^PLANET^JUPITER|I|1234333333333|||||||||||||||||||||||||200503151514
ORC|RE||PHS05-112^CoPathPlus||CM||||200506291433|z196^DEVINE^LISA||505075^PLANET^JUPITER
OBR|1||PHS05-112^CoPathPlus^tst0907183|PHSP^PH Surgical Pathology|||200506291432|||||||200506291432|VALV|505075||||^49^Y|-1|200507051758||SP|F||||||||z196^DEVINE^LISA
OBX|1|CE|ANT|tst0907183.1|VALV^Aortic valve^L||||||F||1^1
OBX|2|CE|ANT|tst0907183.2|AAA^Ascending aortic aneurysm^L||||||F||2^2
OBX|3|ST|BLOCK|tst0907183.1.1|A||||||||1^A|200507221753
OBX|4|ST|BLOCK|tst0907183.2.2|A||||||||1^A|200507221753
OBX|5|ST|BLOCK|tst0907183.1.3|B||||||||2^B|200507221753
OBX|6|ST|BLOCK|tst0907183.1.4|C||||||||3^C|200507221753
OBX|7|CE|PROCESS|tst0907183.1.1.1|$hinit^Initial H&E^L||||||||1^H&E|200508180859
OBX|8|CE|PROCESS|tst0907183.2.2.2|$hinit^Initial H&E^L||||||||1^H&E|200508180859
OBX|9|CE|PROCESS|tst0907183.1.3.3|$hinit^Initial H&E^L||||||||3^H&E|200508180859
OBX|10|CE|PROCESS|tst0907183.1.4.4|$hinit^Initial H&E^L||||||||3^H&E|200508180859
OBX|11|CE|PROCESS|tst0907183.1.4.5|pmc9333^Giemsa Stain (Histo)^L||||||||4^Giemsa|200506291552
OBX|12|CE|PROCESS|tst0907183.2.2.6|pmc1333^Congo Red Stain (Histo)^L||||||||2^CongoRed|200512191038
OBX|13|CE|PROCESS|tst0907183.2.2.7|pmc0653^Hematoxylin & Eosin Recut (Histo)^L||||||||3^H&E Recut|200601132341
OBX|14|TX|GDT|tst0907183|The specimen is mid-unfixed in two parts.\.br\\.br\Part 1 is identified as "aortic valve" and is labeled with the patient's name and initials JLM. Received are two, opaque, rubbery to calcific, yellow, semi-lunar, cardiac valve cusps 3.6 x 1.6 x 0.5 cm and 3.0 x 1.5 x 0.2 cm.  A representative cross-section of each cusp is submitted after decalcification labeled 1A.\.br\\.br\Part 2 is identified as "ascending aortic aneurysm" and is labeled with the patient's name and initials JLM.  Received are three, unoriented excisions of rubbery, arterial vascular tissue 10.0 x 2.6 x 0.3 cm in aggregate.  The intimal surfaces are smooth and uniformly yellow.  The adventitial surfaces are grossly hemorrhagic.  Representative tissue is submitted in one cassette labeled 2A.\.br\\.br\Part 3 is not finished\.br\HAS\.br\||||||F
OBX|15|TX|MDT|tst0907183|     SYNOPTIC - PRIMARY OVARIAN TUMORS INCLUDING BORDERLINE TUMORS\.br\TUMOR LOCATION:      Right\.br\PROCEDURE:      Salpingo-oophorectomy\.br\TUMOR SIZE:      Maximum dimension:  7 cm\.br\TUMOR TYPE:      Papillary serous carcinoma\.br\HISTOLOGIC SILVERBERG GRADE:      Moderately differentiated (6-7 pts)\.br\     ARCHITECTURAL PATTERN:           Papillary (2)\.br\     CYTOLOGIC ATYPIA:           Moderate (2)\.br\     MITOTIC COUNTS / 10hpf:           10-24 (2)\.br\VASCULAR INVASION:      Yes\.br\TUMOR CAPSULE:      Ruptured\.br\SURFACE IMPLANTS:      Invasive\.br\SURFACE IMPLANT SITE:      Fallopian Tubes\.br\SURFACE IMPLANT SIZE:      < 2 cm.\.br\ASSOCIATED OTHER LESION:      Atypical endometriosis\.br\MALIGNANT CELLS IN ASCITES OR\.br\PERITONEAL WASHING:      No\.br\LYMPH NODES EXAMINED:      Total number of lymph nodes examined: 23\.br\LYMPH NODES POSITIVE:      Number of positive lymph nodes, Right: 7\.br\     Number of positive lymph nodes, Left: 1\.br\LYMPH NODE GROUPS INVOLVED:      Pelvic, Right, Pelvic, Left, Obturator, Right, Obturator, Left, Common iliac, Right\.br\EXTRANODAL EXTENSION:      Yes\.br\T STAGE, PATHOLOGIC:      pT1c\.br\N STAGE, PATHOLOGIC:      pN1\.br\M STAGE, PATHOLOGIC:      pM1\.br\FIGO STAGE:      IIC\.br\--------------------------------------------------------\.br\Blue cells\.br\||||||F
OBX|16|TX|FIN|tst0907183|AORTIC VALVE REPLACEMENT\.br\||||||F
OBX|17|CE|IMP|tst0907183|P1279^^SNO||||||||1||A
OBX|18|CE|IMP|tst0907183|T39000^^SNO||||||||1||A
OBX|19|CE|IMP|tst0907183|380.12^^ICD||||||||1

MSH|^~\&|CoPathPlus|X|caBIG||20060210135109||ORU^R01|1000000004515|P|2.3
PID|1||333333333^^^RR|tst1704394|RUBBLE^BARNEY^R||19560304|M|||||||||||333-33-3333|||||||||||N
PV1|1||C1017RR^10C 8-1||||505075^PLANET^JUPITER||||||||||pmc08361^PLANET^JUPITER|I|1234333333333|||||||||||||||||||||||||200503151514
ORC|RE||PHS05-113^CoPathPlus||CM||||200506291434|z196^DEVINE^LISA||505075^PLANET^JUPITER
OBR|1||PHS05-113^CoPathPlus^tst1907183|PHSP^PH Surgical Pathology|||200506291434|||||||200506291434|VALV|505075||||^49^Y|-1|200507051758||SP|F|||||||987654^PATHOID^DOCTOR|z196^DEVINE^LISA
OBX|1|CE|ANT|tst1907183.1|VALV^Aortic valve^L||||||F||1^1
OBX|2|CE|ANT|tst1907183.2|AAA^Ascending aortic aneurysm^L||||||F||2^2
OBX|3|ST|BLOCK|tst1907183.1.1|A||||||||1^A|200507221753
OBX|4|ST|BLOCK|tst1907183.2.2|A||||||||1^A|200507221753
OBX|5|ST|BLOCK|tst1907183.1.3|B||||||||2^B|200507221753
OBX|6|TX|GDT|tst1907183|The specimen is mid-unfixed in two parts.\.br\\.br\Part 1 is identified as "aortic valve" and is labeled with the patient's name and initials JLM. Received are two, opaque, rubbery to calcific, yellow, semi-lunar, cardiac valve cusps 3.6 x 1.6 x 0.5 cm and 3.0 x 1.5 x 0.2 cm.  A representative cross-section of each cusp is submitted after decalcification labeled 1A.\.br\\.br\Part 2 is identified as "ascending aortic aneurysm" and is labeled with the patient's name and initials JLM.  Received are three, unoriented excisions of rubbery, arterial vascular tissue 10.0 x 2.6 x 0.3 cm in aggregate.  The intimal surfaces are smooth and uniformly yellow.  The adventitial surfaces are grossly hemorrhagic.  Representative tissue is submitted in one cassette labeled 2A.\.br\HAS  \.br\||||||F
OBX|7|TX|MDT|tst1907183|     SYNOPTIC - BREAST NEOADJUVANT TREATMENT\.br\MAXIMUM PREADJUVANT TUMOR SIZE:      Maximum dimension invasive component: 8 cm\.br\TUMOR VOLUME REDUCTION: \.br\     Tumor necrosis: 5%\.br\STROMAL ELASTOSIS/FIBROSIS:      No\.br\HORMONAL THERAPY EFFECT**:      Yes, adjacent non-neoplastic breast tissue shows chemotherapy effect\.br\     Metaplasia\.br\--------------------------------------------------------\.br\ \.br\\.br\||||||F
OBX|8|TX|FIN|tst1907183|CARDIOMYOPATHY\.br\||||||F
OBX|9|CE|IMP|tst1907183|380.12^^ICD||||||||1
OBR|2||tst1907183^CoPathPlus^tst1907183.A1|ADD^Addendum||||||||||200506291540|||||||1|200506291540||SP|F|||||||987654^PATHOID^DOCTOR|z196^DEVINE^LISA
OBX|1|TX|ADX|tst1907183|ME KA MEKA MEKA MEKOW!!! GIVE ME BACK MY LITTER PAN!\.br\||||||F

MSH|^~\&|CoPathPlus|X|caBIG||20060210135109||ORU^R01|1000000004516|P|2.3
PID|1||333333333^^^RR|tst1704394|RUBBLE^BARNEY^R||19560304|M|||||||||||333-33-3333|||||||||||N
PV1|1||C1017RR^10C 8-1||||505075^PLANET^JUPITER||||||||||pmc08361^PLANET^JUPITER|I|1234333333333|||||||||||||||||||||||||200503151514
ORC|RE||PHS05-114^CoPathPlus||CM||||200506291436|z196^DEVINE^LISA||505075^PLANET^JUPITER
OBR|1||PHS05-114^CoPathPlus^tst2907183|PHSP^PH Surgical Pathology|||200506291435|||||||200506291435|VALV|505075||||^49^Y|-1|200507051759||SP|F|||||||987654^PATHOID^DOCTOR|z196^DEVINE^LISA
OBX|1|CE|ANT|tst2907183.1|VALV^Aortic valve^L||||||F||1^1
OBX|2|CE|ANT|tst2907183.2|AAA^Ascending aortic aneurysm^L||||||F||2^2
OBX|3|ST|BLOCK|tst2907183.1.1|A||||||||1^A|200507221753
OBX|4|ST|BLOCK|tst2907183.2.2|A||||||||1^A|200507221753
OBX|5|ST|BLOCK|tst2907183.1.3|B||||||||2^B|200507221753
OBX|6|CE|PROCESS|tst2907183.1.1.1|$hinit^Initial H&E^L||||||||1^H&E|200508180859
OBX|7|CE|PROCESS|tst2907183.2.2.2|$hinit^Initial H&E^L||||||||1^H&E|200508180859
OBX|8|TX|GDT|tst2907183|The specimen is mid-unfixed in two parts.\.br\\.br\Part 1 is identified as "huge booger" and is labeled with the patient's name and initials JLM. Received are two, opaque, to calcific, yellow, semi-lunar, cardiac valve cusps 3.6 x 1.6 x 0.5 cm and 3.0 x 1.5 x 0.2 cm.  A representative cross-section of each cusp is submitted after decalcification labeled 1A.\.br\\.br\Part 2 is identified as "ascending aortic pimple" and is labeled with the patient's name and initials JLM.  Received are free, unoriented excisions of chubby, arterial vascular tissue 10.0 x 2.6 x 0.3 cm in aggregate.  The intimal surfaces are smooth and uniformly boring.  The adventitial surfaces are grossly hemorrhagic.  Representative tissue is submitted in one cassette labeled "What  dis???"2A.\.br\HAS  \.br\||||||F
OBX|9|TX|MDT|tst2907183|     SYNOPTIC DATA - LARYNX RESECTIONS\.br\TYPE OF LARYNGECTOMY:      Hemilaryngectomy\.br\TUMOR LOCATION:      Left, Midline\.br\ATTACHED STRUCTURES:      Neck dissection, Pyriform sinus, Base of tongue, Thyroid\.br\TUMOR LOCATION/SEGMENT:      Supraglottic, Glottic-subglottic (greater than 1 cm subglottic extension)\.br\TUMOR SIZE:      Maximum dimension:  7.2 cm\.br\HISTOLOGIC TYPE OF TUMOR:      Carcinoid or atypical carcinoid\.br\HISTOLOGIC GRADE:      Well differentiated\.br\STRUCTURES INVOLVED BY TUMOR:      Anterior commissure, Paraglottic space\.br\LYMPH NODES POSITIVE:      Number of lymph nodes positive:: 2\.br\LYMPH NODES EXAMINED:      Total number of lymph nodes examined: 1\.br\METASTASES\.br\     Yes\.br\INTRA-PERINEURAL INVASION:      Present\.br\VASCULAR INVASION:      Yes\.br\SURGICAL MARGIN INVOLVEMENT:      Free (2 mm or more)\.br\T STAGE, PATHOLOGIC:      Subglottis, pT4a\.br\N STAGE, PATHOLOGIC:      pN2\.br\M STAGE, PATHOLOGIC:      pM0\.br\--------------------------------------------------------\.br\There are many small cells present ..... \.br\\.br\||||||F
OBX|10|TX|FIN|tst2907183|CARDIOMYOPATHY\.br\||||||F
OBX|11|CE|IMP|tst2907183|D7100^^SNO||||||||1||A
OBX|12|CE|IMP|tst2907183|380.12^^ICD||||||||1
OBR|2||tst2907183^CoPathPlus^tst2907183.A1|ADD^Addendum||||||||||200506291540|||||||1|200506291540||SP|F|||||||987654^PATHOID^DOCTOR|z196^DEVINE^LISA
OBX|1|TX|ADX|tst2907183|This is an addendum.\.br\||||||F

MSH|^~\&|CoPathPlus|X|caBIG||20060210135109||ORU^R01|1000000004517|P|2.3
PID|1||333333333^^^RR|tst1704394|RUBBLE^BARNEY^R||19560304|M|||||||||||333-33-3333|||||||||||N
PV1|1||C1017RR^10C 8-1||||505075^PLANET^JUPITER||||||||||pmc08361^PLANET^JUPITER|I|1234333333333|||||||||||||||||||||||||200503151514
ORC|RE||PHS05-115^CoPathPlus||CM||||200506291437|z196^DEVINE^LISA||505075^PLANET^JUPITER
OBR|1||PHS05-115^CoPathPlus^tst3907183|PHSP^PH Surgical Pathology|||200506291437|||||||200506291437|VALV|505075||||^49^Y|-1|200507051759||SP|F|||||||987654^PATHOID^DOCTOR|z196^DEVINE^LISA
OBX|1|CE|ANT|tst3907183.1|VALV^Aortic valve^L||||||F||1^1
OBX|2|CE|ANT|tst3907183.2|AAA^Ascending aortic aneurysm^L||||||F||2^2
OBX|3|ST|BLOCK|tst3907183.1.1|A||||||||1^A|200507221753
OBX|4|ST|BLOCK|tst3907183.2.2|A||||||||1^A|200507221753
OBX|5|ST|BLOCK|tst3907183.1.3|B||||||||2^B|200507221753
OBX|6|CE|PROCESS|tst3907183.1.1.1|$hinit^Initial H&E^L||||||||1^H&E|200508180859
OBX|7|CE|PROCESS|tst3907183.2.2.2|$hinit^Initial H&E^L||||||||1^H&E|200508180859
OBX|8|CE|PROCESS|tst3907183.1.3.3|$hinit^Initial H&E^L||||||||9^H&E|200508180859
OBX|9|CE|PROCESS|tst3907183.1.1.4|pmc9333^Giemsa Stain (Histo)^L||||||||2^Giemsa|200512191038
OBX|10|CE|PROCESS|tst3907183.2.2.5|pmc1333^Congo Red Stain (Histo)^L||||||||2^CongoRed|200512191038
OBX|11|CE|PROCESS|tst3907183.2.2.6|pmc0653^Hematoxylin & Eosin Recut (Histo)^L||||||||3^H&E Recut|200601132341
OBX|12|CE|PROCESS|tst3907183.2.2.7|pmc5174^11q, FISH (PHIS)^L||||||||4^I11Q|200506291603
OBX|13|CE|PROCESS|tst3907183.2.2.8|pmc7873^In situ Blank Slide (IPEX) (WLO)^L||||||||5^IBNKNC|200601132341
OBX|14|TX|GDT|tst3907183|The specimen is mid-unfixed in two parts.\.br\\.br\Part 1 is identified as "aortic valve" and is labeled with the patient's name and initials JLM. Received are two, opaque, rubbery to calcific, yellow, semi-lunar, cardiac valve cusps 3.6 x 1.6 x 0.5 cm and 3.0 x 1.5 x 0.2 cm.  A representative cross-section of each cusp is submitted after decalcification labeled 1A.  I am a great pathologist.\.br\\.br\Part 2 is identified as "ascending aortic aneurysm" and is labeled with the patient's name and initials JLM.  Received are three, unoriented excisions of rubbery, arterial vascular tissue 10.0 x 2.6 x 0.3 cm in aggregate.  The intimal surfaces are smooth and uniformly yellow.  The adventitial surfaces are grossly hemorrhagic.  Representative tissue is submitted in one cassette labeled 2A.\.br\HAS  \.br\||||||F
OBX|15|TX|MDT|tst3907183|     SYNOPTIC DATA - PRIMARY LUNG TUMORS\.br\TUMOR LOCATION:      Right Upper Lobe\.br\LUNG SEGMENT(S) INVOLVED:      Superior\.br\PROCEDURE:      Lobectomy\.br\TUMOR SIZE:      Maximum dimension:  5 cm\.br\     Minor dimension: 2 cm\.br\GROSS SATELLITES:      Number of gross satellite lesions: 2\.br\TUMOR TYPE:      Invasive adenocarcinoma\.br\HISTOLOGIC GRADE:      G2, Moderately differentiated\.br\MICROSCOPIC SATELLITES: \.br\EXTRAPULMONARY PARENCHYMAL\.br\EXTENSION/INVASION OF TUMOR:      None identified\.br\ANGIOLYMPHATIC INVASION:      Yes\.br\TUMOR NECROSIS:      > 50%\.br\SURGICAL MARGIN INVOLVEMENT:      Yes\.br\INFLAMMATORY(DESMOPLASTIC) REACTION:      Moderate\.br\N1 LYMPH NODES:      Number of N1 lymph nodes positive:: 4\.br\     Number of N1 lymph nodes examined: 4\.br\EXTRACAPSULAR SPREAD OF N1 METASTASES:      Yes\.br\N2 LYMPH NODE GROUPS INVOLVED:      Level 2R\.br\N2 LYMPH NODES:      Number of N2 lymph nodes positive: 4\.br\     Number of N2 lymph nodes examined: 5\.br\EXTRACAPSULAR SPREAD OF N2 METASTASES:      Yes\.br\UNDERLYING DISEASE(S):      Atypical alveolar hyperplasia\.br\T STAGE, PATHOLOGIC:      pT0\.br\N STAGE, PATHOLOGIC:      pN1\.br\M STAGE, PATHOLOGIC:      pM0\.br\ANCILLARY STUDIES:      Histochemical stains\.br\--------------------------------------------------------\.br\ \.br\\.br\||||||F
OBX|16|TX|FIN|tst3907183|BAD AORTA\.br\||||||F
OBX|17|CE|IMP|tst3907183|T42000^^SNO||||||||1||A
OBX|18|CE|IMP|tst3907183|380.12^^ICD||||||||1
OBR|2||tst3907183^CoPathPlus^tst3907183.A1|ADD^Addendum||||||||||200506291540|||||||1|200506291540||SP|F|||||||987654^PATHOID^DOCTOR|z196^DEVINE^LISA
OBX|1|TX|ADX|tst3907183|Here' s my addendum.  JTE\.br\||||||F

MSH|^~\&|CoPathPlus|X|caBIG||20060210135109||ORU^R01|1000000004518|P|2.3
PID|1||333333333^^^RR|tst1704394|RUBBLE^BARNEY^R||19560304|M|||||||||||333-33-3333|||||||||||N
PV1|1||C1017RR^10C 8-1||||505075^PLANET^JUPITER||||||||||pmc08361^PLANET^JUPITER|I|1234333333333|||||||||||||||||||||||||200503151514
ORC|RE||PHS05-116^CoPathPlus||CM||||200506291439|z196^DEVINE^LISA||505075^PLANET^JUPITER
OBR|1||PHS05-116^CoPathPlus^tst4907183|PHSP^PH Surgical Pathology|||200506291438|||||||200506291438|VALV|505075||||^49^Y|-1|200507051803||SP|F|||||||987654^PATHOID^DOCTOR|z196^DEVINE^LISA
OBX|1|CE|ANT|tst4907183.1|VALV^Aortic valve^L||||||F||1^1
OBX|2|CE|ANT|tst4907183.2|AAA^Ascending aortic aneurysm^L||||||F||2^2
OBX|3|ST|BLOCK|tst4907183.1.1|A||||||||1^A|200507221753
OBX|4|ST|BLOCK|tst4907183.2.2|A||||||||1^A|200507221753
OBX|5|CE|PROCESS|tst4907183.1.1.1|$hinit^Initial H&E^L||||||||1^H&E|200508180859
OBX|6|CE|PROCESS|tst4907183.2.2.2|$hinit^Initial H&E^L||||||||1^H&E|200508180859
OBX|7|CE|PROCESS|tst4907183.1.1.3|pmc5633^Verhoff Van Geison Stain (Histo)^L||||||||2^VVG|200512191038
OBX|8|TX|GDT|tst4907183|The specimen is mid-unfixed in two parts.\.br\\.br\Part 1 is identified as "aortic valve" and is labeled with the patient's name and initials JLM. Received are two, opaque, rubbery to calcific, yellow, semi-lunar, cardiac valve cusps 3.6 x 1.6 x 0.5 cm and 3.0 x 1.5 x 0.2 cm.  A representative cross-section of each cusp is submitted after decalcification labeled 1A.\.br\\.br\Part 2 is identified as "ascending aortic aneurysm" and is labeled with the patient's name and initials JLM.  Received are three, unoriented excisions of rubbery, arterial vascular tissue 10.0 x 2.6 x 0.3 cm in aggregate.  The intimal surfaces are smooth and uniformly yellow.  The adventitial surfaces are grossly hemorrhagic.  Representative tissue is submitted in one cassette labeled 2A.  this is a test for class.\.br\HAS  \.br\||||||F
OBX|9|TX|MDT|tst4907183|\.br\||||||F
OBX|10|CE|IMP|tst4907183|380.12^^ICD||||||||1

MSH|^~\&|CoPathPlus|X|caBIG||20060210135109||ORU^R01|1000000004519|P|2.3
PID|1||333333333^^^RR|tst1704394|RUBBLE^BARNEY^R||19560304|M|||||||||||333-33-3333|||||||||||N
PV1|1||C1017RR^10C 8-1||||505075^PLANET^JUPITER||||||||||pmc08361^PLANET^JUPITER|I|1234333333333|||||||||||||||||||||||||200503151514
ORC|RE||PHS05-119^CoPathPlus||CM||||200507051117|z196^DEVINE^LISA||505075^PLANET^JUPITER
OBR|1||PHS05-119^CoPathPlus^tst0017183|PHSP^PH Surgical Pathology|||200507051117|||||||200507051117|VALV|505075||||^49^Y|-1|200507051806||SP|F|||||||987654^PATHOID^DOCTOR|z196^DEVINE^LISA
OBX|1|CE|ANT|tst0017183.1|VALV^Aortic Valve^L||||||F||1^1
OBX|2|CE|ANT|tst0017183.2|VALV^Ascending aorta^L||||||F||2^2
OBX|3|ST|BLOCK|tst0017183.1.1|A||||||||1^A|200507221753
OBX|4|ST|BLOCK|tst0017183.2.2|A||||||||1^A|200507221753
OBX|5|CE|PROCESS|tst0017183.1.1.1|$hinit^Initial H&E^L||||||||1^H&E|200508180859
OBX|6|CE|PROCESS|tst0017183.2.2.2|$hinit^Initial H&E^L||||||||2^H&E|200508180859
OBX|7|CE|PROCESS|tst0017183.1.1.3|pmc2043^Estrogen Receptor (IPEX)^L||||||||2^AER|200601132341
OBX|8|CE|PROCESS|tst0017183.1.1.4|pmc9133^Vimentin (IPEX)^L||||||||3^Vimentin|200601132341
OBX|9|CE|PROCESS|tst0017183.2.0.5|pmc8243^mRNA Kappa Chn Restr (PHIS)^L||||||||1^IRKAP|200507051556
OBX|10|CE|PROCESS|tst0017183.2.0.6|pmc7873^In situ Blank Slide (IPEX) (WLO)^L||||||||2^IBNKNC|200601132341
OBX|11|CE|PROCESS|tst0017183.1.1.7|pmc1073^Cytomegalovirus (IPEX)^L||||||||4^CMV|200601132341
OBX|12|CE|PROCESS|tst0017183.1.1.8|pmc1333^Congo Red Stain (Histo)^L||||||||5^CongoRed|200512191038
OBX|13|CE|PROCESS|tst0017183.1.1.9|pmc6734^Elastic Trichrome^L||||||||6^ElsTri|200512191038
OBX|14|CE|PROCESS|tst0017183.2.2.10|pmc1073^Cytomegalovirus (IPEX)^L||||||||3^CMV|200601132341
OBX|15|CE|PROCESS|tst0017183.2.2.11|pmc1333^Congo Red Stain (Histo)^L||||||||4^CongoRed|200512191038
OBX|16|CE|PROCESS|tst0017183.2.2.12|pmc6734^Elastic Trichrome^L||||||||5^ElsTri|200512191038
OBX|17|TX|GDT|tst0017183|The specimen is received unfixed in two parts.\.br\Derin caglar\.br\Part 1 is labeled with the patient's name, initials TH and " aortic valve".  The specimen consists of two tan-gray, irregular, rubbery to firm portions of valve tissue measuring 3.5 x 1.5 x 0.4 cm and 4.5 x 2.0 x 0.5 cm.  The walls are thickened and calcified yellow plaquing present.  The wall thickness ranges from 0.1 to 0.5 cm.  Following adequate decalcification representative cross sections are submitted in decal cassette labeled 1A.\.br\\.br\Part 2 is labeled with the patient's name, initials TH and " ascending aorta".  The specimen consists of multiple tan-pink, irregular, rubbery and hemorrhagic portions of vascular tissue measuring 5.5 x 3.5 x 1.5 cm in aggregate.  There is slight separation of layers.  Representative cross sections are submitted in cassette labeled 2A.\.br\mam\.br\||||||F
OBX|18|TX|MDT|tst0017183|Microscopic examination substantiates the above diagnosis.\.br\SD/dme\.br\||||||F
OBX|19|TX|FIN|tst0017183|PART 1: VALVE, AORTIC, REPLACEMENT \.br\PENDING DECALCIFICATION.  ADDENDUM REPORT TO FOLLOW.\.br\\.br\PART 2: AORTA, ASCENDING, REPAIR \.br\VASCULAR TISSUE WITH ADVENTITIAL HEMORRHAGE.\.br\SD/dme\.br\||||||F
OBX|20|CE|IMP|tst0017183|P1279^^SNO||||||||1||A
OBX|21|CE|IMP|tst0017183|T39000^^SNO||||||||1||A
OBX|22|CE|IMP|tst0017183|T42000^^SNO||||||||1||A
OBX|23|CE|IMP|tst0017183|M37000^^SNO||||||||1||A
OBX|24|CE|IMP|tst0017183|T40000^^SNO||||||||1||A
OBX|25|CE|IMP|tst0017183|T42100^^SNO||||||||1||A
OBX|26|CE|IMP|tst0017183|380.12^^ICD||||||||1
OBR|2||tst0017183^CoPathPlus^tst0017183.A1|ADD^Addendum||||||||||200507051535|||||||1|200507051535||SP|F|||||||002150^BARNES^LEON|z196^DEVINE^LISA
OBX|1|TX|ADX|tst0017183|This is an addendum\.br\||||||F
OBR|3||tst0017183^CoPathPlus^tst0017183.A2|ADD^Addendum||||||||||200510171250|||||||2|200510171250||SP|F|||||||MD.AMIN.RA^AMIN^RAJNIKANT|UXD^Cerner^User
OBX|1|TX|ADX|tst0017183|This is the addendum text....  Line one\.br\Line two\.br\Line three\.br\Line four\.br\Line five\.br\Line six\.br\Line seven\.br\Line eight\.br\Line nine\.br\Line ten\.br\Line eleven\.br\||||||F

MSH|^~\&|CoPathPlus|X|caBIG||20060210135109||ORU^R01|1000000004520|P|2.3
PID|1||333333333^^^RR|tst1704394|RUBBLE^BARNEY^R||19560304|M|||||||||||333-33-3333|||||||||||N
PV1|1||C1017RR^10C 8-1||||505075^PLANET^JUPITER||||||||||pmc08361^PLANET^JUPITER|I|1234333333333|||||||||||||||||||||||||200503151514
ORC|RE||PHS05-120^CoPathPlus||CM||||200507051120|z196^DEVINE^LISA||505075^PLANET^JUPITER
OBR|1||PHS05-120^CoPathPlus^tst1017183|PHSP^PH Surgical Pathology|||200507051120|||||||200507051120|VALV|505075||||^49^Y|-1|200507051800||SP|F|||||||987654^PATHOID^DOCTOR|z196^DEVINE^LISA
OBX|1|CE|ANT|tst1017183.1|VALV^Aortic Valve^L||||||F||1^1
OBX|2|CE|ANT|tst1017183.2|VALV^Ascending aorta^L||||||F||2^2
OBX|3|ST|BLOCK|tst1017183.1.1|A||||||||1^A|200507221753
OBX|4|ST|BLOCK|tst1017183.2.2|A||||||||1^A|200507221753
OBX|5|CE|PROCESS|tst1017183.1.1.1|$hinit^Initial H&E^L||||||||1^H&E|200508180859
OBX|6|CE|PROCESS|tst1017183.2.2.2|$hinit^Initial H&E^L||||||||1^H&E|200508180859
OBX|7|CE|PROCESS|tst1017183.1.1.3|pmc3633^Trichrome Stain (Histo)^L||||||||2^Trichrome|200512191038
OBX|8|CE|PROCESS|tst1017183.1.1.4|pmc8233^Gram Stain (Histo)^L||||||||3^Gram|200512191038
OBX|9|CE|PROCESS|tst1017183.2.2.5|pmc9873^Amyloid A (IPEX)^L||||||||2^AAMY|200601132341
OBX|10|CE|PROCESS|tst1017183.2.2.6|pmc0383^Amyloid P (IPEX)^L||||||||3^AAMP|200601132341
OBX|11|CE|PROCESS|tst1017183.2.2.7|pmc0973^amyloid transthyretin prealbumin(IPEX)^L||||||||4^APREA|200601132341
OBX|12|CE|PROCESS|tst1017183.2.2.8|pmc3834^Kappa amyloid (IPEX)^L||||||||5^AKAPY|200601132341
OBX|13|CE|PROCESS|tst1017183.2.2.9|pmc9724^Amyloid lambda (IPEX)^L||||||||6^ALAMY|200601132341
OBX|14|CE|PROCESS|tst1017183.2.2.10|pmc1333^Congo Red Stain (Histo)^L||||||||7^CongoRed|200512191038
OBX|15|CE|PROCESS|tst1017183.2.2.11|pmc6933^HPV Probe Panel (PHIS)^L||||||||8^IHPV|200507051556
OBX|16|CE|PROCESS|tst1017183.2.2.12|pmc7873^In situ Blank Slide (IPEX) (WLO)^L||||||||9^IBNKNC|200601132341
OBX|17|CE|PROCESS|tst1017183.1.1.13|pmc1073^Cytomegalovirus (IPEX)^L||||||||4^CMV|200601132341
OBX|18|CE|PROCESS|tst1017183.1.1.14|pmc1333^Congo Red Stain (Histo)^L||||||||5^CongoRed|200512191038
OBX|19|CE|PROCESS|tst1017183.1.1.15|pmc3633^Trichrome Stain (Histo)^L||||||||6^Trichrome|200512191038
OBX|20|CE|PROCESS|tst1017183.2.2.16|pmc1073^Cytomegalovirus (IPEX)^L||||||||10^CMV|200601132341
OBX|21|CE|PROCESS|tst1017183.2.2.17|pmc1333^Congo Red Stain (Histo)^L||||||||11^CongoRed|200512191038
OBX|22|CE|PROCESS|tst1017183.2.2.18|pmc3633^Trichrome Stain (Histo)^L||||||||12^Trichrome|200512191038
OBX|23|TX|GDT|tst1017183|1.  Aortic Valve:  46,X #,t(1;19)(q23;p13.3)[#]\.br\\.br\Abnormal #male bone marrow chromosome analysis with a translocation between the long arm of one chromosome 1 and the short arm of one chromosome 19.  The translocation, t(1;19)(q23;p13.3) is strongly associated with ALL, pre-B immunological phenotype, but may be found occasionally in T cell ALL.  The 1;19 translocation disrupts the normal functions of the E2A and PBX1 genes, located on band 19p13.3 and 1q23, respectively, and leads to formation of a fusion gene that encodes a hybrid transcription factor with oncogenic potential [Nichols J, Nimer SD (1992) Blood 80:2953-2963; Privitera E et al. (1992) Blood 79:1781-1788].  The prognostic value of this translocation appears to be obscure [Sharma P et al. (2001) Cancer Genet Cytogenet 124:132-136; Uckun F et al. (1998) J Clin Oncol 16:527-535].\.br\\.br\FINAL RESULTS:\.br\\.br\                                            G-Banding        \.br\No. of Cells Analyzed:                 #\.br\No. of Cells Karyotyped:              #\.br\\.br\No. of Chromosomes:     <46     46     >46\.br\No. of Cells:             #       #      #\.br\\.br\# trypsin-Giemsa banded metaphase cells were analyzed from # hour harvests of unstimulated # cell cultures.  # cells had a 46,X#,t(1;19)(q23;p13.3) chromosome complement.  # cells, each with the same abnormality, had hypodiploid karyotypes, likely as a result of random chromosomal loss.\.br\\.br\Average band level/haploid set:     #\.br\46,X #,t(1;19)(q23;p13.3)[#]\.br\\.br\Abnormal #male bone marrow chromosome analysis with a translocation between the long arm of one chromosome 1 and the short arm of one chromosome 19.  The translocation, t(1;19)(q23;p13.3) is strongly associated with ALL, pre-B immunological phenotype, but may be found occasionally in T cell ALL.  The 1;19 translocation disrupts the normal functions of the E2A and PBX1 genes, located on band 19p13.3 and 1q23, respectively, and leads to formation of a fusion gene that encodes a hybrid transcription factor with oncogenic potential [Nichols J, Nimer SD (1992) Blood 80:2953-2963; Privitera E et al. (1992) Blood 79:1781-1788].  The prognostic value of this translocation appears to be obscure [Sharma P et al. (2001) Cancer Genet Cytogenet 124:132-136; Uckun F et al. (1998) J Clin Oncol 16:527-535].\.br\\.br\FINAL RESULTS:\.br\\.br\                                            G-Banding        \.br\No. of Cells Analyzed:                 #\.br\No. of Cells Karyotyped:              #\.br\\.br\No. of Chromosomes:     <46     46     >46\.br\No. of Cells:             #       #      #\.br\\.br\# trypsin-Giemsa banded metaphase cells were analyzed from # hour harvests of unstimulated # cell cultures.  # cells had a 46,X#,t(1;19)(q23;p13.3) chromosome complement.  # cells, each with the same abnormality, had hypodiploid karyotypes, likely as a result of random chromosomal loss.\.br\\.br\Average band level/haploid set:     #\.br\\.br\2.  Ascending aorta:   \.br\The specimen is received unfixed in two parts.\.br\\.br\Part 1 is labeled with the patient's name, initials TH and " aortic valve".  The specimen consists of two tan-gray, irregular, rubbery to firm portions of valve tissue measuring 3.5 x 1.5 x 0.4 cm and 4.5 x 2.0 x 0.5 cm.  The walls are thickened and calcified yellow plaquing present.  The wall thickness ranges from 0.1 to 0.5 cm.  Following adequate decalcification representative cross sections are submitted in decal cassette labeled 1A.\.br\\.br\Part 2 is labeled with the patient's name, initials TH and " ascending aorta".  The specimen consists of multiple tan-pink, irregular, rubbery and hemorrhagic portions of vascular tissue measuring 5.5 x 3.5 x 1.5 cm in aggregate.  There is slight separation of layers.  Representative cross sections are submitted in cassette labeled 2A.\.br\mam\.br\||||||F
OBX|24|TX|MDT|tst1017183|     SYNOPTIC DATA - LARYNX RESECTIONS\.br\TYPE OF LARYNGECTOMY:      Total\.br\TUMOR LOCATION:      Bilateral\.br\ATTACHED STRUCTURES:      Thyroid\.br\TUMOR LOCATION/SEGMENT:      Transglottic\.br\TUMOR SIZE:      Maximum dimension:  3 cm\.br\HISTOLOGIC TYPE OF TUMOR:      Basaloid squamous carcinoma\.br\HISTOLOGIC GRADE:      Poorly differentiated/Undifferentiated\.br\STRUCTURES INVOLVED BY TUMOR:      Vallecula-base of tumor, Thyroid cartilage, Pre-epiglottic space, Paraglottic space\.br\LYMPH NODES POSITIVE:      Number of lymph nodes positive:: 4\.br\LYMPH NODES EXAMINED:      Total number of lymph nodes examined: 4\.br\METASTASES\.br\     Yes\.br\INTRA-PERINEURAL INVASION:      Present\.br\VASCULAR INVASION:      Yes\.br\SURGICAL MARGIN INVOLVEMENT:      Free (2 mm or more)\.br\T STAGE, PATHOLOGIC:      Glottis, pT3\.br\N STAGE, PATHOLOGIC:      pN2b\.br\M STAGE, PATHOLOGIC:      pMX\.br\--------------------------------------------------------\.br\Microscopic examination substantiates the above diagnosis.\.br\SD/dme\.br\||||||F
OBX|25|TX|FIN|tst1017183|PART 1: VALVE, AORTIC, REPLACEMENT \.br\PENDING DECALCIFICATION.  ADDENDUM REPORT TO FOLLOW.\.br\\.br\PART 2: AORTA, ASCENDING, REPAIR \.br\VASCULAR TISSUE WITH ADVENTITIAL HEMORRHAGE.\.br\SD/dme\.br\||||||F
OBX|26|CE|IMP|tst1017183|P1279^^SNO||||||||1||A
OBX|27|CE|IMP|tst1017183|T39000^^SNO||||||||1||A
OBX|28|CE|IMP|tst1017183|T42000^^SNO||||||||1||A
OBX|29|CE|IMP|tst1017183|M37000^^SNO||||||||1||A
OBX|30|CE|IMP|tst1017183|T40000^^SNO||||||||1||A
OBX|31|CE|IMP|tst1017183|T42100^^SNO||||||||1||A
OBX|32|CE|IMP|tst1017183|380.12^^ICD||||||||1
OBR|2||tst1017183^CoPathPlus^tst1017183.A1|ADD^Addendum||||||||||200507051535|||||||1|200507051535||SP|F|||||||987654^PATHOID^DOCTOR|z196^DEVINE^LISA
OBX|1|TX|ADX|tst1017183|This is an addendum for training. Okay.\.br\||||||F

MSH|^~\&|CoPathPlus|X|caBIG||20060210135109||ORU^R01|1000000004522|P|2.3
PID|1||333333333^^^RR|tst1704394|RUBBLE^BARNEY^R||19560304|M|||||||||||333-33-3333|||||||||||N
PV1|1||C1017RR^10C 8-1||||505075^PLANET^JUPITER||||||||||pmc08361^PLANET^JUPITER|I|1234333333333|||||||||||||||||||||||||200503151514
ORC|RE||PHS05-122^CoPathPlus||CM||||200507051126|z196^DEVINE^LISA||505075^PLANET^JUPITER
OBR|1||PHS05-122^CoPathPlus^tst3017183|PHSP^PH Surgical Pathology|||200507051125|||||||200507051125|VALV|505075||||^49^Y|-1|200507051801||SP|C|||||||987654^PATHOID^DOCTOR|z196^DEVINE^LISA
OBX|1|CE|ANT|tst3017183.1|VALV^Aortic Valve^L||||||C||1^1
OBX|2|CE|ANT|tst3017183.2|VALV^Ascending aorta^L||||||C||2^2
OBX|3|ST|BLOCK|tst3017183.1.1|A||||||||1^A|200507221753
OBX|4|ST|BLOCK|tst3017183.2.2|A||||||||1^A|200507221753
OBX|5|CE|PROCESS|tst3017183.1.1.1|$hinit^Initial H&E^L||||||||1^H&E|200508180859
OBX|6|CE|PROCESS|tst3017183.2.2.2|$hinit^Initial H&E^L||||||||1^H&E|200508180859
OBX|7|CE|PROCESS|tst3017183.1.1.3|pmc2043^Estrogen Receptor (IPEX)^L||||||||2^AER|200507051547
OBX|8|CE|PROCESS|tst3017183.1.1.4|pmc9133^Vimentin (IPEX)^L||||||||3^Vimentin|200601132341
OBX|9|CE|PROCESS|tst3017183.2.2.5|pmc8664^I3P (PHIS)^L||||||||2^I3P|200507051556
OBX|10|CE|PROCESS|tst3017183.2.2.6|pmc7873^In situ Blank Slide (IPEX) (WLO)^L||||||||3^IBNKNC|200601132341
OBX|11|CE|PROCESS|tst3017183.2.2.7|pmc0653^Hematoxylin & Eosin Recut (Histo)^L||||||||4^H&E Recut|200601132341
OBX|12|CE|PROCESS|tst3017183.2.2.8|pmc1073^Cytomegalovirus (IPEX)^L||||||||5^CMV|200601132341
OBX|13|CE|PROCESS|tst3017183.2.2.9|pmc1333^Congo Red Stain (Histo)^L||||||||6^CongoRed|200512191038
OBX|14|CE|PROCESS|tst3017183.2.2.10|pmc3633^Trichrome Stain (Histo)^L||||||||7^Trichrome|200512191038
OBX|15|TX|GDT|tst3017183|specimen is received unfixed in two parts.\.br\\.br\Part 1 is labeled with the patient's \.br\[[\E\\E\\.br\\E\\.br\\E\\.br\][;[p' ojhtyfrzaasA\.br\\.br\46,X#,t(11;14)(q13;q32)[#]/46,X#[#]\.br\\.br\Mosaic abnormal #male bone marrow chromosome analysis with an apparently normal cell line and one that has a translocation between the long arms of chromosomes 11 and 14.\.br\\.br\The translocation, t(11;14)(q13;q32) has been seen in advanced stages of multiple myeloma with a very poor prognosis [Lai JL et al. (1998) Cancer Genet Cytogenet 104:133-138].  As a result ofM,,, this translocation in multiple myeloma, the PRAD-1/CCND1 gene at band 11q13 is juxtaposed to an IgH-switch region at band 14q32 [Hallek M et al. (1998) Blood 91:3-21].  Approximately 30% of patients with multiple myeloma, with or without the 11;14 translocation, were shown to have the CCND1 gene amplification [Hoechtlen-Volmar W et al. (2000) Brit J Halematol 109:30-38].\.br\\.br\\.br\FINAL RESULTS:\.br\\.br\                                            G-Banding        \.br\No. of Cells Analyzed:                 #\.br\No. of Cells Karyotyped:              #\.br\\.br\No. of Chromosomes:     <46     46     >46\.br\No. of Cells:             #       #      #\.br\\.br\# trypsin-Giemsa banded metaphase cells were analyzed from # hour harvests of unstimulated # cell cultures.  # cells had an apparently normal male chromosome complement.  # cells had hypodiploid karyotypes, likely as a result of random chromosomal loss.  # cells had a 46,XY,\.br\\.br\\.br\\.br\\.br\\.br\\.br\\.br\\.br\\.br\\.br\\.br\\.br\\.br\\.br\\.br\\.br\\.br\\.br\\.br\\.br\\.br\\.br\\.br\\.br\\.br\\.br\\.br\\.br\\.br\\.br\\.br\\.br\\.br\\.br\\.br\\.br\\.br\\.br\\.br\\.br\\.br\\.br\\.br\\.br\\.br\\.br\\.br\\.br\\.br\\.br\\.br\ls TH and " aortic valve".  The specimen consists of two tan-gray, irregular, rubbery to firm portions of valve tissue measuring 3.5 x 1.5 x 0.4 cm and 4.5 x 2.0 x 0.5 cm.  The walls are thickened and calcified yellow plaquing present.  The wall thickness ranges from 0.1 to 0.5 cm.  Following adequate decalcification representative cross sections are submitted in decal cassette labeled 1A.\.br\\.br\Part 2 is labeled with the patient's name, initials TH and " ascending aorta".  The specimen consists of multiple tan-pink, irregular, rubbery and hemorrhagic portions of vascular tissue measuring 5.5 x 3.5 x 1.5 cm in aggregate.  There is slight separation of layers.  Representative cross sections are submitted in cassette labeled 2A.\.br\mam\.br\||||||C
OBX|16|TX|MDT|tst3017183|     SYNOPTIC DATA - LARYNX RESECTIONS\.br\TYPE OF LARYNGECTOMY:      Hemilaryngectomy\.br\TUMOR LOCATION:      Right\.br\ATTACHED STRUCTURES:      Neck dissection\.br\TUMOR LOCATION/SEGMENT:      Glottic, Subglottic, Glottic-subglottic (greater than 1 cm subglottic extension)\.br\TUMOR SIZE:      Maximum dimension:  2 cm\.br\HISTOLOGIC TYPE OF TUMOR:      Squamous cell carcinoma\.br\HISTOLOGIC GRADE:      Well differentiated\.br\STRUCTURES INVOLVED BY TUMOR:      True cord, Vallecula-base of tumor\.br\LYMPH NODES POSITIVE:      Number of lymph nodes positive:: 5\.br\LYMPH NODES EXAMINED:      Total number of lymph nodes examined: 8\.br\METASTASES\.br\     No\.br\INTRA-PERINEURAL INVASION:      Present\.br\VASCULAR INVASION:      No\.br\SURGICAL MARGIN INVOLVEMENT:      Free (2 mm or more)\.br\T STAGE, PATHOLOGIC:      pTX\.br\N STAGE, PATHOLOGIC:      pNX\.br\M STAGE, PATHOLOGIC:      pMX\.br\--------------------------------------------------------\.br\IIIIIIIIMicroscopic examination substantiates the above diagnosis.\.br\SD/dme\.br\\E\\E\\E\\E\\.br\||||||C
OBX|17|TX|FIN|tst3017183|   PART 1: VALVE, AORTIC, REPLACEMENT \.br\PENDING DECALCIFICATION.  ADDENDUM REPORT TO FOLLOW.\.br\\.br\PART 2: AORTA, ASCENDING, REPAIR \.br\VASCULAR TISSUE WITH ADVENTITIAL HEMORRHAGE.\.br\SD/dme\.br\||||||C
OBX|18|CE|IMP|tst3017183|P1279^^SNO||||||||1||A
OBX|19|CE|IMP|tst3017183|T39000^^SNO||||||||1||A
OBX|20|CE|IMP|tst3017183|T42000^^SNO||||||||1||A
OBX|21|CE|IMP|tst3017183|M37000^^SNO||||||||1||A
OBX|22|CE|IMP|tst3017183|T40000^^SNO||||||||1||A
OBX|23|CE|IMP|tst3017183|T42100^^SNO||||||||1||A
OBX|24|CE|IMP|tst3017183|380.12^^ICD||||||||1

MSH|^~\&|CoPathPlus|X|caBIG||20060210135109||ORU^R01|1000000004523|P|2.3
PID|1||333333333^^^RR|tst1704394|RUBBLE^BARNEY^R||19560304|M|||||||||||333-33-3333|||||||||||N
PV1|1||C1017RR^10C 8-1||||505075^PLANET^JUPITER||||||||||pmc08361^PLANET^JUPITER|I|1234333333333|||||||||||||||||||||||||200503151514
ORC|RE||PHS05-123^CoPathPlus||CM||||200507051142|z196^DEVINE^LISA||505075^PLANET^JUPITER
OBR|1||PHS05-123^CoPathPlus^tst4017183|PHSP^PH Surgical Pathology|||200507051141|||||||200507051141|VALV|505075||||^49^Y|-1|200507051801||SP|C|||||||987654^PATHOID^DOCTOR|z196^DEVINE^LISA
OBX|1|CE|ANT|tst4017183.1|VALV^Aortic Valve^L||||||C||1^1
OBX|2|CE|ANT|tst4017183.2|VALV^Ascending aorta^L||||||C||2^2
OBX|3|ST|BLOCK|tst4017183.1.1|A||||||||1^A|200507221753
OBX|4|ST|BLOCK|tst4017183.2.2|A||||||||1^A|200507221753
OBX|5|CE|PROCESS|tst4017183.1.1.1|$hinit^Initial H&E^L||||||||1^H&E|200508180859
OBX|6|CE|PROCESS|tst4017183.2.2.2|$hinit^Initial H&E^L||||||||1^H&E|200508180859
OBX|7|CE|PROCESS|tst4017183.1.1.3|pmc2043^Estrogen Receptor (IPEX)^L||||||||2^AER|200601132341
OBX|8|CE|PROCESS|tst4017183.1.1.4|pmc9133^Vimentin (IPEX)^L||||||||3^Vimentin|200601132341
OBX|9|CE|PROCESS|tst4017183.2.2.5|pmc9564^I8 (PHIS)^L||||||||2^I8|200507051556
OBX|10|CE|PROCESS|tst4017183.2.2.6|pmc7873^In situ Blank Slide (IPEX) (WLO)^L||||||||3^IBNKNC|200601132341
OBX|11|CE|PROCESS|tst4017183.2.2.7|pmc0653^Hematoxylin & Eosin Recut (Histo)^L||||||||4^H&E Recut|200601132341
OBX|12|CE|PROCESS|tst4017183.1.1.8|pmc1073^Cytomegalovirus (IPEX)^L||||||||4^CMV|200601132341
OBX|13|CE|PROCESS|tst4017183.1.1.9|pmc1333^Congo Red Stain (Histo)^L||||||||5^CongoRed|200512191038
OBX|14|CE|PROCESS|tst4017183.1.1.10|pmc3633^Trichrome Stain (Histo)^L||||||||6^Trichrome|200512191038
OBX|15|CE|PROCESS|tst4017183.2.2.11|pmc1073^Cytomegalovirus (IPEX)^L||||||||5^CMV|200601132341
OBX|16|CE|PROCESS|tst4017183.2.2.12|pmc1333^Congo Red Stain (Histo)^L||||||||6^CongoRed|200512191038
OBX|17|CE|PROCESS|tst4017183.2.2.13|pmc3633^Trichrome Stain (Histo)^L||||||||7^Trichrome|200512191038
OBX|18|TX|GDT|tst4017183|The specimen is received unfixed in two parts.\.br\\.br\Part 1 is labeled with the patient's name, initials TH and " aortic valve".  The specimen consists of two tan-gray, irregular, rubbery to firm portions of valve tissue measuring 3.5 x 1.5 x 0.4 cm and 4.5 x 2.0 x 0.5 cm.  The walls are thickened and calcified yellow plaquing present.  The wall thickness ranges from 0.1 to 0.5 cm.  Following adequate decalcification representative cross sections are submitted in decal cassette labeled 1A.\.br\\.br\Part 2 is labeled with the patient's name, initials TH and " ascending aorta".  The specimen consists of multiple tan-pink, irregular, rubbery and hemorrhagic portions of vascular tissue measuring 5.5 x 3.5 x 1.5 cm in aggregate.  There is slight separation of layers.  Representative cross sections are submitted in cassette labeled 2A.\.br\mam\.br\||||||C
OBX|19|TX|MDT|tst4017183|     SYNOPTIC DATA - LARYNX RESECTIONS\.br\TYPE OF LARYNGECTOMY:      Hemilaryngectomy\.br\TUMOR LOCATION:      Right, Midline\.br\ATTACHED STRUCTURES:      Pyriform sinus\.br\TUMOR LOCATION/SEGMENT:      Subglottic\.br\TUMOR SIZE:      Maximum dimension:  2 cm\.br\HISTOLOGIC TYPE OF TUMOR:      Mucoepidermoid or adenosquamous carcinoma\.br\HISTOLOGIC GRADE:      Well differentiated\.br\STRUCTURES INVOLVED BY TUMOR:      True cord\.br\LYMPH NODES POSITIVE:      Number of lymph nodes positive:: 8\.br\LYMPH NODES EXAMINED:      Total number of lymph nodes examined: 4\.br\METASTASES\.br\     No\.br\INTRA-PERINEURAL INVASION:      Present\.br\VASCULAR INVASION:      Yes\.br\SURGICAL MARGIN INVOLVEMENT:      Positive (invasive tumor)\.br\T STAGE, PATHOLOGIC:      Glottis, pT4a\.br\N STAGE, PATHOLOGIC:      pN1\.br\M STAGE, PATHOLOGIC:      pMX\.br\--------------------------------------------------------\.br\Microscopic examination substantiates the above diagnosis.\.br\SD/dme\.br\||||||C
OBX|20|TX|FIN|tst4017183|PART 1: VALVE, AORTIC, REPLACEMENT \.br\PENDING DECALCIFICATION.  ADDENDUM REPORT TO FOLLOW.\.br\\.br\PART 2: AORTA, ASCENDING, REPAIR \.br\VASCULAR TISSUE WITH ADVENTITIAL HEMORRHAGE.\.br\SD/dme\.br\||||||C
OBX|21|CE|IMP|tst4017183|P1279^^SNO||||||||1||A
OBX|22|CE|IMP|tst4017183|T39000^^SNO||||||||1||A
OBX|23|CE|IMP|tst4017183|T42000^^SNO||||||||1||A
OBX|24|CE|IMP|tst4017183|M37000^^SNO||||||||1||A
OBX|25|CE|IMP|tst4017183|T40000^^SNO||||||||1||A
OBX|26|CE|IMP|tst4017183|T42100^^SNO||||||||1||A
OBX|27|CE|IMP|tst4017183|380.12^^ICD||||||||1
OBR|2||tst4017183^CoPathPlus^tst4017183.P2|BK^BK Virus (PH)||||||||||200507051540|||||||2|200507051540||SP|F|||||||987654^PATHOID^DOCTOR|z196^DEVINE^LISA
OBR|3||tst4017183^CoPathPlus^tst4017183.P3|FC^Flow Cytometry||||||||||200507051540|||||||3|200507051540||SP|F|||||||987654^PATHOID^DOCTOR|z196^DEVINE^LISA

MSH|^~\&|CoPathPlus|X|caBIG||20060210135109||ORU^R01|1000000004524|P|2.3
PID|1||333333333^^^RR|tst1704394|RUBBLE^BARNEY^R||19560304|M|||||||||||333-33-3333|||||||||||N
PV1|1||C1017RR^10C 8-1||||505075^PLANET^JUPITER||||||||||pmc08361^PLANET^JUPITER|I|1234333333333|||||||||||||||||||||||||200503151514
ORC|RE||PHS05-124^CoPathPlus||CM||||200507051147|z196^DEVINE^LISA||505075^PLANET^JUPITER
OBR|1||PHS05-124^CoPathPlus^tst6017183|PHSP^PH Surgical Pathology|||200507051147|||||||200507051147|VALV|505075||||^49^Y|-1|200507051805||SP|F|||||||012453^SEPULVEDA^ANTONIA|z196^DEVINE^LISA
OBX|1|CE|ANT|tst6017183.1|VALV^Aortic Valve^L||||||F||1^1
OBX|2|CE|ANT|tst6017183.2|VALV^Ascending aorta^L||||||F||2^2
OBX|3|ST|BLOCK|tst6017183.1.1|A||||||||1^A|200507221753
OBX|4|ST|BLOCK|tst6017183.2.2|A||||||||1^A|200507221753
OBX|5|CE|PROCESS|tst6017183.1.1.1|$hinit^Initial H&E^L||||||||1^H&E|200508180859
OBX|6|CE|PROCESS|tst6017183.2.2.2|$hinit^Initial H&E^L||||||||1^H&E|200508180859
OBX|7|CE|PROCESS|tst6017183.1.1.3|pmc1333^Congo Red Stain (Histo)^L||||||||2^CongoRed|200512191038
OBX|8|CE|PROCESS|tst6017183.1.1.4|pmc3474^ABCL6 (IPEX)^L||||||||3^ABCL6|200601132341
OBX|9|CE|PROCESS|tst6017183.1.1.5|pmc9133^Vimentin (IPEX)^L||||||||4^Vimentin|200601132341
OBX|10|CE|PROCESS|tst6017183.2.2.6|pmc6405^46300 Mycoplasma Pneumae DNA PCR (PH)^L||||||||2^Mycopl Pneu DNA PCR|200507051550
OBX|11|CE|PROCESS|tst6017183.2.2.7|pmc5174^11q, FISH (PHIS)^L||||||||3^I11Q|200507051555
OBX|12|CE|PROCESS|tst6017183.2.2.8|pmc7873^In situ Blank Slide (IPEX) (WLO)^L||||||||4^IBNKNC|200601132341
OBX|13|CE|PROCESS|tst6017183.2.2.9|pmc0653^Hematoxylin & Eosin Recut (Histo)^L||||||||5^H&E Recut|200601132341
OBX|14|CE|PROCESS|tst6017183.2.2.10|pmc0383^Amyloid P (IPEX)^L||||||||6^AAMP|200601132341
OBX|15|CE|PROCESS|tst6017183.2.2.11|pmc8724^Amyloid kappa (IPEX)^L||||||||7^AKAMY|200601132341
OBX|16|CE|PROCESS|tst6017183.1.1.12|pmc9133^Vimentin (IPEX)^L||||||||5^Vimentin|200601132341
OBX|17|CE|PROCESS|tst6017183.1.1.13|pmc1073^Cytomegalovirus (IPEX)^L||||||||6^CMV|200601132341
OBX|18|CE|PROCESS|tst6017183.2.2.14|pmc1073^Cytomegalovirus (IPEX)^L||||||||8^CMV|200601132341
OBX|19|CE|PROCESS|tst6017183.2.2.15|pmc1073^Cytomegalovirus (IPEX)^L||||||||9^CMV|200601132341
OBX|20|CE|PROCESS|tst6017183.2.2.16|pmc1333^Congo Red Stain (Histo)^L||||||||10^CongoRed|200512191038
OBX|21|CE|PROCESS|tst6017183.2.2.17|pmc3633^Trichrome Stain (Histo)^L||||||||11^Trichrome|200512191038
OBX|22|TX|GDT|tst6017183|The specimen is received unfixed in two parts.\.br\\.br\Part 1 is labeled with the patient's name, initials TH and " aortic valve".  The specimen consists of two tan-gray, irregular, rubbery to firm portions of valve tissue measuring 3.5 x 1.5 x 0.4 cm and 4.5 x 2.0 x 0.5 cm.  The walls are thickened and calcified yellow plaques are present.  The wall thickness ranges from 0.1 to 0.5 cm.  Following adequate decalcification representative cross sections are submitted in decal cassette labeled 1A.\.br\\.br\Part 2 is labeled with the patient's name, initials TH and "ascending aorta".  The specimen consists of multiple tan-pink, irregular, rubbery and hemorrhagic portions of vascular tissue measuring 5.5 x 3.5 x 1.5 cm in aggregate.  There is slight separation of layers.  Representative cross sections are entirely submitted in cassette labeled 2A.\.br\mam\.br\||||||F
OBX|23|TX|MDT|tst6017183|     SYNOPTIC DATA - PRIMARY CUTANEOUS MELANOMA\.br\     Family history of melanoma is unknown.\.br\     Family history of dysplastic nevi is unknown.\.br\TUMOR LOCATION:      Head and Neck\.br\TYPE OF PROCEDURE:      Punch biopsy\.br\SIZE OF TUMOR:      Maximum surface diameter of neoplasm: 8 mm\.br\GROSS ULCERATION:      No\.br\GROSS SATELLITES:      Yes\.br\HISTOLOGIC TYPE:      Acral lentiginous, Desmoplastic, Nevoid\.br\SURFACE ULCERATION:      < 50%\.br\CLARK'S LEVEL:      3\.br\BRESLOW'S THICKNESS:      12 mm\.br\ANGIOLYMPHATIC INVASION:      Present\.br\PERINEURAL INVASION:      No\.br\EVIDENCE OF REGRESSION:      No\.br\MICROSCOPIC SATELLITES:      No\.br\PREEXISTING NEVUS:      No preexisting nevus\.br\TUMOR INFILTRATING LYMPHOID INFILTRATE:      Marked (Brisk)\.br\MITOTIC RATE:      5 / 10 HPF\.br\VASCULARITY:      Not increased to focally increased\.br\SURGICAL MARGIN INVOLVEMENT:      Deep margin is free of tumor\.br\SENTINEL LYMPH NODE MAPPING:      Yes\.br\SENTINEL LYMPH NODE INVOLVEMENT:      Yes\.br\     Number of sentinel lymph nodes positive: 8\.br\LYMPH NODES EXAMINED:      Total number of lymph nodes examined: 8\.br\COMPLETION DISSECTION:      Yes\.br\EXTRACAPSULAR SPREAD:      Micro <3 foci\.br\LYMPH NODES POSITIVE:      Number of lymph nodes positive at completion dissection: 8\.br\SIZE OF NODAL METASTASES:      < 2mm\.br\T STAGE, PATHOLOGIC:      pTX\.br\N STAGE, PATHOLOGIC:      pNX\.br\M STAGE, PATHOLOGIC:      pM1c\.br\--------------------------------------------------------\.br\SYNOPTIC - PRIMARY INVASIVE CARCINOMA OF BREAST\.br\LATERALITY:      Left\.br\PROCEDURE:      Segmental\.br\LOCATION:      Central subareolar\.br\SIZE OF TUMOR:      Maximum dimension invasive component:  8 cm\.br\MULTICENTRICITY/MULTIFOCALITY OF INVASIVE FOCI:      No\.br\TUMOR AGGREGATE SIZE:      Sum of the sizes of multiple invasive tumors: 8 cm\.br\TUMOR TYPE (invasive component):      Papillary carcinoma\.br\HISTOLOGIC TYPE:      Pleomorphic\.br\NOTTINGHAM SCORE\.br\     Nuclear grade: 7\.br\     Tubule formation: 2\.br\     Mitotic activity score: 2\.br\     Total Nottingham score: 5\.br\     Nottingham grade (1, 2, 3): 1\.br\ANGIOLYMPHATIC INVASION:      Yes\.br\DERMAL LYMPHATIC INVASION:      Yes\.br\CALCIFICATION:      Yes, malignant zones\.br\TUMOR TYPE, IN SITU:      Solid\.br\SURGICAL MARGINS INVOLVED BY INVASIVE COMPONENT:      Yes, focal\.br\SURG MARGINS INVOLVED BY IN SITU COMPONENT:      Yes, focal\.br\PAGET'S DISEASE OF NIPPLE:      Yes\.br\LYMPH NODES POSITIVE:      8\.br\LYMPH NODES EXAMINED:      8\.br\METHOD(S) OF LYMPH NODE EXAMINATION:      Keratin stain\.br\SENTINEL NODE METASTASIS:      Yes\.br\ONLY KERATIN POSITIVE CELLS ARE PRESENT:      Yes\.br\SIZE OF NODAL METASTASES:      Diameter of largest lymph node metastasis: 8 mm\.br\LYMPH NODE METASTASIS(-ES) WITH EXTRACAPSULAR EXTENSION:      Yes\.br\METASTASES TO IPSILATERAL INTERNAL MAMMARY LYMPH NODE (IF APPLICABLE): \.br\     Yes\.br\SKIN INVOLVED (ULCERATION):      Yes\.br\NON-NEOPLASTIC BREAST TISSUE:      Fibroadenoma\.br\T STAGE, PATHOLOGIC:      pT0\.br\N STAGE, PATHOLOGIC:      pN0(mol+)\.br\M STAGE, PATHOLOGIC:      pMX\.br\ESTROGEN RECEPTORS:      positive\.br\PROGESTERONE RECEPTORS:      positive\.br\HER2/NEU:      zero or 1+\.br\--------------------------------------------------------\.br\Microscopic examination substantiates the above diagnosis.\.br\SD/dme\.br\||||||F
OBX|24|TX|FIN|tst6017183|PART 1: VALVE, AORTIC, REPLACEMENT \.br\PENDING DECALCIFICATION.  ADDENDUM REPORT TO FOLLOW.\.br\\.br\PART 2: AORTA, ASCENDING, REPAIR \.br\VASCULAR TISSUE WITH ADVENTITIAL HEMORRHAGE.\.br\SD/dme\.br\||||||F
OBX|25|CE|IMP|tst6017183|P1279^^SNO||||||||1||A
OBX|26|CE|IMP|tst6017183|T39000^^SNO||||||||1||A
OBX|27|CE|IMP|tst6017183|T42000^^SNO||||||||1||A
OBX|28|CE|IMP|tst6017183|M37000^^SNO||||||||1||A
OBX|29|CE|IMP|tst6017183|T40000^^SNO||||||||1||A
OBX|30|CE|IMP|tst6017183|T42100^^SNO||||||||1||A
OBX|31|CE|IMP|tst6017183|380.12^^ICD||||||||1
OBR|2||tst6017183^CoPathPlus^tst6017183.P1|CMVPCR^Cytomegalovirus||||||||||200507051535|||||||1|200507051535||SP|F|||||||SHEKHTER-PCL^SHEKHTER-LEVIN^SOFIA|z196^DEVINE^LISA
OBX|1|TX|PIN|tst6017183|This is an addendumeeeeeeee\.br\||||||F
OBX|2|TX|PRC|tst6017183|eeeee\.br\||||||F

MSH|^~\&|CoPathPlus|X|caBIG||20060210135109||ORU^R01|1000000004525|P|2.3
PID|1||605458532^^^SY|tst9604394|KOKAL^ELLEN^M||19650305|F||W|||||||||605-45-8532|||||||||||N
PV1|1||OP-REG||||999006052^VOGEL^VICTOR||||||||||pmc81802^VOGEL^VICTOR|SY2|0000123456789|||||||||||||||||||||||||200503110834
ORC|RE||PHS05-152^CoPathPlus||CM||||200507221005|z40^KOKAL^ELLEN||999006052^VOGEL^VICTOR
OBR|1||PHS05-152^CoPathPlus^tst7617183|PHSP^PH Surgical Pathology|||200507221005|||||||200507221005|STOBX|999006052||||^40^Y|-1|200512141212||SP|F|||||||052050^YOUSEM^SAMUEL|z40^KOKAL^ELLEN
OBX|1|CE|ANT|tst7617183.1|STOBX^Biopsy^L||||||F||1^1
OBX|2|TX|GDT|tst7617183|The specimen is received in buffered formalin labeled with the patient's name, initials EC and "proximal sigmoid polyp". Received is a single soft, tan, tissue fragment measuring 0.5 cm in greatest dimension.  The specimen is entirely submitted for processing in the cassette labeled A.\.br\||||||F
OBX|3|TX|MDT|tst7617183|Microscopic examination substantiates the above diagnosis.\.br\||||||F
OBX|4|TX|FIN|tst7617183|COLON, PROXIMAL SIGMOID, POLYP, POLYPECTOMY \.br\HYPERPLASTIC POLYP.\.br\||||||F
OBX|5|CE|IMP|tst7617183|M72040^^SNO||||||||1||A
OBX|6|CE|IMP|tst7617183|M76800^^SNO||||||||1||A
OBX|7|CE|IMP|tst7617183|P1100^^SNO||||||||1||A
OBX|8|CE|IMP|tst7617183|T67700^^SNO||||||||1||A
OBR|2||tst7617183^CoPathPlus^tst7617183.A1|ADD^Addendum||||||||||200601121056|||||||1|200601121056||SP|F|||||||987654^PATHOID^DOCTOR|z491^NESTLER^RICK
OBX|1|TX|ADX|tst7617183|Immunostains for CMV, RSV, HSV and adenovirus are negative.\.br\||||||F

MSH|^~\&|CoPathPlus|X|caBIG||20060210135109||ORU^R01|1000000004526|P|2.3
PID|1||100004582^^^RG|tst3508394|TESTRED^ANITA||19540313|F||MWW|12TH STREET^^COULTERS^PA^15028^United States||(412)469-1231|||||||||||||||||N
PV1|1||MW5300^5313||||MW000612^SEIAVITCH^SAMUEL||||||||||pmc28852^SEIAVITCH^SAMUEL|MWW|71391940|MWR||||||||||||||||||||||||200508011144|200508011600
ORC|RE||PHS05-153^CoPathPlus||CM||||200508011513|z41^LOSOS^FRANK||MW000612^SEIAVITCH^SAMUEL
OBR|1||PHS05-153^CoPathPlus^tst4917183|PHSP^PH Surgical Pathology|||200508011513|||||||200508011513|COBX|MW000612||||^51^Y|-1|200508011533||SP|C|||||||987654^PATHOID^DOCTOR|987654^PATHOID^DOCTOR
OBX|1|CE|ANT|tst4917183.1|COBX^Biopsy Colon^L||||||C||1^1
OBX|2|ST|BLOCK|tst4917183.1.1|A||||||||1^A|200508311407
OBX|3|CE|PROCESS|tst4917183.1.1.1|$hinit^Initial H&E^L||||||||1^H&E|200508180859
OBX|4|TX|GDT|tst4917183|\.br\This is the Gross Description     \.br\||||||C
OBX|5|TX|MDT|tst4917183|This is the Microscopic Description\.br\||||||C
OBX|6|TX|FIN|tst4917183|\.br\THIS IS THE FINAL DIAGNOSIS          \.br\||||||C

MSH|^~\&|CoPathPlus|X|caBIG||20060210135109||ORU^R01|1000000004527|P|2.3
PID|1||080520051^^^RR|tst1418394|TWIST^OLIVER||19830503|M|||||||||||080-52-0051|||||||||||N
PV1|1||SDS||||||||||||||pmc97361^PLANET^MARS|S|0001080520051|||||||||||||||||||||||||200508051646
ORC|RE||PHS05-154^CoPathPlus||CM||||200508051700|z41^LOSOS^FRANK||505074^PLANET^MARS
OBR|1||PHS05-154^CoPathPlus^tst5027183|PHSP^PH Surgical Pathology|||200508051655|||||||200508051655|LNENT|505074||||^22^Y|-1|200508121507||SP|F|||||||987654^PATHOID^DOCTOR|987654^PATHOID^DOCTOR
OBX|1|CE|ANT|tst5027183.1|LNENT^Lymph Node, Biopsy or Excision, ENT^L||||||F||1^1
OBX|2|CE|ANT|tst5027183.2|LNENT^Lymph Node, Biopsy or Excision, ENT^L||||||F||2^2
OBX|3|CE|ANT|tst5027183.3|LNENT^Lymph Node, Biopsy or Excision, ENT^L||||||F||3^3
OBX|4|CE|ANT|tst5027183.4|LNENT^Lymph Node, Biopsy or Excision, ENT^L||||||F||4^4
OBX|5|CE|ANT|tst5027183.5|THYLO^Thyroid^L||||||F||5^5
OBX|6|ST|BLOCK|tst5027183.1.1|A||||||||1^A|200508311407
OBX|7|ST|BLOCK|tst5027183.2.2|A||||||||1^A|200508311407
OBX|8|ST|BLOCK|tst5027183.3.3|A||||||||1^A|200508311407
OBX|9|CE|PROCESS|tst5027183.1.1.1|$hinit^Initial H&E^L||||||||1^H&E|200508180859
OBX|10|CE|PROCESS|tst5027183.1.1.2|pmc7764^Frozen Sect Single Block (Surg)^L||||||||2^FRZ Single|200508180859
OBX|11|CE|PROCESS|tst5027183.2.2.3|$hinit^Initial H&E^L||||||||1^H&E|200508180859
OBX|12|CE|PROCESS|tst5027183.2.2.4|pmc7764^Frozen Sect Single Block (Surg)^L||||||||2^FRZ Single|200508180859
OBX|13|CE|PROCESS|tst5027183.3.3.5|$hinit^Initial H&E^L||||||||1^H&E|200508180859
OBX|14|CE|PROCESS|tst5027183.3.3.6|pmc7764^Frozen Sect Single Block (Surg)^L||||||||2^FRZ Single|200508180859
OBX|15|TX|MDT|tst5027183|I am adding this line from signout worklist using the edit option\.br\Microscopic examination substantiates the above diagnosis.\.br\||||||F
OBX|16|TX|FIN|tst5027183|PART 1:  NECK, LEFT LEVELS 2 THRU 4, NECK DISSECTION \.br\A.METASTATIC SQUAMOUS CELL CARCINOMA IN THREE OF THIRTY-SEVEN LYMPH NODES (3/37).\.br\B.POSITIVE LYMPH NODES IN LEVEL 3, NO EXTRANODAL SPREAD IS SEEN\.br\\.br\PART 2:  NECK, RIGHT LEVELS 2 THRU 4, NECK DISSECTION \.br\THIRTY-FIVE (35) BENIGN LYMPH NODES.\.br\\.br\PART 3:  NECK, BILATERAL LEVEL 1, NECK DISSECTION \.br\A.METASTATIC SQUAMOUS CELL CARCINOMA IN THREE OF THREE (3/3) LYMPH NODES.\.br\B.ALL POSITIVE LYMPH NODES ON IN LEFT LEVEL 1.\.br\C.SALIVARY GLAND WITH FIBROSIS, ATROPHY AND CHRONIC INFLAMMATION.\.br\\.br\PART 4:  "SUBMENTAL NODE", EXCISION \.br\FIBRIN BLOOD CLOT, NO LYMPH NODE OR TUMOR SEEN.\.br\\.br\PART 5: RIGHT  MANDIBLE AND PORTION OF MAXILLA WITH ATTACHED BUCCAL MUCOSA , LIP, AND    \.br\                 AND SKIN,  COMPOSITE RESECTION \.br\A.EXOPHYTIC MODERATELY DIFFERENTIATED SQUAMOUS CELL CARCINOMA OF BUCCAL MUCOSA LIP  WITH INVASION INTO DERMIS OF ATTACHED SKIN (5.5 CM).\.br\B.PERINEURAL INVASION IDENTIFIED.\.br\C.MANDIBLE NOT INVOLVED.\.br\D.FINAL MARGINS OF RESECTION FREE OF TUMOR (See parts 6 and 7).\.br\E.PATHOLOGIC STAGE: T4, N2c, Mx.\.br\\.br\||||||F

MSH|^~\&|CoPathPlus|X|caBIG||20060210135109||ORU^R01|1000000004528|P|2.3
PID|1||080520051^^^RR|tst1418394|TWIST^OLIVER||19830503|M|||||||||||080-52-0051|||||||||||N
PV1|1||SDS||||||||||||||pmc97361^PLANET^MARS|S|0001080520051|||||||||||||||||||||||||200508051646
ORC|RE||PHS05-156^CoPathPlus||CM||||200508121500|z41^LOSOS^FRANK||505070^PLANET^NIBIRU
OBR|1||PHS05-156^CoPathPlus^tst7127183|PHSP^PH Surgical Pathology|||200508121458|||||||200508121458|COLTOT|505070||||^22^Y|-1|200508121510||SP|F|||||||987654^PATHOID^DOCTOR|987654^PATHOID^DOCTOR
OBX|1|CE|ANT|tst7127183.1|COLTOT^Colon^L||||||F||1^1
OBX|2|ST|BLOCK|tst7127183.1.1|A||||||||1^A|200508311407
OBX|3|CE|PROCESS|tst7127183.1.1.1|$hinit^Initial H&E^L||||||||1^H&E|200508180859
OBX|4|CE|PROCESS|tst7127183.1.1.2|pmc5553^HH&E (HISTO)^L||||||||2^HHE|200508180859
OBX|5|CE|PROCESS|tst7127183.1.1.3|pmc9333^Giemsa Stain (Histo)^L||||||||3^Giemsa|200512191038
OBX|6|CE|PROCESS|tst7127183.1.1.4|tst2625^in-myc, FISH (PHIS)^L||||||||4^INMYC|200510121746
OBX|7|CE|PROCESS|tst7127183.1.1.5|pmc7873^In situ Blank Slide (IPEX) (WLO)^L||||||||5^IBNKNC|200601132341
OBX|8|CE|PROCESS|tst7127183.1.1.6|pmc0653^Hematoxylin & Eosin Recut (Histo)^L||||||||6^H&E Recut|200601132341
OBX|9|TX|GDT|tst7127183|\.br\This is the gross description\.br\||||||F
OBX|10|TX|MDT|tst7127183|This is the Microscopic Description\.br\||||||F
OBX|11|TX|FIN|tst7127183|THIS IS THE FINAL DIAGNOSIS\.br\||||||F
OBR|2||tst7127183^CoPathPlus^tst7127183.P1|FC^Flow Cytometry||||||||||200508121513|||||||1|200508121513||SP|F|||||||987654^PATHOID^DOCTOR|z196^DEVINE^LISA
OBX|1|TX|PIN|tst7127183|Spellcheck   melanoma muulanoma adinamous booger \.br\||||||F

MSH|^~\&|CoPathPlus|X|caBIG||20060210135109||ORU^R01|1000000004529|P|2.3
PID|1||700000007^^^RG|tst1745394|RUBBLE^BETTY||19620101|F|||||||||||700-00-0007|||||||||||N
PV1|1||MWOR2||||^PLANET^VENUS||||||||||pmc77361^PLANET^VENUS|MWM|0001700000007|||||||||||||||||||||||||200510141042
ORC|RE||PHS05-170^CoPathPlus||CM||||200510211719|z32^PICCOLI^ANTHONY||^PLANET^VENUS
OBR|1||PHS05-170^CoPathPlus^tst0647183|^PH Transplant Pathology|||200510211030|||||||200510211718|LO|||||^43^Y|-1|200601261056||SP|F|||||||987654^PATHOID^DOCTOR|987654^PATHOID^DOCTOR
OBX|1|CE|ANT|tst0647183.1|LO^Liver (O)^L||||||F||1^1
OBX|2|ST|BLOCK|tst0647183.1.1|A||||||||1^A|200511181341
OBX|3|ST|BLOCK|tst0647183.1.2|B||||||||2^B|200511181351
OBX|4|ST|BLOCK|tst0647183.1.3|C||||||||3^C|200511181341
OBX|5|ST|BLOCK|tst0647183.1.4|D||||||||4^D|200511181341
OBX|6|ST|BLOCK|tst0647183.1.5|E||||||||5^E|200511181341
OBX|7|CE|PROCESS|tst0647183.1.1.1|$hinit^Initial H&E^L||||||||4^H&E|200511181407
OBX|8|CE|PROCESS|tst0647183.1.2.2|$hinit^Initial H&E^L||||||||4^H&E|200511181407
OBX|9|CE|PROCESS|tst0647183.1.3.3|$hinit^Initial H&E^L||||||||7^H&E|200511181407
OBX|10|CE|PROCESS|tst0647183.1.4.4|$hinit^Initial H&E^L||||||||7^H&E|200511181407
OBX|11|CE|PROCESS|tst0647183.1.5.5|$hinit^Initial H&E^L||||||||7^H&E|200511181407
OBX|12|CE|PROCESS|tst0647183.1.2.6|pmc5533^PAS w/Diastase (Histo)^L||||||||5^PASD|200512191038
OBX|13|CE|PROCESS|tst0647183.1.2.7|pmc3633^Trichrome Stain (Histo)^L||||||||6^Trichrome|200512191038
OBX|14|CE|PROCESS|tst0647183.1.2.8|pmc5433^Iron Stain (Histo)^L||||||||7^Iron|200512191038
OBX|15|CE|PROCESS|tst0647183.1.0.9|pmc4653^Tissue Banked OCT Frozen (Surg)^L||||||||1|200510211718
OBX|16|CE|PROCESS|tst0647183.1.0.10|pmc5653^Tissue Banked Bulk Frozen (Surg)^L||||||||2|200510211718
OBX|17|CE|PROCESS|tst0647183.1.0.11|pmc6653^Formalin Stocked Tissue (PHSP)^L||||||||3^FST|200510211718
OBX|18|CE|PROCESS|tst0647183.1.0.12|pmc1383^Imaging Surgical Specimen (PHSP)^L||||||||4^IMSU|200510211718
OBX|19|TX|GDT|tst0647183|Voice Rec Testing\.br\\.br\||||||F
OBX|20|TX|MDT|tst0647183|Voice Rec Testing\.br\||||||F
OBX|21|TX|FIN|tst0647183|This is a test of Voice Rec Testing\.br\\.br\Testing to see if these edits save win save recorded document ask me is set in the Dragon properties.\.br\\.br\||||||F

MSH|^~\&|CoPathPlus|X|caBIG||20060210135109||ORU^R01|1000000004530|P|2.3
PID|1||605458532^^^SY|tst9604394|KOKAL^ELLEN^M||19650305|F||W|||||||||605-45-8532|||||||||||N
PV1|1||OP-REG||||999006052^VOGEL^VICTOR||||||||||pmc81802^VOGEL^VICTOR|SY2|0000123456789|||||||||||||||||||||||||200503110834
ORC|RE||PHS05-171^CoPathPlus||CM||||200510241226|z40^KOKAL^ELLEN||999006052^VOGEL^VICTOR
OBR|1||PHS05-171^CoPathPlus^tst1647183|^PH Transplant Pathology|||200510241225|||||||200510241225|POSTLB|999006052||||^40^Y|-1|200601261142||SP|F|||||||008325^DEMETRIS^ANTHONY|987654^PATHOID^DOCTOR
OBX|1|CE|ANT|tst1647183.1|POSTLB^Liver Biopsy Post Perfusion^L||||||F||1^1
OBX|2|ST|BLOCK|tst1647183.1.1|A||||||||1^A|200511181341
OBX|3|CE|PROCESS|tst1647183.1.1.1|$hinit^Initial H&E^L||||||||1^H&E|200511181407
OBX|4|CE|PROCESS|tst1647183.1.1.2|pmc5553^HH&E (HISTO)^L||||||||2^HHE|200511181407
OBX|5|TX|GDT|tst1647183|Voice Rec Testing\.br\||||||F
OBX|6|TX|MDT|tst1647183|Voice Rec Testing\.br\||||||F
OBX|7|TX|FIN|tst1647183|Voice Rec Testing\.br\This is a test of voice recognition, testing the dragon property for recording dictation to "ask me".\.br\||||||F

MSH|^~\&|CoPathPlus|X|caBIG||20060210135109||ORU^R01|1000000004531|P|2.3
PID|1||171474264^^^RS|tst8857394|SYNOPTEST^SOUTHSIDE^TWO||19320709|F||W|||||||||171-47-4264|||||||||||N
PV1|1||3A^A0312||||505071^PLANET^MERCURY||||||||||pmc48361^PLANET^PLUTO|S|0001171474264|||||||||||||||||||||||||200506011610
ORC|RE||PHS05-172^CoPathPlus||CM||||200510241257|z32^PICCOLI^ANTHONY||505071^PLANET^MERCURY
OBR|1||PHS05-172^CoPathPlus^tst2647183|PHSP^PH Surgical Pathology|||200510241030|||||||200510241255|LNTH|505071||||^73^Y|-1|200601261100||SP|F|||||||987654^PATHOID^DOCTOR|987654^PATHOID^DOCTOR
OBX|1|CE|ANT|tst2647183.1|LNTH^R10 Lymph Node, Additional Edit^L||||||F||1^1
OBX|2|CE|ANT|tst2647183.2|LNTH^R9 Lymph Node^L||||||F||2^2
OBX|3|CE|ANT|tst2647183.3|LNTH^L10 Lymph Node^L||||||F||3^3
OBX|4|CE|ANT|tst2647183.4|LUNL^RUL Lung^L||||||F||4^4
OBX|5|ST|BLOCK|tst2647183.1.1|A||||||||1^A|200511181341
OBX|6|ST|BLOCK|tst2647183.2.2|AFS||||||||1^AFS|200511181341
OBX|7|ST|BLOCK|tst2647183.2.3|B||||||||2^B|200511181341
OBX|8|ST|BLOCK|tst2647183.3.4|A||||||||1^A|200511181341
OBX|9|ST|BLOCK|tst2647183.4.5|A||||||||1^A|200511181341
OBX|10|ST|BLOCK|tst2647183.4.6|B||||||||2^B|200511181341
OBX|11|ST|BLOCK|tst2647183.4.7|C||||||||3^C|200511181341
OBX|12|ST|BLOCK|tst2647183.4.8|D||||||||4^D|200511181341
OBX|13|ST|BLOCK|tst2647183.4.9|E||||||||5^E|200511181341
OBX|14|ST|BLOCK|tst2647183.4.10|F||||||||6^F|200511181341
OBX|15|CE|PROCESS|tst2647183.1.1.1|$hinit^Initial H&E^L||||||||1^H&E|200511181407
OBX|16|CE|PROCESS|tst2647183.1.1.2|pmc7764^Frozen Sect Single Block (Surg)^L||||||||2^FRZ Single|200511181407
OBX|17|CE|PROCESS|tst2647183.2.2.3|$hinit^Initial H&E^L||||||||1^H&E|200511181407
OBX|18|CE|PROCESS|tst2647183.2.2.4|pmc7764^Frozen Sect Single Block (Surg)^L||||||||2^FRZ Single|200511181407
OBX|19|CE|PROCESS|tst2647183.2.3.5|$hinit^Initial H&E^L||||||||2^H&E|200511181407
OBX|20|TX|GDT|tst2647183|Specimen is received unfixed in the operating room, labeled with patient initials "STS", and in four parts.\.br\\.br\Part 1, labeled "R10 Lymph Node for Frozen Section", consists of...........\.br\||||||F
OBX|21|TX|MDT|tst2647183|Voice Rec Testing\.br\||||||F
OBX|22|TX|FIN|tst2647183|Voice Rec Testing\.br\\.br\This is a test of voice recognition, signing out the case way that saved recorded dictation dragon property is said to "ask me".\.br\||||||F

MSH|^~\&|CoPathPlus|X|caBIG||20060210135109||ORU^R01|1000000004532|P|2.3
PID|1||333333333^^^RR|tst1704394|RUBBLE^BARNEY^R||19560304|M|||||||||||333-33-3333|||||||||||N
PV1|1||C1017RR^10C 8-1||||505075^PLANET^JUPITER||||||||||pmc08361^PLANET^JUPITER|I|1234333333333|||||||||||||||||||||||||200503151514
ORC|RE||PHS05-173^CoPathPlus||CM||||200510281313|z196^DEVINE^LISA||505075^PLANET^JUPITER
OBR|1||PHS05-173^CoPathPlus^tst8647183|PHSP^PH Surgical Pathology|||200510281313|||||||200510281313|LNGI|505075||||^49^Y|-1|200601261140||SP|F|||||||987654^PATHOID^DOCTOR|987654^PATHOID^DOCTOR
OBX|1|CE|ANT|tst8647183.1|LNGI^Lymph Node, Biopsy or Excision, GI^L||||||F||1^1
OBX|2|TX|GDT|tst8647183|Voice Rec Testing\.br\||||||F
OBX|3|TX|MDT|tst8647183|     SYNOPTIC DATA - GASTROINTESTINAL LYMPHOMA\.br\TUMOR SITE(S):      testing this text field\.br\TUMOR SIZE (LARGEST SINGLE MASS):      Greatest dimension: 5 cm\.br\Note: This is NOT the final diagnosis.  Use final diagnosis and/or diagnosis comment for therapeutic decisions.\.br\     Hodgkin Lymphoma- Nodular lymphocyte predominance Hodgkin lymphoma (NLPHL)\.br\     B-cell lymphoma- Splenic marginal zone lymphoma\.br\     B-cell lymphoma- Follicular lymphoma, grade 3, minimally follicular\.br\     T-cell Lymphoma- T-cell prolymphocytic leukemia\.br\PHENOTYPING:      Flow cytometry immunophenotype performed, see separate report\.br\     Immunohistochemistry/Insitu Hybridization performed, see microscopic description\.br\     Classical cytogenetic studies performed, see separate report\.br\     Cytogenetic FISH studies pending, report to follow\.br\     Genotypic (Molecular) studies pending, report to follow\.br\EXTENT OF INVOLVEMENT:      Penetration of serosa, perforation present\.br\MARGINS:      Distal margin involved by lymphoma\.br\REGIONAL LYMPH NODES:      No regional lymph node involvement\.br\     Number of regional lymph nodes examined: 5\.br\     Number of regional lymph nodes involved: 0\.br\NONREGIONAL LYMPH NODES:      No nonregional lymph node involvement\.br\ADDITIONAL PATHOLOGIC FINDINGS:      Helicobacter pylori gastritis\.br\     --------------------------------------------------------\.br\\.br\||||||F
OBX|4|TX|FIN|tst8647183|Voice Rec Testing\.br\This is the test of voice recognition, this is a test of the Dragon property to save the Dragon dictation per setting "ask me". \.br\||||||F
OBX|5|CE|SYNOP|tst8647183.W1|399692007^^CT||||||||406061006^1||1
OBX|6|CE|SYNOP|tst8647183.W1|399545001^^CT||||||||406061006^1||1
OBX|7|CE|SYNOP|tst8647183.W1|399647000^^CT||||||||406061006^1||1
OBX|8|CE|SYNOP|tst8647183.W1|396788005^^CT||||||||406061006^1||1
OBX|9|CE|SYNOP|tst8647183.W1|89538001^^CT||||||||406061006^1||1
OBX|10|CE|SYNOP|tst8647183.W1|372309006^5^CT||||||||406061006^1||1
OBX|11|CE|SYNOP|tst8647183.W1|372308003^0^CT||||||||406061006^1||1
OBX|12|CE|SYNOP|tst8647183.W1|371479009^5^CT||||||||406061006^1||1
OBX|13|CE|SYNOP|tst8647183.W1|70600005^^CT||||||||406061006^1||1
OBX|14|CE|SYNOP|tst8647183.W1|128802003^^CT||||||||406061006^1||1
OBX|15|CE|SYNOP|tst8647183.W1|128821006^^CT||||||||406061006^1||1
OBX|16|CE|SYNOP|tst8647183.W1|397000001^^CT||||||||406061006^1||1
OBX|17|CE|IMP|tst8647183|380.12^^ICD||||||||1

MSH|^~\&|CoPathPlus|X|caBIG||20060210135109||ORU^R01|1000000004533|P|2.3
PID|1||999998888|tst2477394|TRAINING^MARIE^LISA||19591002|F|||||||||||999-99-8888|||||||||||N
PV1|1||PATHOS||||505077^PLANET^NEPTUNE||||||||||pmc28361^PLANET^NEPTUNE|OSD|0002999998888|||||||||||||||||||||||||200506221457
ORC|RE||PHS05-187^CoPathPlus||CM||||200511161554|z196^DEVINE^LISA||505079^PLANET^PLUTO
OBR|1||PHS05-187^CoPathPlus^tpmc6157183|^PH Dental Pathology|||200511131530|||||||200511161540|LFM|505079||||^46^Y|-1|200511301444||SP|F|||||||^PRASAD^JOANNE|^PRASAD^JOANNE
OBX|1|CE|ANT|tpmc6157183.1|LFM^Mouth, Left Floor^L||||||F||1^1
OBX|2|CE|ANT|tpmc6157183.2|MXLLI^Maxillary, Left Lateral Incisor^L||||||F||2^2
OBX|3|CE|ANT|tpmc6157183.3|MO^Mouth^L||||||F||3^3
OBX|4|CE|ANT|tpmc6157183.4|AMX^Maxilla, Anterior^L||||||F||4^4
OBX|5|ST|BLOCK|tpmc6157183.1.1|A||||||||1^A|200511181341
OBX|6|CE|PROCESS|tpmc6157183.1.1.1|$hinit^Initial H&E^L||||||||1^H&E|200511181407
OBX|7|TX|GDT|tpmc6157183|1.  Mouth, Left Floor:   \.br\2.  Maxillary, Left Lateral Incisor:   \.br\3.  Mouth:   \.br\4.  Maxilla, Anterior:   \.br\The specimen is received in formalin labeled blah blah blah and consists of more stuff\.br\\.br\||||||F
OBX|8|TX|MDT|tpmc6157183|     There are many small, pretty cells.\.br\||||||F
OBX|9|TX|FIN|tpmc6157183|GRANULAR CELL TUMOR\.br\||||||F
OBX|10|CE|IMP|tpmc6157183|M95800^^SNO||||||||1||A
OBX|11|CE|IMP|tpmc6157183|873.63^^ICD||||||||1

MSH|^~\&|CoPathPlus|X|caBIG||20060210135109||ORU^R01|1000000004534|P|2.3
PID|1||580141-00^^^RG|tpmc2298394|TESTVTWOFIVE^BILLING^DOUGLAS||19301103|M|||||||||||198-26-1576|||||||||||N
PV1|1||MWBRI||||505073^PLANET^EARTH||||||||||pmc97361^PLANET^MARS|MWO|38029013|||||||||||||||||||||||||200511161000
ORC|RE||PHS05-192^CoPathPlus||CM||||200511181517|z37^ANDERSON^RALPH||505073^PLANET^EARTH
OBR|1||PHS05-192^CoPathPlus^tpmc8357183|^PH Transplant Pathology|||200511161513|||||||200511181513|PANBX|505073||||^75^Y|-1|200601040859||SP|F|||||||987654^PATHOID^DOCTOR|z491^NESTLER^RICK
OBX|1|CE|ANT|tpmc8357183.1|PANBX^Pancreas allograft biopsy^L||||||F||1^1
OBX|2|ST|BLOCK|tpmc8357183.1.1|A||||||||1^A|200601061423
OBX|3|CE|PROCESS|tpmc8357183.1.1.1|$hinit^Initial H&E^L||||||||1^H&E|200512061357
OBX|4|CE|PROCESS|tpmc8357183.1.1.2|$hinit^Initial H&E^L||||||||2^H&E|200512061357
OBX|5|CE|PROCESS|tpmc8357183.1.1.3|pmc4873^Blank Slide (HISTO) (WLO)^L||||||||3^HBNKNC|200601132341
OBX|6|CE|PROCESS|tpmc8357183.1.1.4|pmc4873^Blank Slide (HISTO) (WLO)^L||||||||4^HBNKNC|200601132341
OBX|7|CE|PROCESS|tpmc8357183.1.1.5|pmc4873^Blank Slide (HISTO) (WLO)^L||||||||5^HBNKNC|200601132341
OBX|8|CE|PROCESS|tpmc8357183.1.0.6|pmc2514^Biopsy Evaluation (PHEM)^L||||||||1^EVAL|200511181514
OBX|9|TX|GDT|tpmc8357183|The specimen is received in buffered formalin labeled with the patient's name and initials .   The specimen is identified as  " small bowel transplant biopsy".  Received are two irregular, unoriented, soft, tan, tissue fragments ranging from 5 to 0 cm in greatest dimension.  The specimen is entirely submitted for processing in the cassette labeled A.\.br\||||||F
OBX|10|TX|MDT|tpmc8357183| (3 H\T\E)\.br\1.   TOTAL FRAGMENTS. . . . . . . . . . . . . .#\.br\\.br\2.   FRAGMENTS OF ENDOMYOCARDIUM. . . . . . . .#\.br\\.br\3.   FRAGMENTS WITH INFLAMMATION. . . . . . . #\.br\\.br\4.   GREATEST DEGREE OF INFLAMMATION. . . . . .\.br\      ( ) NONE   ( ) MILD   ( ) MODERATE   ( ) SEVERE\.br\\.br\5.   LOCATION OF INFLAMMATION . . . . . . . . .\.br\      ( ) N/A  ( ) ENDOCARDIAL  ( ) PERIVASCULAR  ( ) INTERSTITIAL\.br\\.br\6.   EOSINOPHILS (>10/HPF in most areas). . . .( ) NO. .( ) YES\.br\\.br\7.   MYOCYTE NECROSIS/DROPOUT . . . . . . . . .( ) NO. .( ) YES\.br\\.br\8.   VENULITIS  . . . . . . . . . . . . . . . .( ) NO. .( ) YES\.br\\.br\9.   ARTERITIS (necrotizing or inflammatory). .( ) NO. .( ) YES\.br\\.br\10.  INTERSTITIAL HEMORRHAGE . . . . .( ) NO. .( ) YES\.br\\.br\11.  INFECTIOUS AGENTS . . . . . . . .( ) NO. .( ) YES\.br\\.br\     11A.  (IF YES, SPECIFY). . . . . . . . . .         \.br\\.br\12.  QUILTY LESION  . . . . . . . . . ( ) NO. .( ) YES\.br\\.br\13.  TYPE . . . . . . . . . . . . . . . . . . .\.br\          ( ) N/A\.br\\.br\          ( ) ENDOCARDIAL                  ( ) PERIVASCULAR\.br\          ( ) EPICARDIAL                  ( ) INFILTRATING\.br\\.br\14.  FIBROSIS SEVERITY. . . . . . . . . . . . .\.br\        ( ) NONE   ( ) MILD   ( ) MODERATE   ( ) SEVERE\.br\\.br\15.  FIBROSIS LOCATION. . . . . . . . . . . . .\.br\       ( ) N/A   ( ) ENDOCARDIAL   ( ) INTERSTITIAL   ( ) BOTH\.br\\.br\16.  OTHER FINDINGS:\.br\         #\.br\\.br\17.  IHLTS GRADE. . . . . . . . . . . . . . . .\.br\       ( )0  ( )1A  ( )1B  ( )2  ( )3A  ( )3B  ( )4  ( )5\.br\\.br\     7/8/03\.br\\.br\||||||F
OBX|11|TX|FIN|tpmc8357183|ALLOGRAFT SMALL BOWEL, ENDOSCOPIC BIOPSY \.br\A.NO EVIDENCE OF ACUTE REJECTION (APOPTOSIS PRESENT IN APPROXIMATELY 1-2 CELLS PER 10 CRYPTS).\.br\B.MINIMAL MIXED LAMINA PROPRIA INFLAMMATION.\.br\||||||F
OBX|12|CE|IMP|tpmc8357183|F44110^^SNO||||||||1||A
OBX|13|CE|IMP|tpmc8357183|P1140^^SNO||||||||1||A
OBX|14|CE|IMP|tpmc8357183|T64000^^SNO||||||||1||A
OBX|15|CE|IMP|tpmc8357183|T64026^^SNO||||||||1||A
OBX|16|CE|IMP|tpmc8357183|593.9^^ICD||||||||1
OBR|2||tpmc8357183^CoPathPlus^tpmc8357183.P1|EM^Electron Microscopy||||||||||200601040650|||||||1|200601040650||SP|F|||||||^PARWANI^ANIL|^PARWANI^ANIL
OBX|1|TX|PIN|tpmc8357183|This confirms the findings of no evidence of acute rejection\.br\||||||F
OBX|2|TX|PRC|tpmc8357183|Results verify above interpretation.\.br\||||||F

MSH|^~\&|CoPathPlus|X|caBIG||20060210135109||ORU^R01|1000000004535|P|2.3
PID|1||222221^^^RF|tst5745394|PITSTOP^PENELOPE||19880218|F|||||||||||222-22-2221|||||||||||N
PV1|1||BMOP||||505074^PLANET^MARS||||||||||pmc97361^PLANET^MARS|BMC|0000001222221|||||||||||||||||||||||||200510051015
ORC|RE||PHS05-199^CoPathPlus||CM||||200511281609|^LASSIGE^KAREN||505074^PLANET^MARS
OBR|1||PHS05-199^CoPathPlus^tpmc0757183|PHSP^PH Surgical Pathology|||200511281606|||||||200511281606||505074||||^17^Y|-1|||SP|F
OBX|1|CE|ANT|tpmc0757183.1|^Brushing^L||||||F||1^1
OBR|2||tpmc0757183^CoPathPlus^tpmc0757183.P1|HPV^HPV Testing||||||||||200511281609|||||||1|200511281609||SP|F||||||||^LASSIGE^KAREN
OBX|1|TX|PIN|tpmc0757183|Negative for high/intermediate HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and/or 68\.br\\.br\The sample, a crude cell lysate, was tested for the presence of Human Papillomavirus  (HPV) using the Hybrid Capture 2 (HC2) High Risk HPV DNA test from Digene.  The technology utilizes a specific HPV RNA probe cocktail to detect types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68 in cervical specimens.  The target DNA hybridizes with a specific RNA probe that is captured by antibodies specific for RNA:DNA hybrids.  Hybrid detection occurs via chemiluminescent substrate and subsequent light emission.\.br\\.br\The Digene HC2 assay is an FDA-cleared, qualitative, in vitro diagnostic test for the detection  of HPV from cervical specimens.  \.br\||||||F

MSH|^~\&|CoPathPlus|X|caBIG||20060210135109||ORU^R01|1000000004536|P|2.3
PID|1||311111111^^^UP|tpmc8482694|TESTVTWOFIVE^PH^THREE||19530826|M||||||||||||||||||||||N
PV1|1||PATHOS||||PO^OUTSIDE^PATHOLOGIST||||||||||pmc675^OUTSIDE^PATHOLOGIST|OSD|0001311111111|||||||||||||||||||||||||200511291136
ORC|RE||PHS05-200^CoPathPlus||CM||||200511291153|^JOYCE^KATHLEEN||505073^PLANET^EARTH
OBR|1||PHS05-200^CoPathPlus^tpmc3757183|^PH Transcription|||200511291140|||||||200511291140|CS9|505073||||^52^Y|-1|200601041128||SP|F|||||||^PARWANI^ANIL|^PARWANI^ANIL
OBX|1|CE|ANT|tpmc3757183.1|CS9^10 CONSULT SLIDES^L||||||F||1^1
OBX|2|CE|ANT|tpmc3757183.2|COM^1 CONSULT BLOCK^L||||||F||2^2
OBX|3|ST|BLOCK|tpmc3757183.2.1|A||||||||1^A|200601061423
OBX|4|ST|BLOCK|tpmc3757183.2.2|B||||||||2^B|200601061423
OBX|5|TX|MDT|tpmc3757183|Microscopic examination substantiates the above diagnosis.\.br\||||||F
OBX|6|TX|FIN|tpmc3757183|PART 1: PROSTATE, RIGHT LOBE, BIOPSY (OSS ACHS-1014-05, 11/16/2005, Aliquippa Community Hospital) \.br\A.          BENIGN PROSTATIC TISSUE.\.br\B.     NO EVIDENCE OF MALIGNANCY.\.br\\.br\PART 2: PROSTATE, LEFT LOBE, BIOPSY (OSS ACHS-1014-05, 11/16/2005, Aliquippa Community Hospital) \.br\A.          BENIGN PROSTATIC TISSUE.\.br\B.     NO EVIDENCE OF MALIGNANCY.\.br\/dme   \.br\||||||F
OBX|7|CE|IMP|tpmc3757183|V65.9^^ICD||||||||1

MSH|^~\&|CoPathPlus|X|caBIG||20060210135109||ORU^R01|1000000004537|P|2.3
PID|1||185540310^^^RZ|tst0507394|SYNOPTEST^HORIZON^ONE||19400811|M||W|||||||||185-54-0310||||||||||20050829|Y
PV1|1||Z2WE^0218||||505073^PLANET^EARTH|^PLANET^VENUS|||||||||pmc87361^PLANET^EARTH|I|0001185540310|||||||||||||||||||||||||200503101743
ORC|RE||HHS05-200^CoPathPlus||CM||||200505111821|z32^PICCOLI^ANTHONY||505073^PLANET^EARTH
OBR|1||HHS05-200^CoPathPlus^tst7596183|^HH Histology|||200505111819|||||||200505111819|ILN|505073||||^64^Y|-1|200506031654||SP|F|||||||000760^PERRY^LINA|000760^PERRY^LINA
OBX|1|CE|ANT|tst7596183.1|ILN^Right Iliac Lymph Nodes - Frozen^L||||||F||1^1
OBX|2|CE|ANT|tst7596183.2|ILN^Left Iliac Lymph Nodes - Frozen^L||||||F||2^2
OBX|3|CE|ANT|tst7596183.3|PROST^Prostate^L||||||F||3^3
OBX|4|ST|BLOCK|tst7596183.1.1|A||||||||1^A|200601132338
OBX|5|ST|BLOCK|tst7596183.2.2|A||||||||1^A|200601132338
OBX|6|ST|BLOCK|tst7596183.3.3|A||||||||1^A|200601132338
OBX|7|ST|BLOCK|tst7596183.3.4|B||||||||2^B|200601132338
OBX|8|ST|BLOCK|tst7596183.3.5|C||||||||3^C|200601132338
OBX|9|ST|BLOCK|tst7596183.3.6|D||||||||4^D|200601132338
OBX|10|ST|BLOCK|tst7596183.3.7|E||||||||5^E|200601132338
OBX|11|ST|BLOCK|tst7596183.3.8|F||||||||6^F|200601132338
OBX|12|ST|BLOCK|tst7596183.3.9|G||||||||7^G|200601132338
OBX|13|ST|BLOCK|tst7596183.3.10|H||||||||8^H|200601132338
OBX|14|ST|BLOCK|tst7596183.3.11|I||||||||9^I|200601132338
OBX|15|ST|BLOCK|tst7596183.3.12|J||||||||10^J|200601132338
OBX|16|ST|BLOCK|tst7596183.3.13|K||||||||11^K|200601132338
OBX|17|ST|BLOCK|tst7596183.3.14|L||||||||12^L|200601132338
OBX|18|ST|BLOCK|tst7596183.3.15|M||||||||13^M|200601132338
OBX|19|ST|BLOCK|tst7596183.3.16|N||||||||14^N|200601132338
OBX|20|ST|BLOCK|tst7596183.3.17|O||||||||15^O|200601132338
OBX|21|ST|BLOCK|tst7596183.3.18|P||||||||16^P|200601132338
OBX|22|ST|BLOCK|tst7596183.3.19|Q||||||||17^Q|200601132338
OBX|23|ST|BLOCK|tst7596183.3.20|R||||||||18^R|200601132338
OBX|24|ST|BLOCK|tst7596183.3.21|S||||||||19^S|200601132338
OBX|25|ST|BLOCK|tst7596183.3.22|T||||||||20^T|200601132338
OBX|26|CE|PROCESS|tst7596183.1.1.1|$hinit^Initial H&E^L||||||||1^H&E|200512191416
OBX|27|CE|PROCESS|tst7596183.1.1.2|pmc5044^Frozen Section Initial Slide (HH)^L||||||||2^FS|200512191416
OBX|28|CE|PROCESS|tst7596183.2.2.3|$hinit^Initial H&E^L||||||||1^H&E|200512191416
OBX|29|CE|PROCESS|tst7596183.2.2.4|pmc5044^Frozen Section Initial Slide (HH)^L||||||||2^FS|200512191416
OBX|30|CE|PROCESS|tst7596183.3.3.5|$hinit^Initial H&E^L||||||||1^H&E|200512191416
OBX|31|CE|PROCESS|tst7596183.3.4.6|$hinit^Initial H&E^L||||||||1^H&E|200512191416
OBX|32|CE|PROCESS|tst7596183.3.5.7|$hinit^Initial H&E^L||||||||1^H&E|200512191416
OBX|33|CE|PROCESS|tst7596183.3.6.8|$hinit^Initial H&E^L||||||||1^H&E|200512191416
OBX|34|CE|PROCESS|tst7596183.3.7.9|$hinit^Initial H&E^L||||||||1^H&E|200512191416
OBX|35|CE|PROCESS|tst7596183.3.8.10|$hinit^Initial H&E^L||||||||1^H&E|200512191416
OBX|36|CE|PROCESS|tst7596183.3.9.11|$hinit^Initial H&E^L||||||||1^H&E|200512191416
OBX|37|CE|PROCESS|tst7596183.3.10.12|$hinit^Initial H&E^L||||||||1^H&E|200512191416
OBX|38|CE|PROCESS|tst7596183.3.11.13|$hinit^Initial H&E^L||||||||1^H&E|200512191416
OBX|39|CE|PROCESS|tst7596183.3.12.14|$hinit^Initial H&E^L||||||||1^H&E|200512191416
OBX|40|CE|PROCESS|tst7596183.3.13.15|$hinit^Initial H&E^L||||||||1^H&E|200512191416
OBX|41|CE|PROCESS|tst7596183.3.14.16|$hinit^Initial H&E^L||||||||1^H&E|200512191416
OBX|42|CE|PROCESS|tst7596183.3.15.17|$hinit^Initial H&E^L||||||||1^H&E|200512191416
OBX|43|CE|PROCESS|tst7596183.3.16.18|$hinit^Initial H&E^L||||||||1^H&E|200512191416
OBX|44|CE|PROCESS|tst7596183.3.17.19|$hinit^Initial H&E^L||||||||1^H&E|200512191416
OBX|45|CE|PROCESS|tst7596183.3.18.20|$hinit^Initial H&E^L||||||||1^H&E|200512191416
OBX|46|CE|PROCESS|tst7596183.3.19.21|$hinit^Initial H&E^L||||||||1^H&E|200512191416
OBX|47|CE|PROCESS|tst7596183.3.20.22|$hinit^Initial H&E^L||||||||1^H&E|200512191416
OBX|48|CE|PROCESS|tst7596183.3.21.23|$hinit^Initial H&E^L||||||||1^H&E|200512191416
OBX|49|CE|PROCESS|tst7596183.3.22.24|$hinit^Initial H&E^L||||||||1^H&E|200512191416
OBX|50|TX|GDT|tst7596183|\.br\The specimen is received fresh for frozen section in two parts and in buffered formalin in one part.  All three parts are identified with the patients name and initials H.S.\.br\\.br\Part 1: Received labeled with right iliac node specimen frozen section.  FS1A  one lymph node, bisected for frozen section.\.br\\.br\\.br\Part 2: labeled left iliac node.  FS2A  one lymph node bisected\.br\\.br\\.br\Part 3: labeled prostate.  Lots more information.\.br\||||||F
OBX|51|TX|MDT|tst7596183|     SYNOPTIC DATA - PRIMARY PROSTATE TUMORS\.br\CLINICAL DATA:      PSA value: 0.0\.br\INVASIVE CA IDENTIFIED?:      Yes\.br\TUMOR HISTOLOGY:      Adenocarcinoma NOS\.br\PRIMARY GLEASON GRADE:      3.0\.br\SECONDARY GLEASON GRADE:      3.0\.br\GLEASON SUM SCORE:      6.0\.br\GLEASON 4/5 PERCENTAGE:      0%\.br\WEIGHT OF PROSTATE:      34.0gm\.br\TUMOR SIZE:      Maximum dimension:  0.0 cm\.br\LOBE LATERALITY:      Right and Left Lobes\.br\PERCENT OF SPECIMEN INVOLVED BY TUMOR:      5 - 25%\.br\MULTIFOCAL DISEASE:      Unknown\.br\HIGH GRADE PIN:      Yes - 1 or 2 foci away from tumor\.br\EXTRAPROSTATIC EXTENSION:      No\.br\PERINEURAL INVASION:      No\.br\ANGIOLYMPHATIC INVASION:      No\.br\SEMINAL VESICLE INVASION:      No\.br\SURGICAL MARGIN INVOLVEMENT:      All surgical margins free of tumor\.br\LYMPH NODES EXAMINED:      2.0\.br\LYMPH NODES POSITIVE:      0.0\.br\T STAGE, PATHOLOGIC:      pT2\.br\N STAGE, PATHOLOGIC:      pN0\.br\M STAGE, PATHOLOGIC:      pMX\.br\HISTOLOGIC GRADE:      G2, Moderately differentiated\.br\--------------------------------------------------------\.br\ \.br\\.br\||||||F
OBX|52|CE|IMP|tst7596183|000^^ICD||||||||1

MSH|^~\&|CoPathPlus|X|caBIG||20060210135109||ORU^R01|1000000004538|P|2.3
PID|1||200160194^^^RS|tst7857394|SYNOPTEST^SOUTHSIDE^ONE||19171108|M||W|||||||||200-16-0194|||||||||||N
PV1|1||SDSS||||505075^PLANET^JUPITER||||||||||pmc18361^PLANET^SATURN|S|0001200160194|||||||||||||||||||||||||200506011607
ORC|RE||SSS05-200^CoPathPlus||CM||||200506021615|z32^PICCOLI^ANTHONY||505075^PLANET^JUPITER
OBR|1||SSS05-200^CoPathPlus^tst6407183|SSHS^SS Histology|||200506011213|||||||200506021613||505075||||^87^Y|-1|200507111300||SP|F|||||||010728^KHASNABIS^SUKAMAL|010728^KHASNABIS^SUKAMAL
OBX|1|CE|ANT|tst6407183.1|^right breast mass nipple in nss^L||||||F||1^1
OBX|2|CE|ANT|tst6407183.2|AXILLA^right axillarynode in nss^L||||||F||2^2
OBX|3|ST|BLOCK|tst6407183.1.1|A||||||||1^A|200506021614
OBX|4|ST|BLOCK|tst6407183.1.2|B||||||||2^B|200506021614
OBX|5|ST|BLOCK|tst6407183.1.3|C||||||||3^C|200506021614
OBX|6|ST|BLOCK|tst6407183.1.4|D||||||||4^D|200506021614
OBX|7|ST|BLOCK|tst6407183.1.5|E||||||||5^E|200506021614
OBX|8|ST|BLOCK|tst6407183.1.6|F||||||||6^F|200506021614
OBX|9|ST|BLOCK|tst6407183.1.7|G||||||||7^G|200506021614
OBX|10|ST|BLOCK|tst6407183.2.8|A||||||||1^A|200506021614
OBX|11|ST|BLOCK|tst6407183.2.9|B||||||||2^B|200506021614
OBX|12|ST|BLOCK|tst6407183.2.10|C||||||||3^C|200506021614
OBX|13|ST|BLOCK|tst6407183.2.11|D||||||||4^D|200506021614
OBX|14|ST|BLOCK|tst6407183.2.12|E||||||||5^E|200506021614
OBX|15|CE|PROCESS|tst6407183.1.1.1|$hinit^Initial H&E^L||||||||1^H&E|200506021614
OBX|16|CE|PROCESS|tst6407183.1.2.2|$hinit^Initial H&E^L||||||||2^H&E|200506021614
OBX|17|CE|PROCESS|tst6407183.1.3.3|$hinit^Initial H&E^L||||||||5^H&E|200506021614
OBX|18|CE|PROCESS|tst6407183.1.4.4|$hinit^Initial H&E^L||||||||5^H&E|200506021614
OBX|19|CE|PROCESS|tst6407183.1.5.5|$hinit^Initial H&E^L||||||||5^H&E|200506021614
OBX|20|CE|PROCESS|tst6407183.1.6.6|$hinit^Initial H&E^L||||||||5^H&E|200506021614
OBX|21|CE|PROCESS|tst6407183.1.7.7|$hinit^Initial H&E^L||||||||5^H&E|200506021614
OBX|22|CE|PROCESS|tst6407183.2.8.8|$hinit^Initial H&E^L||||||||1^H&E|200506021614
OBX|23|CE|PROCESS|tst6407183.2.9.9|$hinit^Initial H&E^L||||||||1^H&E|200506021614
OBX|24|CE|PROCESS|tst6407183.2.10.10|$hinit^Initial H&E^L||||||||1^H&E|200506021614
OBX|25|CE|PROCESS|tst6407183.2.11.11|$hinit^Initial H&E^L||||||||1^H&E|200506021614
OBX|26|CE|PROCESS|tst6407183.2.12.12|$hinit^Initial H&E^L||||||||1^H&E|200506021614
OBX|27|CE|PROCESS|tst6407183.1.1.13|pmc3324^Frozen Section Consult (Surg)^L||||||||2^FR|200506021614
OBX|28|CE|PROCESS|tst6407183.1.2.14|pmc2043^Estrogen Receptor (IPEX)^L||||||||3^AER|200601132341
OBX|29|CE|PROCESS|tst6407183.1.2.15|pmc9043^Progesterone Receptor (IPEX)^L||||||||4^APR|200601132341
OBX|30|CE|PROCESS|tst6407183.1.2.16|pmc7624^Her-2/neu c-erb (IPEX)^L||||||||5^ANEU|200601132341
OBX|31|TX|GDT|tst6407183|Part 1 is labeled as "right breast with nipple".  It consists of an irregularly shaped piece of fibrofatty breast tissue which includes the overlying skin with nipple and areola.  The breast tissue measures 5.5 cm in maximum diameter and the ellipse of skin measures 4.0 x 2.2 cm.  The superior margin is identified by two metallic staples and the lateral margin is identified by one metallic staple.  The excisional surfaces are painted by green ink.  On section, and underneath the nipple, there is a circumscribed but unencapsulated firm grayish-white, slightly concave tumor measuring 2.0 cm in maximum diameter.  The overlying skin shows fine granularity.  The nipple is somewhat deformed and retracted.  Frozen section done on block "1A".  Representative sections are submitted as follows:\.br\1B,1C          -     tumor,\.br\1D          -     superior margin,\.br\1E          -     lateral margin,\.br\1F,1G          -     additional tumor.\.br\\.br\Part 2 is labeled as "right axillary nodes".  It consists of a fairly large piece of adipose tissue which measures 7.5 cm in maximum diameter.  Nine lymph nodes are dissected and submitted in cassettes "2A" through "2E".\.br\||||||F
OBX|32|TX|MDT|tst6407183|     SYNOPTIC - PRIMARY INVASIVE CARCINOMA OF BREAST\.br\LATERALITY:      Right\.br\PROCEDURE:      Segmental\.br\LOCATION:      Not specified\.br\SIZE OF TUMOR:      Maximum dimension invasive component:  2.0 cm\.br\MULTICENTRICITY/MULTIFOCALITY OF INVASIVE FOCI:      No\.br\TUMOR TYPE (invasive component):      Ductal adenocarcinoma, NOS\.br\NOTTINGHAM SCORE\.br\     Nuclear grade: 3\.br\     Tubule formation: 2\.br\     Mitotic activity score: 3\.br\     Total Nottingham score: 8\.br\     Nottingham grade (1, 2, 3): 3\.br\ANGIOLYMPHATIC INVASION:      No\.br\DERMAL LYMPHATIC INVASION:      No\.br\CALCIFICATION:      No\.br\SURGICAL MARGINS INVOLVED BY INVASIVE COMPONENT:      No\.br\LYMPH NODES POSITIVE:      0\.br\LYMPH NODES EXAMINED:      9\.br\METHOD(S) OF LYMPH NODE EXAMINATION:      H/E stain\.br\LYMPH NODE METASTASIS(-ES) WITH EXTRACAPSULAR EXTENSION:      No\.br\SKIN INVOLVED (ULCERATION):      No\.br\T STAGE, PATHOLOGIC:      pT1c\.br\N STAGE, PATHOLOGIC:      pN0\.br\M STAGE, PATHOLOGIC:      pMX\.br\ESTROGEN RECEPTORS:      positive\.br\PROGESTERONE RECEPTORS:      positive\.br\HER2/NEU:      zero or 1+\.br\--------------------------------------------------------\.br\12 H\T\E) - Microscopic examination substantiates the above diagnosis.\.br\||||||F
OBX|33|TX|FIN|tst6407183|PART 1:          BREAST, RIGHT, COMPLETE EXCISION LESS THAN TOTAL MASTECTOMY WITH AXILLARY \.br\          CONTENTS \.br\A.          INVASIVE DUCTAL CARCINOMA (2.0 CM).\.br\B.     HISTOLOGIC GRADE (NOTTINGHAM SCORE):\.br\               TUBULE FORMATION:  MODERATE (SCORE 2).\.br\          NUCLEAR PLEOMORPHISM:  MARKED (SCORE 3).\.br\          MITOTIC COUNT:  GREATER THAN 10 MITOSIS/10 HPF (SCORE 3).\.br\     TOTAL NOTTINGHAM SCORE (8):  GREADE III/III.\.br\C.          PATHOLOGIC STAGING (pTMN):\.br\               PRIMARY TUMOR:  pT1c (TUMOR MORE THAN 1.0 CM BUT NOT MORE THAN 2.0 CM\.br\          IN GREATEST DIMENSION.\.br\          NOTE:  THE TUMOR SHOWS DERMAL INVASION.  DERMAL INVASION ALONE \.br\     WITHOUT ULCERATION, SATELLETE NODULES OR INFLAMMATORY BREAST CANCER DOES NOT ALTER T CATEGORY.\.br\D.          REGIONAL LYMPH NODES (pN):\.br\               NO REGIONAL LYMPH NODE METASTASIS (pNO).\.br\          NUMBER EXAMINED:  NINE (9).\.br\E.          DISTANT METASTASIS (pM):\.br\               CANNOT BE ASSESSED (pMX).\.br\F.          MARGINS:  UNINVOLVED BY INVASIVE CARCINOMA.\.br\G.     VENOUS/LYMPHATIC INVASION:  NOT IDENTIFIED.\.br\H.     MICROCALCIFICATIONS:  ABSENT.\.br\I.     ADDITIONAL PATHOLOGIC FINDINGS:  NONE.\.br\\.br\PART 2:          SEE ABOVE.\.br\     \.br\||||||F
OBX|34|CE|IMP|tst6407183|M85003^^SNO||||||||1||A
OBX|35|CE|IMP|tst6407183|P1100^^SNO||||||||1||A
OBX|36|CE|IMP|tst6407183|T04050^^SNO||||||||1||A
OBX|37|CE|IMP|tst6407183|TY8100^^SNO||||||||1||A
OBX|38|CE|IMP|tst6407183|M40000^^SNO||||||||1||A
OBX|39|CE|IMP|tst6407183|M80003^^SNO||||||||1||A
OBX|40|CE|IMP|tst6407183|T04000^^SNO||||||||1||A
OBX|41|CE|IMP|tst6407183|T04040^^SNO||||||||1||A
OBX|42|CE|IMP|tst6407183|T08000^^SNO||||||||1||A
OBX|43|CE|IMP|tst6407183|M55400^^SNO||||||||1||A
OBX|44|CE|IMP|tst6407183|M80103^^SNO||||||||1||A
OBX|45|CE|IMP|tst6407183|T00100^^SNO||||||||1||A
OBX|46|CE|IMP|tst6407183|T09010^^SNO||||||||1||A
OBX|47|CE|IMP|tst6407183|T48000^^SNO||||||||1||A

MSH|^~\&|CoPathPlus|X|caBIG||20060210135109||ORU^R01|1000000004539|P|2.3
PID|1||195974845^^^RA|tst8208394|SYNOPTEST^STMARGARET^TWO||19590703|F||W|||||||||195-97-4845|||||||||||N
PV1|1||A6A^613||||505077^PLANET^NEPTUNE|505079^PLANET^PLUTO|||||||||pmc28361^PLANET^NEPTUNE|S|0001195974845|||||||||||||||||||||||||200507141740
ORC|RE||SMS05-201^CoPathPlus||CM||||200507151501|z32^PICCOLI^ANTHONY||505077^PLANET^NEPTUNE
OBR|1||SMS05-201^CoPathPlus^tst3217183|^SM Histology|||200507121300|||||||200507151455|BRSEG|505077||||^46^Y|-1|200510041710||SP|F|||||||^PRIMAVERA^JAMES|^PRIMAVERA^JAMES
OBX|1|CE|ANT|tst3217183.1|BRSEG^RIGHT BREAST MASS^L||||||F||1^1
OBX|2|CE|ANT|tst3217183.2|^RIGHT ADDITIONAL NIPPLE MARGIN^L||||||F||2^2
OBX|3|CE|ANT|tst3217183.3|SLNBSM^SENTINEL NODE #1^L||||||F||3^3
OBX|4|CE|ANT|tst3217183.4|^FAT^L||||||F||4^4
OBX|5|CE|ANT|tst3217183.5|SLNBSM^SENTINEL NODE #2^L||||||F||5^5
OBX|6|ST|BLOCK|tst3217183.2.1|A||||||||1^A|200507151456
OBX|7|ST|BLOCK|tst3217183.3.2|A||||||||1^A|200507151456
OBX|8|ST|BLOCK|tst3217183.4.3|A||||||||1^A|200507151456
OBX|9|ST|BLOCK|tst3217183.5.4|A||||||||1^A|200507151456
OBX|10|ST|BLOCK|tst3217183.1.5|A||||||||1^A|200507151457
OBX|11|ST|BLOCK|tst3217183.1.6|B||||||||2^B|200507151457
OBX|12|ST|BLOCK|tst3217183.1.7|C||||||||3^C|200507151457
OBX|13|ST|BLOCK|tst3217183.1.8|D||||||||4^D|200507151457
OBX|14|ST|BLOCK|tst3217183.1.9|E||||||||5^E|200507151457
OBX|15|ST|BLOCK|tst3217183.1.10|F||||||||6^F|200507151457
OBX|16|ST|BLOCK|tst3217183.1.11|G||||||||7^G|200507151457
OBX|17|ST|BLOCK|tst3217183.1.12|H||||||||8^H|200507151457
OBX|18|ST|BLOCK|tst3217183.1.13|I||||||||9^I|200507151457
OBX|19|CE|PROCESS|tst3217183.2.1.1|$hinit^Initial H&E^L||||||||1^H&E|200507151456
OBX|20|CE|PROCESS|tst3217183.3.2.2|$hinit^Initial H&E^L||||||||1^H&E|200507151456
OBX|21|CE|PROCESS|tst3217183.3.2.3|pmc5553^HH&E (HISTO)^L||||||||2^HHE|200507151456
OBX|22|CE|PROCESS|tst3217183.3.2.4|pmc4873^Blank Slide (HISTO) (WLO)^L||||||||3^HBNKNC|200507151456
OBX|23|CE|PROCESS|tst3217183.3.2.5|pmc1554^CONTROL NEG IMMUNO SM^L||||||||4^-CONT|200507151456
OBX|24|CE|PROCESS|tst3217183.3.2.6|pmc4873^Blank Slide (HISTO) (WLO)^L||||||||5^HBNKNC|200507151456
OBX|25|CE|PROCESS|tst3217183.4.3.7|$hinit^Initial H&E^L||||||||1^H&E|200507151456
OBX|26|CE|PROCESS|tst3217183.5.4.8|$hinit^Initial H&E^L||||||||1^H&E|200507151456
OBX|27|CE|PROCESS|tst3217183.5.4.9|pmc5553^HH&E (HISTO)^L||||||||2^HHE|200507151456
OBX|28|TX|GDT|tst3217183|1.  RIGHT BREAST MASS:  The specimen is received unfixed labeled with the patient' s name and "right breast mass."  It consists of an irregularly shaped portion of yellow-pink, lobulated, fibrofatty tissue with an attached portion of skin, measuring 7 x 5.5 x 5 cm. in total dimension.  The attached skin measures 3.5 x 1 cm.  The specimen is oriented by one long black stitch designated lateral, and one short black stitch designated superior.  The tissue has been previously injected with blue dye. The skin is centrally located and the epidermal surface is tan, smooth and unremarkable.   The anterior aspect is inked blue and the posterior aspect is inked black for orientation.  Multiple cross sections reveal an ill-defined stellate pale white-tan, gritty mass, centrally located, directly subjacent to the skin, measuring approximately 2.5 cm. in greatest dimension.  The mass measures 1 cm. from the lateral margin, 2 cm. from the medial margin, 1 cm. from the deep margin, 0.2 cm. from the anterior margin, 2 cm. from the superior margin, and 1 cm. from the inferior margin at the nearest points.  The remainder of the cross sections show yellow-pink, lobulated adipose tissue with interlacing white fibrous tissue.  Representative sections submitted, labeled:  1A-C-mass, anterior aspect (A contains mass nearest anterior margin), 1D-inferior margin, 1E-random section of dense fibrous tissue adjacent to mass, 1F-lateral margin to include fibrous tissue, 1G-medial margin to include fibrous tissue, 1H-lateral margin directly adjacent mass, 1I-deep margin directly adjacent to mass.  \.br\2.  RIGHT ADDITIONAL NIPPLE MARGIN: The specimen is received unfixed labeled with the patient' s name and "additional right breast margin."  It consists of an irregularly shaped portion of yellow-pink, lobulated, fibrofatty tissue, measuring 3 x 1.4 x 0.4 cm.  The exterior surface is inked black.  The specimen is serially sectioned and entirely submitted, labeled 2A.\.br\3.  SENTINEL NODE #1:  The specimen is received unfixed labeled with the patient' s name and "sentinel node #1."  It consists of an irregularly shaped portion of yellow-pink, finely lobulated, rubbery tissue, measuring 2.7 x 1.5 x 0.8 cm.  Within the finely lobulated adipose tissue is pink-tan, rubbery, presumed lymph node which measures 2 x 0.8 x 0.4 cm.  The specimen is bisected and entirely submitted, labeled 3A.\.br\4.  FAT: The specimen is received unfixed labeled with the patient' s name and "fat."  It consists of 2, similar, irregularly shaped portions of finely lobulated, yellow-pink, fatty and rubbery tissue, measuring 2.2 x 2.4 x 0.9 cm. and 2 x 1 x 0.6 cm.  Thorough inspection of the lobulated adipose tissue reveals 2 presumed lymph nodes, measuring 1 x 0.7 x 0.5 cm. and 0.5 x 0.4 x 0.3 cm.  The lymph nodes are entirely submitted exclusive the adipose tissue, in block labeled 4A-presumed lymph nodes, larger lymph node inked black and bisected.   \.br\5.  SENTINEL NODE #2:   The specimen is received unfixed labeled with the patient' s name and "sentinel node #2."  It consists of an irregularly shaped portion of yellow-pink, lobulated, adipose tissue and rubbery tissue, measuring 1.9 x 1.2 x 0.3 cm.   Thorough inspection of the lobulated adipose tissue reveals one, pink-tan, rubbery lymph node, which measures 0.5 x 0.4 cm.  The lymph node is entirely submitted, exclusive of the adipose tissue in block labeled 5A.\.br\||||||F
OBX|29|TX|MDT|tst3217183|     SYNOPTIC - PRIMARY INVASIVE CARCINOMA OF BREAST\.br\LATERALITY:      Right\.br\PROCEDURE:      Segmental\.br\LOCATION:      Not specified\.br\SIZE OF TUMOR:      Maximum dimension invasive component:  2.5 cm\.br\MULTICENTRICITY/MULTIFOCALITY OF INVASIVE FOCI:      No\.br\TUMOR TYPE (invasive component):      Ductal adenocarcinoma, NOS\.br\NOTTINGHAM SCORE\.br\     Nuclear grade: 2\.br\     Tubule formation: 3\.br\     Mitotic activity score: 1\.br\     Total Nottingham score: 6\.br\     Nottingham grade (1, 2, 3): 2\.br\ANGIOLYMPHATIC INVASION:      Yes\.br\DERMAL LYMPHATIC INVASION:      No\.br\CALCIFICATION:      Yes, malignant zones\.br\TUMOR TYPE, IN SITU:      Cribriform, Solid\.br\SURGICAL MARGINS INVOLVED BY INVASIVE COMPONENT:      Yes, focal\.br\SURG MARGINS INVOLVED BY IN SITU COMPONENT:      Yes, focal\.br\PAGET'S DISEASE OF NIPPLE:      No\.br\LYMPH NODES POSITIVE:      1\.br\LYMPH NODES EXAMINED:      4\.br\METHOD(S) OF LYMPH NODE EXAMINATION:      H/E stain\.br\SENTINEL NODE METASTASIS:      Yes\.br\ONLY KERATIN POSITIVE CELLS ARE PRESENT:      No\.br\SIZE OF NODAL METASTASES:      Diameter of largest lymph node metastasis: 0.7 mm\.br\LYMPH NODE METASTASIS(-ES) WITH EXTRACAPSULAR EXTENSION:      No\.br\METASTASES TO IPSILATERAL INTERNAL MAMMARY LYMPH NODE (IF APPLICABLE): \.br\     No\.br\SKIN INVOLVED (ULCERATION):      No\.br\NON-NEOPLASTIC BREAST TISSUE:      FCD\.br\T STAGE, PATHOLOGIC:      pT2\.br\N STAGE, PATHOLOGIC:      pN1\.br\M STAGE, PATHOLOGIC:      pMX\.br\ESTROGEN RECEPTORS:      unknown\.br\PROGESTERONE RECEPTORS:      unknown\.br\HER2/NEU:      unknown\.br\--------------------------------------------------------\.br\ \.br\\.br\||||||F

MSH|^~\&|CoPathPlus|X|caBIG||20060210135109||ORU^R01|1000000004540|P|2.3
PID|1||N0000085^^^RV|tpmc3531494|TESTVTWOFIVE^PASSAVANT^PAUL||19300520|M||PVW|888 STREET^^PITTSBURGH^PA^15237^United States||412-367-6100|724-625-3184|||||888-55-2223|||||||||||N
PV1|1||PVLAB||||ABU.KA^ABU-HAMAD^GHASSAN|||||||||||PVSDC|N00000001370|PVBC||||||||||||||||||||||||200511210857
ORC|RE||PHS05-201^CoPathPlus||CM||||200511301743|z41^LOSOS^FRANK||505074^PLANET^MARS
OBR|1||PHS05-201^CoPathPlus^tpmc1067183|PHSP^PH Surgical Pathology|||200511301743|||||||200511301743|FBM|505074||||^75^Y|-1|||SP|F
OBX|1|CE|ANT|tpmc1067183.1|FBM^Filtered Bone Marrow^L||||||F||1^1
OBX|2|CE|PROCESS|tpmc1067183.1.0.1|pmc7904^Alcian Blue pH 1.0 (Histo)^L||||||||1^AlBlue1.0|200512151343
OBX|3|CE|PROCESS|tpmc1067183.1.0.2|pmc9333^Giemsa Stain (Histo)^L||||||||2^Giemsa|200512151343
OBX|4|CE|PROCESS|tpmc1067183.1.0.3|pmc2233^Acid Fast Stain (Histo)^L||||||||3^AcidFast|200512151343
OBX|5|CE|PROCESS|tpmc1067183.1.0.4|pmc4014^Bielschowsky Stain (Histo)^L||||||||4^Biels|200512151343
OBR|2||tpmc1067183^CoPathPlus^tpmc1067183.A2|ADD^Addendum||||||||||200511301747|||||||2|200511301747||SP|F|||||||987654^PATHOID^DOCTOR|z41^LOSOS^FRANK
OBX|1|TX|ADX|tpmc1067183|THIS IS A TEST ADDENDUM TO CHECK STATUS OF OBX:11 FLAGGING ALGORITHM\.br\||||||F
OBR|3||tpmc1067183^CoPathPlus^tpmc1067183.P1|FC^Flow Cytometry||||||||||200511301743|||||||1|200511301743||SP|F|||||||987654^PATHOID^DOCTOR|z41^LOSOS^FRANK
OBX|1|TX|PIN|tpmc1067183|# OF Events/Cells: _______________     Flow File Name:______________________\.br\TOPOGRAPHY: ________________     \.br\TECHNOLOGIST FLOW__________________\.br\\.br\============================================================================\.br\INTERPRETATION: DNA analysis was performed on ___________ using\.br\flow cytometry.\.br\\.br\Reference:\.br\\.br\============================================================================\.br\\.br\Representation of tumor on slide  __________________________________________\.br\FLOW  Test Date: ____________  \.br\\.br\Normal Control - G0/G1 ______________   DNA Index of Normal Cells __________\.br\\.br\Reference Peak ______________           CV _________________________________\.br\\.br\\.br\.             FLOW\.br\\.br\.            PEAK 1\.br\\.br\G0/G1 peak   ________\.br\\.br\CV           ________\.br\\.br\DNA Index    ________\.br\\.br\.       Cell Cycle Statistics\.br\\.br\G0/G1        ________\.br\\.br\S            ________\.br\\.br\G2M          ________\.br\\.br\============================================================================\.br\||||||F
OBX|2|TX|PRC|tpmc1067183|\.br\DNA analysis was performed on # using flow cytometry.\.br\||||||F

MSH|^~\&|CoPathPlus|X|caBIG||20060210135109||ORU^R01|1000000004541|P|2.3
PID|1||162808395^^^RY|tst1507394|SYNOPTEST^HORIZON^TWO||19510718|M||W|||||||||162-80-8395|||||||||||N
PV1|1||Y3CC^Y3CC||||505078^PLANET^URANUS|505074^PLANET^MARS|||||||||pmc38361^PLANET^URANUS|I|0001162808395|||||||||||||||||||||||||200503161746
ORC|RE||HHS05-201^CoPathPlus||CM||||200505111825|z32^PICCOLI^ANTHONY||505078^PLANET^URANUS
OBR|1||HHS05-201^CoPathPlus^tst8596183|^HH Histology|||200503161122|||||||200505111822||505078||||^53^Y|-1|200506031646||SP|F|||||||000760^PERRY^LINA|000760^PERRY^LINA
OBX|1|CE|ANT|tst8596183.1|^#7 Node - Frozen^L||||||F||1^1
OBX|2|CE|ANT|tst8596183.2|^#4 Node - Frozen^L||||||F||2^2
OBX|3|CE|ANT|tst8596183.3|HEBB^Proximal Bronchus Right Lung - Frozen^L||||||F||3^3
OBX|4|CE|ANT|tst8596183.4|^Parietal Pleura (Tumor Site) - Frozen^L||||||F||4^4
OBX|5|CE|ANT|tst8596183.5|LUNL^Right Lung^L||||||F||5^5
OBX|6|ST|BLOCK|tst8596183.1.1|A||||||||1^A|200601132338
OBX|7|ST|BLOCK|tst8596183.2.2|A||||||||1^A|200601132338
OBX|8|ST|BLOCK|tst8596183.3.3|A||||||||1^A|200601132338
OBX|9|ST|BLOCK|tst8596183.4.4|A||||||||1^A|200601132338
OBX|10|ST|BLOCK|tst8596183.5.5|A||||||||1^A|200601132338
OBX|11|ST|BLOCK|tst8596183.5.6|B||||||||2^B|200601132338
OBX|12|ST|BLOCK|tst8596183.5.7|C||||||||3^C|200601132338
OBX|13|ST|BLOCK|tst8596183.5.8|D||||||||4^D|200601132338
OBX|14|ST|BLOCK|tst8596183.5.9|E||||||||5^E|200601132338
OBX|15|ST|BLOCK|tst8596183.5.10|F||||||||6^F|200601132338
OBX|16|ST|BLOCK|tst8596183.5.11|G||||||||7^G|200601132338
OBX|17|ST|BLOCK|tst8596183.5.12|H||||||||8^H|200601132338
OBX|18|ST|BLOCK|tst8596183.5.13|I||||||||9^I|200601132338
OBX|19|ST|BLOCK|tst8596183.5.14|J||||||||10^J|200601132338
OBX|20|ST|BLOCK|tst8596183.5.15|K||||||||11^K|200601132338
OBX|21|ST|BLOCK|tst8596183.5.16|L||||||||12^L|200601132338
OBX|22|ST|BLOCK|tst8596183.5.17|M||||||||13^M|200601132338
OBX|23|CE|PROCESS|tst8596183.1.1.1|$hinit^Initial H&E^L||||||||1^H&E|200512191416
OBX|24|CE|PROCESS|tst8596183.1.1.2|pmc5044^Frozen Section Initial Slide (HH)^L||||||||2^FS|200512191416
OBX|25|CE|PROCESS|tst8596183.2.2.3|$hinit^Initial H&E^L||||||||1^H&E|200512191416
OBX|26|CE|PROCESS|tst8596183.2.2.4|pmc5044^Frozen Section Initial Slide (HH)^L||||||||2^FS|200512191416
OBX|27|CE|PROCESS|tst8596183.3.3.5|$hinit^Initial H&E^L||||||||1^H&E|200512191416
OBX|28|CE|PROCESS|tst8596183.3.3.6|pmc5044^Frozen Section Initial Slide (HH)^L||||||||2^FS|200512191416
OBX|29|CE|PROCESS|tst8596183.4.4.7|$hinit^Initial H&E^L||||||||1^H&E|200512191416
OBX|30|CE|PROCESS|tst8596183.4.4.8|pmc5044^Frozen Section Initial Slide (HH)^L||||||||2^FS|200512191416
OBX|31|CE|PROCESS|tst8596183.5.5.9|$hinit^Initial H&E^L||||||||1^H&E|200512191416
OBX|32|CE|PROCESS|tst8596183.5.6.10|$hinit^Initial H&E^L||||||||1^H&E|200512191416
OBX|33|CE|PROCESS|tst8596183.5.7.11|$hinit^Initial H&E^L||||||||1^H&E|200512191416
OBX|34|CE|PROCESS|tst8596183.5.8.12|$hinit^Initial H&E^L||||||||1^H&E|200512191416
OBX|35|CE|PROCESS|tst8596183.5.9.13|$hinit^Initial H&E^L||||||||1^H&E|200512191416
OBX|36|CE|PROCESS|tst8596183.5.10.14|$hinit^Initial H&E^L||||||||1^H&E|200512191416
OBX|37|CE|PROCESS|tst8596183.5.11.15|$hinit^Initial H&E^L||||||||1^H&E|200512191416
OBX|38|CE|PROCESS|tst8596183.5.12.16|$hinit^Initial H&E^L||||||||1^H&E|200512191416
OBX|39|CE|PROCESS|tst8596183.5.13.17|$hinit^Initial H&E^L||||||||1^H&E|200512191416
OBX|40|CE|PROCESS|tst8596183.5.14.18|$hinit^Initial H&E^L||||||||1^H&E|200512191416
OBX|41|CE|PROCESS|tst8596183.5.15.19|$hinit^Initial H&E^L||||||||1^H&E|200512191416
OBX|42|CE|PROCESS|tst8596183.5.16.20|$hinit^Initial H&E^L||||||||1^H&E|200512191416
OBX|43|CE|PROCESS|tst8596183.5.17.21|$hinit^Initial H&E^L||||||||1^H&E|200512191416
OBX|44|TX|GDT|tst8596183|The specimen is received fresh for frozen section in five parts.  All five parts are identified with the patient' s name and initials R.C.\.br\\.br\Part 1:  is labeled #7 node.  It consists of a grossly recognizable lymph node  which is black in color and measures 9.0 x6.0 x4.0 mm.  The specimen is bisected and entirely submitted for frozen section as FS1A.\.br\\.br\\.br\Part 2: is labeled #4 node.  It consists of two grossly recognizable lymph nodes which are black in color and measure 8.0 x 6.0 mm in maximum dimension.  Each node is bisected and entirely submitted in cassette FS2A\.br\\.br\\.br\Part 3: is labeled proximal bronchus frozen section.  It consists of two tan-red semi-circular rings of tissue, the second is just a strip and they measure approximately 1.5 cm in diameter, and 0.3cm in thickness.  The specimen is entirely submitted for frozen section.\.br\\.br\\.br\Part 4: is labeled parietal pleura tumor site.  It consists of three pieces of bright red soft tissue fragments measuring in aggregate 1.0 x 0.2x 0.4 cm.  The specimen is entirely submitted for frozen section as FS4A.\.br\\.br\\.br\Part 5: is labeled right lung.  Lots more information that I' m not going to bother typing in.\.br\||||||F
OBX|45|TX|MDT|tst8596183|     SYNOPTIC DATA - PRIMARY LUNG TUMORS\.br\TUMOR LOCATION:      Right Upper Lobe\.br\LUNG SEGMENT(S) INVOLVED:      Basilar\.br\PROCEDURE:      Pneumonectomy\.br\TUMOR SIZE:      Maximum dimension:  0.5 cm\.br\GROSS SATELLITES:      Number of gross satellite lesions: 0.0\.br\TUMOR TYPE:      Invasive squamous carcinoma\.br\HISTOLOGIC GRADE:      G2, Moderately differentiated\.br\MICROSCOPIC SATELLITES:      Number of microscopic satellite lesions: 0\.br\EXTRAPULMONARY PARENCHYMAL\.br\EXTENSION/INVASION OF TUMOR:      None identified\.br\ANGIOLYMPHATIC INVASION:      No\.br\TUMOR NECROSIS:      < or = to 50%\.br\SURGICAL MARGIN INVOLVEMENT:      No\.br\SURGICAL MARGIN SITE:      Distance of invasive tumor to closest margin: 10.0 mm, Bronchial margin\.br\INFLAMMATORY(DESMOPLASTIC) REACTION:      Mild\.br\N1 LYMPH NODES:      Number of N1 lymph nodes positive:: 0.0\.br\     Number of N1 lymph nodes examined: 3.0\.br\EXTRACAPSULAR SPREAD OF N1 METASTASES:      No\.br\N2 LYMPH NODES:      Number of N2 lymph nodes positive: 0\.br\     Number of N2 lymph nodes examined: 2.0\.br\EXTRACAPSULAR SPREAD OF N2 METASTASES:      No\.br\UNDERLYING DISEASE(S):      Obstructive pneumonia, focal\.br\T STAGE, PATHOLOGIC:      pT1\.br\N STAGE, PATHOLOGIC:      pN0\.br\M STAGE, PATHOLOGIC:      pMX\.br\--------------------------------------------------------\.br\ \.br\\.br\||||||F

MSH|^~\&|CoPathPlus|X|caBIG||20060210135109||ORU^R01|1000000004542|P|2.3
PID|1||171474264^^^RS|tst8857394|SYNOPTEST^SOUTHSIDE^TWO||19320709|F||W|||||||||171-47-4264|||||||||||N
PV1|1||3A^A0312||||505071^PLANET^MERCURY||||||||||pmc48361^PLANET^PLUTO|S|0001171474264|||||||||||||||||||||||||200506011610
ORC|RE||SSS05-201^CoPathPlus||CM||||200506021618|z32^PICCOLI^ANTHONY||505071^PLANET^MERCURY
OBR|1||SSS05-201^CoPathPlus^tst7407183|SSHS^SS Histology|||200506011130|||||||200506021616|BRMSS|505071||||^72^Y|-1|200507111301||SP|F|||||||010728^KHASNABIS^SUKAMAL|010728^KHASNABIS^SUKAMAL
OBX|1|CE|ANT|tst7407183.1|BRMSS^right lower inner quadrant breast mass^L||||||F||1^1
OBX|2|CE|ANT|tst7407183.2|^lesion right shoulder^L||||||F||2^2
OBX|3|ST|BLOCK|tst7407183.1.1|A||||||||1^A|200506021617
OBX|4|ST|BLOCK|tst7407183.1.2|B||||||||2^B|200506021617
OBX|5|ST|BLOCK|tst7407183.1.3|C||||||||3^C|200506021617
OBX|6|ST|BLOCK|tst7407183.1.4|D||||||||4^D|200506021617
OBX|7|ST|BLOCK|tst7407183.1.5|E||||||||5^E|200506021617
OBX|8|ST|BLOCK|tst7407183.1.6|F||||||||6^F|200506021617
OBX|9|ST|BLOCK|tst7407183.2.7|A||||||||1^A|200506021617
OBX|10|CE|PROCESS|tst7407183.1.1.1|$hinit^Initial H&E^L||||||||1^H&E|200506021617
OBX|11|CE|PROCESS|tst7407183.1.2.2|$hinit^Initial H&E^L||||||||4^H&E|200506021617
OBX|12|CE|PROCESS|tst7407183.1.3.3|$hinit^Initial H&E^L||||||||4^H&E|200506021617
OBX|13|CE|PROCESS|tst7407183.1.4.4|$hinit^Initial H&E^L||||||||4^H&E|200506021617
OBX|14|CE|PROCESS|tst7407183.1.5.5|$hinit^Initial H&E^L||||||||4^H&E|200506021617
OBX|15|CE|PROCESS|tst7407183.1.6.6|$hinit^Initial H&E^L||||||||4^H&E|200506021617
OBX|16|CE|PROCESS|tst7407183.2.7.7|$hinit^Initial H&E^L||||||||1^H&E|200506021617
OBX|17|CE|PROCESS|tst7407183.1.1.8|pmc2043^Estrogen Receptor (IPEX)^L||||||||2^AER|200601132341
OBX|18|CE|PROCESS|tst7407183.1.1.9|pmc9043^Progesterone Receptor (IPEX)^L||||||||3^APR|200601132341
OBX|19|CE|PROCESS|tst7407183.1.1.10|pmc7624^Her-2/neu c-erb (IPEX)^L||||||||4^ANEU|200601132341
OBX|20|TX|GDT|tst7407183|Part 1 is labeled as "right lower inner quadrant breast mass".  It consists of a spherical piece of breast tissue measuring 4.5 x 4.2 x 4.2 cm.  The external surfaces are covered by a generous amount of adipose tissue.  It also includes a separate piece of skin and adipose tissue.  The external surface of the breast mass is painted by green ink.  On section, there is a well-circumscribed but unencapsulated, firm, grayish-pink tumor which measures 2.7 cm in maximum diameter.  The cut surface of the tumor is slightly concave and solid with very fine linear chalky streaks.  The separate piece of skin measures 4.5 cm in m maximum diameter and\.br\0.6 cm in maximum width.  Representative sections from the breast tumor are placed in cassettes "1A" through "1D" and the separate piece of skin and adipose tissue is submitted in cassettes "1E" and "1F".\.br\\.br\Part 2  is labeled as "lesion right shoulder".  It consists of a piece of papillary grayish-pink tissue measuring 0.8 cm in maximum diameter.  It is entirely submitted in cassette "2A".\.br\||||||F
OBX|21|TX|MDT|tst7407183|     SYNOPTIC - PRIMARY INVASIVE CARCINOMA OF BREAST\.br\LATERALITY:      Right\.br\PROCEDURE:      Segmental\.br\LOCATION:      Not specified\.br\SIZE OF TUMOR:      Maximum dimension invasive component:  2.7 cm\.br\MULTICENTRICITY/MULTIFOCALITY OF INVASIVE FOCI:      No\.br\TUMOR TYPE (invasive component):      Ductal adenocarcinoma, NOS\.br\NOTTINGHAM SCORE\.br\     Nuclear grade: 3\.br\     Tubule formation: 3\.br\     Mitotic activity score: 3\.br\     Total Nottingham score: 9\.br\     Nottingham grade (1, 2, 3): 3\.br\ANGIOLYMPHATIC INVASION:      No\.br\DERMAL LYMPHATIC INVASION:      No\.br\CALCIFICATION:      No\.br\SURGICAL MARGINS INVOLVED BY INVASIVE COMPONENT:      No\.br\LYMPH NODES POSITIVE:      0\.br\LYMPH NODES EXAMINED:      0\.br\METHOD(S) OF LYMPH NODE EXAMINATION:      H/E stain\.br\LYMPH NODE METASTASIS(-ES) WITH EXTRACAPSULAR EXTENSION:      No\.br\SKIN INVOLVED (ULCERATION):      No\.br\T STAGE, PATHOLOGIC:      pT2\.br\N STAGE, PATHOLOGIC:      pNX\.br\M STAGE, PATHOLOGIC:      pMX\.br\ESTROGEN RECEPTORS:      negative\.br\PROGESTERONE RECEPTORS:      negative\.br\HER2/NEU:      zero or 1+\.br\--------------------------------------------------------\.br\(7 H\T\E) - Microscopic examination substantiates the above diagnosis.\.br\||||||F
OBX|22|TX|FIN|tst7407183|PART 1:          BREAST, RIGHT, LESS THAN TOTAL  MASTECTOMY WITHOUT AXILLARY CONTENTS \.br\A.          INVASIVE DUCTAL CARCINOMA (2.7 CM).\.br\B.     NOTTINGHAM HISTOLOGIC SCORE:\.br\               TUBULE OFRMATION MINIMAL LESS THAN 10% (SCORE 3).\.br\          NUCLEAR PLEOMORPHISM:  MARGINED VARIATION IN SIZE, NUCLEOLI,\.br\          CHROMATIN CLUMPING (SCORE 3).\.br\          MITOTIC COUNT FOR A 40 X OBJECTIVE GREATER THAN 10 MITOSIS/10 HPF\.br\          (SCIRE 3),\.br\     TOTAL NOTTINGHAM SCORE:  NINE (9).\.br\     GRADE III OF III.\.br\C.          PATHOLOGIC STAGING (pTNM):\.br\               pT2 - TUMOR MORE THAN 2.0 CM BUT NOT MORE THAN 5.0 CM IN GREATEST\.br\          DIMENSION.\.br\D.          REGIONAL LYIMPH NODES (pN):\.br\               NOT REMOVED FOR PATHOLOGIC STUDY.\.br\E.          DISTANT METASTASIS (pMX):\.br\               CANNOT BE ASSESSED.\.br\F.          MARGINS UNINVOLVED BY INVASIVE CARCINOMA.\.br\               DISTANCE FROM CLOSEST MARGIN:  0.6 MM.\.br\G.          VENOUS/LYMPHATIC INVASION:  ABSENT.\.br\H.     MICROCALCIFICATIONS:  NOT IDENTIFIED.\.br\I.     ADDITIONAL PATHOLOGIC FINDINGS:  DCIS LESS THAN 1%.\.br\\.br\PART 2:          SKIN, RIGHT SHOULDER, EXCISION \.br\          FIBROEPITHELIAL PAPILLOMA.\.br\||||||F
OBX|23|CE|IMP|tst7407183|M85003^^SNO||||||||1||A
OBX|24|CE|IMP|tst7407183|P1100^^SNO||||||||1||A
OBX|25|CE|IMP|tst7407183|T04000^^SNO||||||||1||A
OBX|26|CE|IMP|tst7407183|T04020^^SNO||||||||1||A
OBX|27|CE|IMP|tst7407183|M80001^^SNO||||||||1||A
OBX|28|CE|IMP|tst7407183|M80006^^SNO||||||||1||A
OBX|29|CE|IMP|tst7407183|M55400^^SNO||||||||1||A
OBX|30|CE|IMP|tst7407183|M80103^^SNO||||||||1||A
OBX|31|CE|IMP|tst7407183|T00100^^SNO||||||||1||A
OBX|32|CE|IMP|tst7407183|T09010^^SNO||||||||1||A
OBX|33|CE|IMP|tst7407183|T48000^^SNO||||||||1||A
OBX|34|CE|IMP|tst7407183|M76810^^SNO||||||||1||A
OBX|35|CE|IMP|tst7407183|P1100^^SNO||||||||1||A
OBX|36|CE|IMP|tst7407183|T02410^^SNO||||||||1||A

MSH|^~\&|CoPathPlus|X|caBIG||20060210135109||ORU^R01|1000000004543|P|2.3
PID|1||204544381^^^RZ|tst2507394|SYNOPTEST^HORIZON^THREE||19441231|F||W|||||||||204-54-4381|||||||||||N
PV1|1||Z2WE^0212||||505071^PLANET^MERCURY||||||||||pmc07361^PLANET^MERCURY|I|0001204544381|||||||||||||||||||||||||200503181748
ORC|RE||HHS05-202^CoPathPlus||CM||||200505111829|z32^PICCOLI^ANTHONY||505071^PLANET^MERCURY
OBR|1||HHS05-202^CoPathPlus^tst9596183|^HH Histology|||200503181027|||||||200505111827|BRBX|505071||||^60^Y|-1|200506061459||SP|F|||||||^PETRICK^MARCIA|^PETRICK^MARCIA
OBX|1|CE|ANT|tst9596183.1|BRBX^Portion of Left Pectoris Major - Frozen^L||||||F||1^1
OBX|2|CE|ANT|tst9596183.2|BRRED^Left Breast - Suture is Medial Aspect^L||||||F||2^2
OBX|3|CE|ANT|tst9596183.3|AXILLA^Left Breast Tissue - Inlet to Axilla^L||||||F||3^3
OBX|4|CE|ANT|tst9596183.4|FASMUS^Portions of Pectoralis Left^L||||||F||4^4
OBX|5|ST|BLOCK|tst9596183.1.1|A||||||||1^A|200601132338
OBX|6|ST|BLOCK|tst9596183.2.2|A||||||||1^A|200601132338
OBX|7|ST|BLOCK|tst9596183.2.3|B||||||||2^B|200601132338
OBX|8|ST|BLOCK|tst9596183.2.4|C||||||||3^C|200601132338
OBX|9|ST|BLOCK|tst9596183.2.5|D||||||||4^D|200601132338
OBX|10|ST|BLOCK|tst9596183.2.6|E||||||||5^E|200601132338
OBX|11|ST|BLOCK|tst9596183.2.7|F||||||||6^F|200601132338
OBX|12|ST|BLOCK|tst9596183.2.8|G||||||||7^G|200601132338
OBX|13|ST|BLOCK|tst9596183.2.9|H||||||||8^H|200601132338
OBX|14|ST|BLOCK|tst9596183.2.10|I||||||||9^I|200601132338
OBX|15|ST|BLOCK|tst9596183.2.11|J||||||||10^J|200601132338
OBX|16|ST|BLOCK|tst9596183.2.12|K||||||||11^K|200601132338
OBX|17|ST|BLOCK|tst9596183.3.13|A||||||||1^A|200601132338
OBX|18|ST|BLOCK|tst9596183.3.14|B||||||||2^B|200601132338
OBX|19|ST|BLOCK|tst9596183.3.15|C||||||||3^C|200601132338
OBX|20|ST|BLOCK|tst9596183.3.16|D||||||||4^D|200601132338
OBX|21|ST|BLOCK|tst9596183.3.17|E||||||||5^E|200601132338
OBX|22|ST|BLOCK|tst9596183.4.18|A||||||||1^A|200601132338
OBX|23|ST|BLOCK|tst9596183.4.19|B||||||||2^B|200601132338
OBX|24|ST|BLOCK|tst9596183.4.20|C||||||||3^C|200601132338
OBX|25|ST|BLOCK|tst9596183.3.21|F||||||||6^F|200601132338
OBX|26|CE|PROCESS|tst9596183.1.1.1|$hinit^Initial H&E^L||||||||1^H&E|200512191416
OBX|27|CE|PROCESS|tst9596183.1.1.2|pmc5044^Frozen Section Initial Slide (HH)^L||||||||2^FS|200512191416
OBX|28|CE|PROCESS|tst9596183.2.2.3|$hinit^Initial H&E^L||||||||1^H&E|200512191416
OBX|29|CE|PROCESS|tst9596183.2.3.4|$hinit^Initial H&E^L||||||||1^H&E|200512191416
OBX|30|CE|PROCESS|tst9596183.2.4.5|$hinit^Initial H&E^L||||||||1^H&E|200512191416
OBX|31|CE|PROCESS|tst9596183.2.5.6|$hinit^Initial H&E^L||||||||1^H&E|200512191416
OBX|32|CE|PROCESS|tst9596183.2.6.7|$hinit^Initial H&E^L||||||||1^H&E|200512191416
OBX|33|CE|PROCESS|tst9596183.2.7.8|$hinit^Initial H&E^L||||||||1^H&E|200512191416
OBX|34|CE|PROCESS|tst9596183.2.8.9|$hinit^Initial H&E^L||||||||1^H&E|200512191416
OBX|35|CE|PROCESS|tst9596183.2.9.10|$hinit^Initial H&E^L||||||||1^H&E|200512191416
OBX|36|CE|PROCESS|tst9596183.2.10.11|$hinit^Initial H&E^L||||||||1^H&E|200512191416
OBX|37|CE|PROCESS|tst9596183.2.11.12|$hinit^Initial H&E^L||||||||1^H&E|200512191416
OBX|38|CE|PROCESS|tst9596183.2.12.13|$hinit^Initial H&E^L||||||||1^H&E|200512191416
OBX|39|CE|PROCESS|tst9596183.3.13.14|$hinit^Initial H&E^L||||||||1^H&E|200512191416
OBX|40|CE|PROCESS|tst9596183.3.14.15|$hinit^Initial H&E^L||||||||1^H&E|200512191416
OBX|41|CE|PROCESS|tst9596183.3.15.16|$hinit^Initial H&E^L||||||||1^H&E|200512191416
OBX|42|CE|PROCESS|tst9596183.3.16.17|$hinit^Initial H&E^L||||||||1^H&E|200512191416
OBX|43|CE|PROCESS|tst9596183.3.17.18|$hinit^Initial H&E^L||||||||1^H&E|200512191416
OBX|44|CE|PROCESS|tst9596183.4.18.19|$hinit^Initial H&E^L||||||||1^H&E|200512191416
OBX|45|CE|PROCESS|tst9596183.4.19.20|$hinit^Initial H&E^L||||||||1^H&E|200512191416
OBX|46|CE|PROCESS|tst9596183.4.20.21|$hinit^Initial H&E^L||||||||1^H&E|200512191416
OBX|47|CE|PROCESS|tst9596183.3.21.22|$hinit^Initial H&E^L||||||||1^H&E|200512191416
OBX|48|TX|GDT|tst9596183|The specimen is received fresh for frozen section in one part and in formalin in three parts.  The part is identified with the patient's name and initials\.br\\.br\Part 1:  Received labeled "portion left pectoralis major".  It consists of a beefy red piece of muscle and attached bright yellow adipose tissue measuring 2.5 x 1.7 x 1.2 cm in overall dimensions.  The tissue has a somewhat rubbery consistency that is throughout with some firm rubbery possible tan nodules seen within the specimen.  The specimen is entirely submitted for frozen section.\.br\FS1A  Remainder of the frozen section\.br\\.br\\.br\Part 2:  is labeled "left breast".  It consists of a 1298.7 gram modified radical mastectomy specimen.  It has a suture indicating the medial aspect.  There is an ellipse of skin on the specimen including the nipple.  The ellipse measures 21.0 x 10.0 cm with a centrally located nipple measuring 1.5 cm and an areola measures approximately 3.2 cm.  The skin is mottled with brown and the nipple is somewhat partially inverted with erythema on the skin surface as well as focal areas of indentation and a firm indurated area particularly lateral to the nipple.  A palpable mass is noted from the skin surface.  The overall specimen dimensions are 30.0 x 27.0 x 7.5 cm.  The lateral portion/axillary tail is removed and will be submitted in GEWF fixative.  There is a tan-white node that appears to be grossly involved by tumor measuring 2.2 x 1.0 x 1.5 cm present in the middle of the node dissection.  The specimen is inked.  The entire deep posterior aspect is inked black, superior portion is inked red, medial portion is inked blue and the inferior portion is inked green.  On sectioning, there is a large ill-defined gray-white gritty and calcific area located at the deep mid portion of the specimen.  On sectioning, a serous type fluid filled cavity is also identified.  This overall area by palpation measures at least 11.0 x 7.0 x 11.0 cm.  The serous filled cavity and prior biopsy cavity site is approximately 2.0 cm in diameter.  Sections are submitted as follows:\.br\\.br\2A  Section across the nipple and areola\.br\2B  Section across the skin scar\.br\2C, 2D and 2E  Sections of the tumor mass\.br\2F  Section of the tumor in its relationship to the deep margin of resection\.br\2G and 2H  Representative sections of breast tissue not involved by tumor\.br\2I, 2J and 2K  Sections of axillary lymph nodes\.br\\.br\Part 3:  is labeled "left breast tissue-inlet to axilla".  Verbal communication with Dr. Henwood indicates that this is a possible area of sentinal node.  The overall specimen dimensions are 5.5 x 3.0 x 1.5 cm.  The specimen is entirely submitted in 3A through 3F.\.br\3A through 3F  Toto\.br\\.br\Part 4:  is labeled "pectoralis major muscle".  It consists of seven fragments of soft tissue consisting of an admixture of brown tissue, hemorrhagic tissue, and bright yellow adipose tissue with intervening areas of gray-white.  The specimen in aggregate is 7.0 x 5.5 x 2.5 cm.  The margin of resection is not denoted on the specimen.  Representative sections are submitted in cassettes 4A through 4C.\.br\4A through 4C  Representative sections\.br\||||||F
OBX|49|TX|MDT|tst9596183|     SYNOPTIC - PRIMARY INVASIVE CARCINOMA OF BREAST\.br\LATERALITY:      Left\.br\PROCEDURE:      Modified radical mastectomy\.br\LOCATION:      Not specified\.br\SIZE OF TUMOR:      Maximum dimension invasive component:  2.2 cm\.br\MULTICENTRICITY/MULTIFOCALITY OF INVASIVE FOCI:      No\.br\TUMOR AGGREGATE SIZE:      Sum of the sizes of multiple invasive tumors: 2.2 cm\.br\TUMOR TYPE (invasive component):      Ductal adenocarcinoma, NOS\.br\NOTTINGHAM SCORE\.br\     Nuclear grade: 3\.br\     Tubule formation: 2\.br\     Mitotic activity score: 2\.br\     Total Nottingham score: 7\.br\     Nottingham grade (1, 2, 3): 2\.br\ANGIOLYMPHATIC INVASION:      Yes\.br\DERMAL LYMPHATIC INVASION:      Yes\.br\CALCIFICATION:      No\.br\TUMOR TYPE, IN SITU:      Apocrine, Comedo\.br\SURGICAL MARGINS INVOLVED BY INVASIVE COMPONENT:      No\.br\SURG MARGINS INVOLVED BY IN SITU COMPONENT:      No\.br\PAGET'S DISEASE OF NIPPLE:      No\.br\LYMPH NODES POSITIVE:      4\.br\LYMPH NODES EXAMINED:      6\.br\METHOD(S) OF LYMPH NODE EXAMINATION:      H/E stain\.br\SENTINEL NODE METASTASIS:      No\.br\ONLY KERATIN POSITIVE CELLS ARE PRESENT:      No\.br\SIZE OF NODAL METASTASES:      Diameter of largest lymph node metastasis: 2 mm\.br\LYMPH NODE METASTASIS(-ES) WITH\.br\EXTRACAPSULAR EXTENSION:      No\.br\METASTASES TO IPSILATERAL INTERNAL\.br\MAMMARY LYMPH NODE (IF APPLICABLE):      No\.br\SKIN INVOLVED (ULCERATION):      No\.br\NON-NEOPLASTIC BREAST TISSUE:      FCD\.br\T STAGE, PATHOLOGIC:      pT4\.br\N STAGE, PATHOLOGIC:      pN3b\.br\M STAGE, PATHOLOGIC:      pMX\.br\ESTROGEN RECEPTORS:      unknown\.br\PROGESTERONE RECEPTORS:      unknown\.br\HER2/NEU:      unknown\.br\--------------------------------------------------------\.br\ \.br\\.br\||||||F
OBX|50|CE|IMP|tst9596183|000^^ICD||||||||1

MSH|^~\&|CoPathPlus|X|caBIG||20060210135109||ORU^R01|1000000004544|P|2.3
PID|1||123456790^^^RR|tpmc5198394|TESTVTWOFIVE^BARBARA||19501215|F||||||||||||||||||||||N
PV1|1||PPAT||||^PLANET^VENUS||||||||||pmc28361^PLANET^NEPTUNE|OSD|0244276653054|||||||||||||||||||||||||200512011506
ORC|RE||PHS05-202^CoPathPlus||CM||||200512021211|z37^ANDERSON^RALPH||^PLANET^VENUS
OBR|1||PHS05-202^CoPathPlus^tpmc6267183|^PH Transcription|||200512011206|||||||200512021206|CS8|||||^55^Y|-1|200512111201||SP|F|||||||987654^PATHOID^DOCTOR
OBX|1|CE|ANT|tpmc6267183.1|CS8^4 CONSULT SLIDES^L||||||F||1^1
OBX|2|CE|ANT|tpmc6267183.2|COM^1 CONSULT SLIDESl^L||||||F||2^2

MSH|^~\&|CoPathPlus|X|caBIG||20060210135109||ORU^R01|1000000004545|P|2.3
PID|1||112233435^^^RR|tpmc7198394|TESTVTWOFIVE^JACK||19551215|M||U||||||||||||||||||||N
PV1|1||PPAT||||505075^PLANET^JUPITER||||||||||pmc87361^PLANET^EARTH|OSD|0263745535324|||||||||||||||||||||||||200511281144
ORC|RE||PHS05-203^CoPathPlus||CM||||200512021222|z37^ANDERSON^RALPH||505075^PLANET^JUPITER
OBR|1||PHS05-203^CoPathPlus^tpmc7267183|^PH Transcription|||200512021219|||||||200512021219|COM|505075||||^50^Y|-1|200601040854||SP|F|||||||987654^PATHOID^DOCTOR|z491^NESTLER^RICK
OBX|1|CE|ANT|tpmc7267183.1|COM^Paraffin Blocks^L||||||F||1^1
OBX|2|CE|ANT|tpmc7267183.2|CS8^7 CONSULT SLIDES^L||||||F||2^2
OBX|3|CE|ANT|tpmc7267183.3|CS9^14 UNSTAINED CONSULT SLIDES^L||||||F||3^3
OBX|4|TX|MDT|tpmc7267183|Slides reviewed and retained. \.br\||||||F
OBX|5|TX|FIN|tpmc7267183|LUNG, LEFT UPPER LOWER LOBES, WEDGE BIOPSIES (OSS# ZA12345) \.br\USUAL INTERSTITIAL PNEUMONIA PATTERN OF FIBROSIS ASSOCIATED WITH ALVEOLAR PROTEINOSIS AND CHOLESTEROL GRANULOMAS (see comment).\.br\||||||F
OBX|6|CE|IMP|tpmc7267183|191.9^^ICD||||||||1

MSH|^~\&|CoPathPlus|X|caBIG||20060210135109||ORU^R01|1000000004547|P|2.3
PID|1||123123654^^^RR|tpmc0426005|KRINGLE^KRIS^N||19201206|M|||||||||||123-12-3654|||||||||||N
PV1|1||OSD||||505073^PLANET^EARTH||||||||||pmc87361^PLANET^EARTH|OSD|0001123123654|||||||||||||||||||||||||200512120930
ORC|RE||PHS05-204^CoPathPlus||CM||||200512120938|^LASSIGE^KAREN||505073^PLANET^EARTH
OBR|1||PHS05-204^CoPathPlus^tpmc3767183|PHSP^PH Surgical Pathology|||200512120935|||||||200512120935|SB|505073||||^85^Y|-1|200512121009||SP|F|||||||^LASSIGE^KAREN|^LASSIGE^KAREN
OBX|1|CE|ANT|tpmc3767183.1|SB^Biopsy Small Bowel^L||||||F||1^1
OBX|2|ST|BLOCK|tpmc3767183.1.1|A||||||||1^A|200601061423
OBX|3|CE|PROCESS|tpmc3767183.1.1.1|$hinit^Initial H&E^L||||||||1^H&E|200512120936
OBX|4|TX|GDT|tpmc3767183|The specimen labeled " Small Bowel " and the initials "LL".  The specimen measures 0.5 cm x 0/4 cm and is submitted entirely is cassette A. \.br\||||||F
OBX|5|TX|MDT|tpmc3767183|Microscopic examination substantiates the above diagnosis.\.br\||||||F
OBX|6|TX|FIN|tpmc3767183|PART 1: SMALL BOWEL BIOPSY\.br\A.          NEGATIVE FOR MALIGANCY\.br\B.          INFLAMATION.\.br\||||||F
OBX|7|CE|IMP|tpmc3767183|P1140^^SNO||||||||1||A
OBX|8|CE|IMP|tpmc3767183|T64000^^SNO||||||||1||A

MSH|^~\&|CoPathPlus|X|caBIG||20060210135109||ORU^R01|1000000004548|P|2.3
PID|1||000999911^^^RR|tpmc9326005|TUBA^TUBBIE||19230101|M|||||||||||121-21-3222|||||||||||N
PV1|1||9D||||505075^PLANET^JUPITER||||||||||pmc87361^PLANET^EARTH|I|9898989898989|||||||||||||||||||||||||200512120928
ORC|RE||PHS05-205^CoPathPlus||CM||||200512120939|z37^ANDERSON^RALPH||505075^PLANET^JUPITER
OBR|1||PHS05-205^CoPathPlus^tpmc4767183|PHSP^PH Surgical Pathology|||200512120937|||||||200512120937|ABD|505075||||^83^Y|-1|200512121009||SP|F|||||||987654^PATHOID^DOCTOR|z37^ANDERSON^RALPH
OBX|1|CE|ANT|tpmc4767183.1|ABD^Soft Tissue Mass, Resection^L||||||F||1^1
OBX|2|ST|BLOCK|tpmc4767183.1.1|A||||||||1^A|200601061423
OBX|3|CE|PROCESS|tpmc4767183.1.1.1|$hinit^Initial H&E^L||||||||1^H&E|200512120937
OBX|4|TX|GDT|tpmc4767183|This is a test refresher cause I forgot how to make a macro\.br\Kjkjkjehhjheihohidjklhkljhwiuhyebn hjhe jkhk e  hehhhjw  \.br\||||||F
OBX|5|TX|MDT|tpmc4767183|This is a test refresher cause I forgot how to make a macro\.br\||||||F
OBX|6|TX|FIN|tpmc4767183|This is a test refresher, so enter on the fly.\.br\||||||F
OBR|2||tpmc4767183^CoPathPlus^tpmc4767183.A1|ADD^Addendum||||||||||200601121051|||||||1|200601121051||SP|F|||||||987654^PATHOID^DOCTOR|z491^NESTLER^RICK
OBX|1|TX|ADX|tpmc4767183|Trichrome stain highlights large airway scarring.\.br\||||||F

MSH|^~\&|CoPathPlus|X|caBIG||20060210135109||ORU^R01|1000000004549|P|2.3
PID|1||555121221^^^CHPALL|tpmc7326005|STEELER^JOE^A.||19801225|M||W|||||||||555-12-1221|||||||||||N
PV1|1||E1017||||||||||||||pmc87361^PLANET^EARTH|CHC|1234567891111|||||||||||||||||||||||||200512120948
ORC|RE||PHS05-206^CoPathPlus||CM||||200512121001|^SOLTESZ^BENJAMIN||^PLANAS^ANTONIO
OBR|1||PHS05-206^CoPathPlus^tpmc7767183|PHSP^PH Surgical Pathology|||200512121001|||||||200512121001|NANEU|||||^24^Y|-1|200601121049||SP|C|||||||MD.AMIN.RA^AMIN^RAJNIKANT|z491^NESTLER^RICK
OBX|1|CE|ANT|tpmc7767183.1|NANEU^Aneurysm^L||||||C||1^1
OBX|2|TX|GDT|tpmc7767183|\.br\Gross Description:\.br\Tissue was received in glutaraldehyde labeled "Henerson, Loretta, Myocardium".   The specimen was processed in entirety for Electron Microscopic examination.\.br\\.br\||||||C
OBX|3|TX|FIN|tpmc7767183|\.br\46,X #,t(1;19)(q23;p13.3)[#]\.br\\.br\Abnormal #male bone marrow chromosome analysis with a translocation between the long arm of one chromosome 1 and the short arm of one chromosome 19.  The translocation, t(1;19)(q23;p13.3) is strongly associated with ALL, pre-B immunological phenotype, but may be found occasionally in T cell ALL.  The 1;19 translocation disrupts the normal functions of the E2A and PBX1 genes, located on band 19p13.3 and 1q23, respectively, and leads to formation of a fusion gene that encodes a hybrid transcription factor with oncogenic potential [Nichols J, Nimer SD (1992) Blood 80:2953-2963; Privitera E et al. (1992) Blood 79:1781-1788].  The prognostic value of this translocation appears to be obscure [Sharma P et al. (2001) Cancer Genet Cytogenet 124:132-136; Uckun F et al. (1998) J Clin Oncol 16:527-535].\.br\\.br\FINAL RESULTS:\.br\\.br\                                            G-Banding        \.br\No. of Cells Analyzed:                 #\.br\No. of Cells Karyotyped:              #\.br\\.br\No. of Chromosomes:     <46     46     >46\.br\No. of Cells:             #       #      #\.br\\.br\# trypsin-Giemsa banded metaphase cells were analyzed from # hour harvests of unstimulated # cell cultures.  # cells had a 46,X#,t(1;19)(q23;p13.3) chromosome complement.  # cells, each with the same abnormality, had hypodiploid karyotypes, likely as a result of random chromosomal loss.\.br\\.br\Average band level/haploid set:     #\.br\\.br\||||||C
OBX|4|CE|IMP|tpmc7767183|M00100^^SNO||||||||1||A
OBX|5|CE|IMP|tpmc7767183|T06000^^SNO||||||||1||A
OBX|6|CE|IMP|tpmc7767183|TY8000^^SNO||||||||1||A
OBX|7|CE|IMP|tpmc7767183|M13500^^SNO||||||||1||A
OBX|8|CE|IMP|tpmc7767183|M80003^^SNO||||||||1||A
OBX|9|CE|IMP|tpmc7767183|T0X000^^SNO||||||||1||A

MSH|^~\&|CoPathPlus|X|caBIG||20060210135109||ORU^R01|1000000004550|P|2.3
PID|1||999987654^^^SY|tpmc0681594|TESTVTWOFIVE^SY TWO||19560701|M||W|||||||||222-88-9999|||||||||||N
PV1|1||I6P||||505079^PLANET^PLUTO||||||||||pmc48361^PLANET^PLUTO|SYA|0192222222222|||||||||||||||||||||||||200511231642
ORC|RE||PHS05-210^CoPathPlus||CM||||200512141605|z196^DEVINE^LISA||505079^PLANET^PLUTO
OBR|1||PHS05-210^CoPathPlus^tpmc2967183|PHSP^PH Surgical Pathology|||200512141557|||||||200512141557|LNFC|505079||||^49^Y|-1|200601041129||SP|C|||||||^PARWANI^ANIL|^PARWANI^ANIL
OBX|1|CE|ANT|tpmc2967183.1|LNFC^Submental neck lymph node^L||||||C||1^1
OBX|2|CE|ANT|tpmc2967183.2|CLNF^Submental Neck Lymph Node for FISH^L||||||C||2^2
OBX|3|ST|BLOCK|tpmc2967183.1.1|ACMB/DNA||||||||1^ACMB/DNA|200601061423
OBX|4|ST|BLOCK|tpmc2967183.1.2|BB+||||||||2^BB+|200601061423
OBX|5|ST|BLOCK|tpmc2967183.1.3|C||||||||3^C|200601061423
OBX|6|ST|BLOCK|tpmc2967183.1.4|D||||||||4^D|200512141558
OBX|7|CE|PROCESS|tpmc2967183.1.1.1|$hinit^Initial H&E^L||||||||15^H&E|200512141557
OBX|8|CE|PROCESS|tpmc2967183.1.1.2|pmc5553^HH&E (HISTO)^L||||||||16^HHE|200512141557
OBX|9|CE|PROCESS|tpmc2967183.1.2.3|$hinit^Initial H&E^L||||||||30^H&E|200512141557
OBX|10|CE|PROCESS|tpmc2967183.1.3.4|$hinit^Initial H&E^L||||||||32^H&E|200512141557
OBX|11|CE|PROCESS|tpmc2967183.1.0.5|pmc0753^Touch Preparation (Surg)^L||||||||1|200512141557
OBX|12|CE|PROCESS|tpmc2967183.1.0.6|pmc4653^Tissue Banked OCT Frozen (Surg)^L||||||||2|200512141557
OBX|13|CE|PROCESS|tpmc2967183.1.0.7|pmc6553^CMB Tissue Prep (PHSP)^L||||||||3|200512141557
OBX|14|CE|PROCESS|tpmc2967183.1.0.8|pmc1273^DNA Tissue Frozen (Surg)^L||||||||4^DNAFR|200512141557
OBX|15|CE|PROCESS|tpmc2967183.1.0.9|pmc0534^Flow Cyto Tissue Prep (Surg)^L||||||||5^FLOWCY|200512141557
OBX|16|CE|PROCESS|tpmc2967183.1.2.10|tst8525^B+ Fixation (Surg)^L||||||||31^B5|200512141557
OBX|17|CE|PROCESS|tpmc2967183.1.4.11|$hinit^Initial H&E^L||||||||33^H&E|200512141558
OBX|18|CE|PROCESS|tpmc2967183.1.0.12|pmc2424^DNA Purification (PHMO)^L||||||||6^DNAPUR|200512141558
OBX|19|CE|PROCESS|tpmc2967183.1.0.13|pmc8425^Flow Cytometry, First Marker^L||||||||7^FCFRSTM|200512141558
OBX|20|CE|PROCESS|tpmc2967183.1.0.14|pmc9425^Flow Cyto, Add'l Markers (PHFC)^L||||||||8^FCADDLM|200512141558
OBX|21|CE|PROCESS|tpmc2967183.1.0.15|pmc6893^Lymphoma/CLL (WLO) (PHFC)^L||||||||9^LYMPH|200512141559
OBX|22|CE|PROCESS|tpmc2967183.1.2.16|pmc0653^Hematoxylin & Eosin Recut (Histo)^L||||||||32^H&E Recut|200601132341
OBX|23|CE|PROCESS|tpmc2967183.1.3.17|pmc0653^Hematoxylin & Eosin Recut (Histo)^L||||||||33^H&E Recut|200601132341
OBX|24|CE|PROCESS|tpmc2967183.1.4.18|pmc0653^Hematoxylin & Eosin Recut (Histo)^L||||||||34^H&E Recut|200601132341
OBX|25|CE|PROCESS|tpmc2967183.1.1.19|pmc3323^CD3 T Lymphocytes (IPEX)^L||||||||17^CD3|200601132341
OBX|26|CE|PROCESS|tpmc2967183.1.1.20|pmc8623^L26 B lymphocyte (IPEX)^L||||||||18^L26|200601132341
OBX|27|CE|PROCESS|tpmc2967183.1.1.21|pmc6604^CD5 T/some B Lymphocytes (IPEX)^L||||||||19^ACD5|200601132341
OBX|28|CE|PROCESS|tpmc2967183.1.1.22|pmc8624^CD10 CALLA paraffin (IPEX)^L||||||||20^CD10|200601132341
OBX|29|CE|PROCESS|tpmc2967183.1.1.23|pmc6323^CD43 L60 T Lymphocytes (IPEX)^L||||||||21^CD43|200601132341
OBX|30|CE|PROCESS|tpmc2967183.1.1.24|pmc8733^Bcl-2 Oncoprotein (IPEX)^L||||||||22^Bcl-2|200601132341
OBX|31|CE|PROCESS|tpmc2967183.1.1.25|pmc3474^ABCL6 (IPEX)^L||||||||23^ABCL6|200601132341
OBX|32|CE|PROCESS|tpmc2967183.1.1.26|pmc6324^cyclin D1 Bcl-1 (IPEX)^L||||||||24^ACYCLD1|200601132341
OBX|33|CE|PROCESS|tpmc2967183.1.1.27|pmc3923^Control NEG (WLO) (IPEX)^L||||||||25^ANEG|200601132341
OBX|34|CE|PROCESS|tpmc2967183.1.1.28|pmc6623^Kappa Light Chain (IPEX)^L||||||||26^Kappa|200601132341
OBX|35|CE|PROCESS|tpmc2967183.1.1.29|pmc1723^Lambda Light Chain (IPEX)^L||||||||27^Lambda|200601132341
OBX|36|CE|PROCESS|tpmc2967183.1.1.30|pmc8104^Kappa-Lambda Chn Dbl Lbl (PHIS)^L||||||||28^IKPLM|200512141602
OBX|37|CE|PROCESS|tpmc2967183.1.1.31|pmc7873^In situ Blank Slide (IPEX) (WLO)^L||||||||29^IBNKNC|200601132341
OBX|38|CE|PROCESS|tpmc2967183.1.1.32|pmc1073^Cytomegalovirus (IPEX)^L||||||||30^CMV|200601132341
OBX|39|CE|PROCESS|tpmc2967183.1.4.33|pmc1073^Cytomegalovirus (IPEX)^L||||||||35^CMV|200601132341
OBX|40|CE|PROCESS|tpmc2967183.1.4.34|pmc3923^Control NEG (WLO) (IPEX)^L||||||||36^ANEG|200601132341
OBX|41|CE|PROCESS|tpmc2967183.1.0.35|pmc9124^Immunoglobulin Heavy Chain,PCR (PHMO)^L||||||||10^IGHP|200512141603
OBX|42|CE|PROCESS|tpmc2967183.1.0.36|pmc0224^Immunoglobulin Heavy Chain,SB (PHMO)^L||||||||11^IGHS|200512141603
OBX|43|CE|PROCESS|tpmc2967183.1.0.37|pmc0174^T-Cell Receptor Gamma PCR (PHMO)^L||||||||12^T-Cell Receptor Gamma PCR|200512141604
OBX|44|CE|PROCESS|tpmc2967183.1.0.38|pmc9224^TCell Receptor B-Chain SB  (PHMO)^L||||||||13^TCS|200512141604
OBX|45|CE|PROCESS|tpmc2967183.1.0.39|pmc9425^Flow Cyto, Add'l Markers (PHFC)^L||||||||14^FCADDLM|200512141604
OBX|46|CE|PROCESS|tpmc2967183.1.0.40|pmc0143^ISH CNTRL Insitu Hybrid (WLO) (PHIS)^L||||||||15^IISH|200512141604
OBX|47|TX|GDT|tpmc2967183|The specimen is received in RPMI labeled with the patient' s name, initials JW, medical record number and submental neck lymph node.  It consists of two pieces of fleshy tan, soft tissue, the largest measuring 2.0 x 1.1 x 1.0 cm and the other measuring 1.5 x 1.3 x 1.0 cm.  Touch preparations are performed.  Material is snap frozen (3 blocks), and sent for cell suspension immunophenotypic studies (flow cytometry).  A portion is sent to the molecular diagnostics laboratory with an adjacent section submitted in formalin fixative labeled A (CMB/DNA).  Additional material is sent for cytogenetic studies.  The remainder of the lymph node is submitted in cassette BB+ after B+ fixation and in blocks C and D after formalin fixation.  \.br\LF/kmr\.br\||||||C
OBX|48|TX|MDT|tpmc2967183|Histologic sections of the submental lymph node specimen show overall basic preservation of the lymph node architecture with many large reactive-appearing germinal centers, some with attenuated mantle zones and some T-zone nodules.  Focally prominent monocytoid B-cell areas with occasional large cells that contain intranuclear and focal cytoplasmic inclusions are also identified.  Interfollicular areas with many small lymphocytes and moderately numerous plasma cells are also seen.\.br\DM/js\.br\\.br\PARAFFIN SECTION IMMUNOHISTOCHEMISTRY\.br\\.br\In order to characterize the lymphoid/plasma cell population, paraffin section immunohistologic  studies were performed on the submental lymph node biopsy specimen.  The following results were found:\.br\\.br\Antigen/Antibody        Usual Reactivity                   Result\.br\\.br\anti-kappa              B-cell subset                      Scattered positive plasma cells.\.br\\.br\anti-lambda             B-cell subset                      Scattered positive plasma cells;\.br\somewhat less than kappa.\.br\\.br\double kappa/lambda     Lambda staining is too weak to \.br\accurately assess.\.br\\.br\CD20/L26                B-cells                            Numerous positive cells in follicles\.br\and monocytoid B-cell areas.\.br\\.br\bcl-2                   Lymphocyte subset, other           Monocytoid B-cell areas and germinal\.br\centers mostly negative; numerous\.br\positive cells between germinal\.br\centers.\.br\\.br\bcl-6                   Follicular center cells, other     Highlights germinal center cells and\.br\scattered interfollicular cells.\.br\\.br\CD10                    B-cell subset                      Highlights germinal center cells.\.br\\.br\Cyclin D1               Mantle cell lymphoma, other        Negative.\.br\\.br\CD3                     T-cells                            Numerous positive cells between\.br\follicles; scattered positive cells\.br\in follicles and monocytoid\.br\B-cell areas.\.br\\.br\CD5                     T-cells, B-cell subset             Similar to CD3.\.br\\.br\CD43/Leu 22             T cells, some       \.br\                        B cells, myeloid                   B-cells appear negative.\.br\\.br\CMV                     Cytomegalovirus                    (Blocks 1A \T\ 1D)\.br\       Scattered large positive cells.\.br\_______________________________________________________________________________\.br\\.br\Medical necessity justification for the immunohistochemical stains that were needed in addition to the flow cytometric immunophenotypic studies for the best diagnosis possible is as follows:  The flow cytometric studies did not define the precise nature of all the cellular elements of concern in this specimen.\.br\\.br\RS/shm\.br\||||||C
OBX|49|TX|FIN|tpmc2967183|LYMPH NODE, SUBMENTAL, EXCISION  \.br\FOLLICULAR HYPERPLASIA AND OTHER REACTIVE CHANGES ASSOCIATED WITH CYTOMEGALOVIRUS INCLUSIONS (see comment).\.br\DM/js/RS/shm\.br\||||||C
OBX|50|CE|IMP|tpmc2967183|E3222^^SNO||||||||1||A
OBX|51|CE|IMP|tpmc2967183|M72020^^SNO||||||||1||A
OBX|52|CE|IMP|tpmc2967183|P1100^^SNO||||||||1||A
OBX|53|CE|IMP|tpmc2967183|T08170^^SNO||||||||1||A
OBX|54|CE|IMP|tpmc2967183|000^^ICD||||||||1
OBR|2||tpmc2967183^CoPathPlus^tpmc2967183.P1|FC^Flow Cytometry||||||||||200512141607|||||||1|200512141607||SP|F|||||||^PARWANI^ANIL|z491^NESTLER^RICK
OBX|1|TX|PIN|tpmc2967183|Amending the flow cytometry on this case for cabig testing purposes. This is the interpretation amended text.\.br\\.br\Flow cytometric immunophenotypic studies performed on the submental lymph node demonstrate polyclonal B-cells, surface immunoglobulin negative B-cells, heterogeneous T-cells.  The CD10 positive B-cells are Bcl-2 negative.  A final report will follow after additional pending ancillary studies are completed and reviewed.\.br\DM/js\.br\||||||C
OBX|2|TX|PRC|tpmc2967183|Cell suspension immunophenotypic studies were performed on the submental lymph node and two regions were analyzed.\.br\\.br\     Region 1 represents the small non-complex cells. (78% of the events)\.br\     Region 2 represents the larger non-complex cells. (19% of the events)\.br\\.br\     VIABILITY:  83%\.br\\.br\   -----------------------------B Cells---------------------R1-----R2\.br\\.br\   Antigen+                  Usual Specificity                % Positive\.br\\.br\   Kappa+....................B cell subset................. 8      14      \.br\   Lambda+...................B cell subset................. 4      10      \.br\   Kappa:Lambda\S\........................................... 1.7    1.4      \.br\   CD19+.....................B cell........................ 32     77      \.br\   CD19+/CD5+................B cell subset................. 1      1      \.br\   CD20+.....................B cell........................ 26     78      \.br\   CD20+/CD10+...............B cell subset................. 12     55\.br\   CD19+/CD23+...............B cell subset................. 17     35      \.br\   CD19+/FMC7+...............B cell subset................. 17     49  \.br\   BCL2+/CD10+*............................................ 8      19\.br\   BCL2+/CD20+*............................................ 26     26    \.br\\.br\   -----------------------------T cells---------------------R1-----R2\.br\\.br\   Antigen                   Usual Specificity                % Positive\.br\\.br\   CD2+......................T cell........................ 64     13      \.br\   CD3+......................T cell........................ 65     15      \.br\   CD5+/CD19-................T cell........................ 64     11      \.br\   CD7+......................T cell........................ 58     15      \.br\   CD4+/CD3+.................T helper...................... 52     12      \.br\   CD8+/CD3+.................T cytotoxic/suppressor........ 12     4      \.br\   CD4+/CD8+.................T cell subset................. 1      1      \.br\   CD4:CD8\S\..................T helper:suppressor ratio..... 4.4    3.2      \.br\   CD16,CD57+/CD3+...........T cell subset................. 5      7     \.br\   CD16,CD57+/CD3-...........NK cell, other................ 0      1      \.br\   CD56+/CD3+................NK-like T cell................ 1      3      \.br\   CD56+/CD3-................NK cell, other................ 1      2 \.br\\.br\   -----------------------------Myeloid---------------------R1-----R2\.br\\.br\   Antigen                   Usual Specificity               % Positive\.br\\.br\   CD14+.....................Myeloid,monocyte.............. 3      11     \.br\ \.br\   ------------------------Additional Antibodies------------R1-----R2\.br\\.br\   Antigen                   Usual Specificity                % Positive\.br\\.br\   CD45+.....................Leukocytes.................... 100    100      \.br\ \.br\\S\\R\The results for all antigens are rounded to the nearest whole number.  However, the ratio values (kappa:lambda and CD4:CD8) are calculated using the original results (including two decimal places).\.br\\.br\* The gates used for these antibodies may differ from those used for the other antibodies because of different fixation and/or permeabilization procedures.  Cytoplasmic staining denoted with a "Cyto" can detect both surface and cytoplasmic expression.\.br\\.br\Antigen/Antibody\.br\CD1/BL6         CD13/L138      CD33/P67.6            CD138/B-B4 \.br\CD2/S5.2        CD14+/MOP9     CD34/8G12             Glycophorin A/D2.10\.br\CD3/SK7         CD15/PM81      CD43/DF-T1            HLA-DR/L243\.br\CD4/SK3         CD15s/CSLex1   CD45/2D1              FMC7/FMC7\.br\CD5/L17F12      CD16/B73.1     CD45RA/L48            Kappa/TB 28-2\.br\CD5/BL1a        CD18/L130      CD45RO/UCHL-1         Lambda/1-155-2\.br\CD7/4H9         CD19/J4.119    CD56/Ncam-16.2        MPO/H-43-5\.br\CD7/8H8.1       CD20/L27       CD56/MY31             TCR1,alpha-beta/WT31\.br\CD8/SK1         CD22/S-HCL-1   CD57/HNK-1            TCR,gamma-delta-1/11F2\.br\CD10/SS2/36     CD23/EBVCS-5   CD61/RUU-PL7F12       TdT/HTdT-6\.br\CD11c/S-HCL-3   CD25/3G10      CD103/B-ly7           BCL2/124\.br\\.br\This test was developed and its performance characteristics determined by the Flow Cytometry Laboratory at the University of Pittsburgh Medical Center.  It has not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes.  It should not be regarded as investigational or for research. This laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity testing.\.br\\.br\The results of these studies should be used in the context of the clinical history, and routine morphologic analysis.\.br\\.br\||||||C
OBR|3||tpmc2967183^CoPathPlus^tpmc2967183.P2|MOPR^Molecular Oncology||||||||||200512141608|||||||2|200512141608||SP|F|||||||^PARWANI^ANIL|^PARWANI^ANIL
OBX|1|TX|PIN|tpmc2967183|Tissue from submental lymph node, 15 x 10 x 3 mm (MO05-1099):\.br\Immunoglobulin heavy chain gene rearrangement is NOT detected by Southern Blot and PCR.\.br\T-cell receptor gene rearrangement is NOT detected by Southern Blot and PCR.\.br\||||||C
OBX|2|TX|PRC|tpmc2967183|TESTS:DNA purification\.br\Immunoglobulin heavy chain gene rearrangement (Southern \T\ PCR)\.br\T-cell receptor gamma chain gene rearrangement (PCR)\.br\T-cell receptor beta chain gene rearrangement (Southern Blot)\.br\\.br\Gene rearrangement studies:  Southern blot analysis of the immunoglobulin heavy chain gene using a probe to the J region shows only germline bands with three restriction enzymes (Bam HI, Hind III and Bgl II).  Sensitivity of the current run is below the normal 10% threshold.  Negative sample performs as expected.  A longer exposure of the blot has been ordered and if the results are not consistent, they will be reported in the amended report. \.br\IGH PCR using consensus framework III and J region primers also shows a ladder pattern indicating a polyclonal B-cell population. The measured limit of sensitivity for this assay in our laboratory is approximately 1% clonal cells, although values this low may be difficult to discern unequivocally on new specimens without a known prior positive sample.  Controls for DNA amplification performed within acceptable limits. \.br\Southern blot analysis of the T-cell receptor beta chain gene using a probe to the TCR-Beta constant region shows only germline bands with three restriction enzymes (EcoRV, NdeI and BamHI).  Controls perform within expected limits.\.br\Extended PCR analysis for the T-cell receptor gamma chain gene was performed using oligonucleotide primers for the V1-8, V9, V10, V11 and J1/2 regions under homoduplex conditions.  A polyclonal pattern is observed with all primers tested. This assay should detect the vast majority of clonally rearranged T-cell gamma chain genes; rare rearrangements involving the JP locus may not be detected.  Amplification controls performed within expected ranges.\.br\\.br\PCR gel # 05-275/276/277\.br\SB gel #    05-101/102/103\.br\\.br\This test(s) was developed and its performance characteristics determined by the Division of Molecular Diagnostics at the University of Pittsburgh Medical Center.  It has not been cleared or approved by the U.S. Food and Drug Administration.  The FDA has determined that such clearance or approval is not necessary.  This test(s) is used for clinical purposes.  It should not be regarded as investigational or for research.  This laboratory is certified under the Clinical Laboratory Improvements Amendments of 1988 (CLIA-88) as qualified to perform high complexity clinical laboratory testing.\.br\||||||C
OBR|4||tpmc2967183^CoPathPlus^tpmc2967183.P3|CG^Cytogenetics||||||||||200512191430|||||||3|200512191430||SP|F|||||||GOLLIN-PCL^GOLLIN^SUSANNE|GOLLIN-PCL^GOLLIN^SUSANNE
OBX|1|TX|PIN|tpmc2967183|This specimen yielded no metaphases, precluding classical chromosome analysis.\.br\\.br\\.br\FINAL RESULTS:\.br\\.br\                                            G-Banding        \.br\No. of Cells Analyzed:                 #\.br\No. of Cells Karyotyped:              #\.br\\.br\No. of Chromosomes:     <46     46     >46\.br\No. of Cells:             #       #      #\.br\\.br\Twenty-four hour harvests of unstimulated lymph node cell cultures yielded no metaphase cells.  Harvests of specimens from other patients cultured the same day resulted in analyzable metaphase cells.\.br\||||||C

MSH|^~\&|CoPathPlus|X|caBIG||20060210135109||ORU^R01|1000000004551|P|2.3
PID|1||200000022^^^RR|tpmc7690494|TESTVTWOFIVE^PH ONE||19500729|F||W|||||||||200-00-0022|||||||||||N
PV1|1||CCAR||||505079^PLANET^PLUTO|505073^PLANET^EARTH|||||||||pmc48361^PLANET^PLUTO|S|0202449191919|||||||||||||||||||||||||200511210835
ORC|RE||PHS05-211^CoPathPlus||CM||||200512151131|^MARCH^JILL||505079^PLANET^PLUTO
OBR|1||PHS05-211^CoPathPlus^tpmc3967183|^PH Transcription|||200512151059|||||||200512151059||505079||||^55^Y|-1|200601041116||SP|F|||||||^PARWANI^ANIL|^PARWANI^ANIL
OBX|1|CE|ANT|tpmc3967183.1|^2 Consult Blocks^L||||||F||1^1
OBX|2|ST|BLOCK|tpmc3967183.1.1|A||||||||1^A|200512151135
OBX|3|TX|MDT|tpmc3967183|The specimen consists of three (3) cores of liver tissue and more than 20 portal tracts are sampled.  The liver architecture is intact with normal spacing between portal tracts and central veins.  The portal tracts contain minimal, mixed, but predominantly lymphocytic, inflammation with no interface activity.  The interlobular bile ducts show occasional foci of intraepithelial lymphocyte, but there are no florid duct lesions, significant ductal fibrosis, or ductopenia.  Occasional portal tracts show a low-grade ductular reaction.  No portal or periportal granulomas are seen.\.br\\.br\There is no significant interface activity.\.br\\.br\The lobules show no significant inflammation or confluent necrosis.  However, the perivenular regions show predominantly mild microvesicular steatosis.  Occasional steatotic hepatocytes show ballooning degeneration.  However, no ground glass cells, prominent pigment deposits, or Mallory's hyaline is seen.  The trichrome stain shows mild focal portal fibrosis and mild subsinusoidal fibrosis.  The PAS-D stain is negative for hepatocyte globules.  The iron stain shows few Kupffer's cells granules, (0-1+ on a scale of 0-4).  Copper stain did not reveal evidence of intracytoplasmic accumulation, although only a small portion of the tissue is available on the block for current material. \.br\\.br\The copper stain performed on the previous material from 2004, (PHS04-4307), is only focally positive in the area adjacent to the location of lymphocytic cholangitis lesion.  S-100 immuno stain did not reveal increased intraepithelial dendritic cells.  There is minimal increase in periductal mast cells on the tryptase and c-KIT stains.  These immuno stains were also performed on the 2004 biopsy material, with similar results.\.br\||||||F
OBX|4|TX|FIN|tpmc3967183|LIVER, NEEDLE BIOPSIES (OSS TMS-05-13713, 10/28/05; THE MEDICAL CENTER OF BEAVER) \.br\A.          MIXED PORTAL INFLAMMATION WITH LYMPHOCYTIC CHOLANGITIS AND FOCAL GRANULOMATOUS CHOLANGITIS, MOST CONSISTENT WITH PRIMARY BILIARY CIRRHOSIS, (SEE COMMENT).\.br\B.     MILD PORTAL AND PERIPORTAL FIBROSIS WITH NO BRIDGING. \.br\||||||F
OBX|5|CE|IMP|tpmc3967183|V42.1^^ICD||||||||1
OBR|2||tpmc3967183^CoPathPlus^tpmc3967183.A1|ADD^Addendum||||||||||200512201307|||||||1|200512201307||SP|F|||||||^PARWANI^ANIL|^PARWANI^ANIL
OBX|1|TX|ADX|tpmc3967183|Copper stain reveals no increased cytoplasmic accumulation.  \.br\GMS and AFB stains are negative for micro-organisms.\.br\\.br\Original impression remains unchanged.\.br\||||||F

MSH|^~\&|CoPathPlus|X|caBIG||20060210135109||ORU^R01|1000000004552|P|2.3
PID|1||163263398^^^RR|tpmc9445694|SMITH^LORETTA^M||19321028|F||W|637 PARK STREET^^MONONGAHELA^PA^15063^United States||(724)258-2398|(888)888-8888|||||163-26-3399|||||||||||N
PV1|1||SDSP||||083743^HOLETS^JOHN|||||||||||S|0263110125327|MS
ORC|RE||PHS05-215^CoPathPlus||CM||||200512161611|z41^LOSOS^FRANK||083743^HOLETS^JOHN
OBR|1||PHS05-215^CoPathPlus^tpmc4077183|PHSP^PH Surgical Pathology|||200512161611|||||||200512161611|COBX|083743||||^73^Y|-1|200512161633||SP|F|||||||987654^PATHOID^DOCTOR|987654^PATHOID^DOCTOR
OBX|1|CE|ANT|tpmc4077183.1|COBX^Biopsy Colon^L||||||F||1^1
OBX|2|TX|GDT|tpmc4077183|\.br\THIS IS THE GROSS DESCRIPTION\.br\||||||F
OBX|3|TX|MDT|tpmc4077183|THIS IS THE MICROSCOPIC DESCRIPTION\.br\||||||F
OBX|4|TX|FIN|tpmc4077183|THIS IS THE FINAL DIAGNOSIS.  TESTING ADT CONSISTENCY CHECKS.\.br\...\.br\||||||F

MSH|^~\&|CoPathPlus|X|caBIG||20060210135109||ORU^R01|1000000004553|P|2.3
PID|1||434553605^^^RR|tpmc0219994|TESTVTWOFIVE^CHNGNAMEMRNSO||19720102|M||U|826 JEFFERSON DR^^PITTSBURGH^PA^15229^United States||(412)367-2702|(412)692-3255|||||434-55-3604|||||||||||N
PV1|1||CIN3||||028200^PAINTER^THOMAS|028200^PAINTER^THOMAS|||||||||pmc2312^PAINTER^THOMAS|SV|0264666015341|UH||||||||||||||||||||||||200512120000
ORC|RE||PHS05-217^CoPathPlus||CM||||200512161614|z41^LOSOS^FRANK||028200^PAINTER^THOMAS
OBR|1||PHS05-217^CoPathPlus^tpmc6077183|PHSP^PH Surgical Pathology|||200512161613|||||||200512161613|COBX|028200||||^33^Y|-1|200601111348||SP|C|||||||987654^PATHOID^DOCTOR|z491^NESTLER^RICK
OBX|1|CE|ANT|tpmc6077183.1|COBX^Biopsy Colon^L||||||C||1^1
OBX|2|TX|GDT|tpmc6077183|\.br\THIS IS THE GROSS DESCRIPTION\.br\||||||C
OBX|3|TX|MDT|tpmc6077183|\.br\THIS IS THE MICROSCOPIC DESCRIPTION\.br\||||||C
OBX|4|TX|FIN|tpmc6077183|THIS IS THE AMENDED TEXT I AM ENTERING TO TEST AMENDING A CASE FOR CABIG.\.br\\.br\THIS IS THE FINAL DIAGNOSIS.  TESTING FOR ADT PURPOSES ONLY\.br\||||||C
